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Abstract 
1,2-Diols and 1,2-ketoalcohols are important functional groups that can require 
multiple steps to synthesise, which increases yield losses, waste and often 
uses stoichiometric reagents and toxic/expensive catalysts. The ability to 
transform simple substrates into more complex products in one-pot with two or 
more catalysed steps is desirable, especially if a single catalyst can carry out 
both reactions.  
A multifunctional catalyst system was designed to transform primary alcohols 
into 1,2-diols through three sequential catalysed transformations; transfer 
dehydrogenation, benzoin condensation, and transfer hydrogenation. Two 
families of novel ligands and iridium(III) complexes bearing either thiazole or 
triazole rings were synthesised towards creating a multifunctional catalyst and 
characterised using mass spectrometry, NMR spectroscopy and x-ray 
crystallography. During the synthesis of the ligands, the alkylation of thiazole 
compounds and the DIBAL-H reduction of a thiazole ester were developed. 
The organo-organometallic complexes were tested for the transfer 
dehydrogenation of benzyl alcohol and the reaction was investigated to show 
that the equilibrium between the forward and reverse reaction, and not catalyst 
deactivation, was the cause of limited conversion. The hydrogen acceptor was 
varied and acetone was found to be the most effective when used as a dilute 
solvent with strictly inert reaction conditions, reaching up to 78% conversion. 
Four of the novel complexes gave comparable conversions to the control 
catalyst; however, the benzoin condensation reaction was not successful.  
The transfer hydrogenation of benzaldehyde was tested and found give 
quantitative conversions with the majority of novel complexes. A substrate 
scope identified that the more electron rich substrates were more easily 
oxidised. With a secondary alcohol, the transfer dehydrogenations occurred at 
a faster rate compared to the primary alcohol, reaching quantitative 
conversion. 
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1. Introduction 
This chapter introduces the topics of multicatalysis, organometallic catalysts 
for hydrogen transfer reactions and organo catalysts for the benzoin 
condensation and related reactions. Examples of the research reported in 
these areas are reviewed.   
1.1. Multicatalysis 
Multicatalysis has been a growing area for the use in organic synthesis over 
the last two decades (Figure 1). Combining multiple catalysts in a one-pot 
process to carry out sequential reactions is a desirable method of reaching 
complex targets and improving reaction efficiency.1 
 
Figure 1 The number of publications from 1996 to 2015 as identified by Web of 
Science™ to include in the topics either: “multicatalysis”, “multifunctional catalysis”, 
“tandem catalysis”, “domino catalysis”, “relay catalysis”, “sequential catalysis”, and 
“cooperative catalysis”. 
 
Multicatalysis is defined as two or more catalysed reactions that have distinct 
catalytic cycles, which are carried out on a single substrate in the same 
reaction vessel (Figure 2). Catalysts or reagents can be added during the 
reaction in order to activate or control the sequence of reactions. 
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Figure 2 Multicatalysis with two catalysts in one-pot, where the product of the first 
reaction is the substrate for the second reaction. 
 
Multicatalysis has enormous potential, as many metal/metal, organo/organo, 
metal/organo, enzyme/metal and enzyme/enzyme catalysts can theoretically 
be combined; provided the desired reaction sequence is feasible. 
1.2. Advantages 
The work-up and isolation of products throughout a synthesis are often the 
most expensive, time consuming and wasteful stages of an experiment. By 
combining two or more catalytic reactions in one-pot, with only a single work-
up stage, syntheses can be made more efficient and reduce yield losses. 
Desai, senior chemist at The Dow Chemical Company at the time of 
publication, has estimated the scale of the costings for a palladium catalysed 
Suzuki-Miyuara coupling, organolithiation and aromatisation route, as 
compared to telescoping the last two reactions (Scheme 1).2 For a tonne scale 
process, the total costs for producing one kilogram of product for the original 
route and the telescoped route is $31,000 and $14,700 respectively; a cost 
reduction of 53%. In addition, the batch cycle time was reduced by 61 hours. 
 
 
Scheme 1 a) Original three stage route with the isolation of two intermediates, and 
b) the improved two stage route with a single intermediate.  
  
By utilizing selective catalysts in one-pot, intermediates can be further reacted 
upon without the need for protecting groups. Where the intermediates are 
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reactive species, yield losses due to degradation or side reactions can be 
reduced, as the lifetime of the intermediates will be shortened.  
As the reactions occur in one-pot with the same solvent, the process is less 
wasteful. In addition, as the reactions will be at the same temperature, heating 
or cooling the reactor is more economical. However, the catalysts must be 
active under the same conditions for this to apply. 
1.3. Disadvantages 
By combing multiple catalysts in one-pot, there is a larger probability that side 
products will be produced if the catalysts are less than perfectly selective; a 
problem which requires careful planning of the reaction sequence and 
investigation of catalytic intermediates to overcome. Biological synthesis has 
evolved to have selective catalysts; which produce key intermediates without 
side reaction or deactivation. Catalyst deactivation is more prevalent; 
therefore, previous mechanistic knowledge of the individual catalysts is 
beneficial when designing a novel multicatalysis process. 
Optimization of multicatalysis can be difficult, as it is rare that all the catalysts 
will share optimal conditions. In addition, any reagents used in the reactions 
must be tolerated by all the catalysts as well as any intermediates formed. This 
can be improved with compartmentalised catalysts in micelles or membranes 
to allow reactions to occur in different solvents.3 The substrate scope of the 
reactions can be narrow, as the substrates (and their successive 
intermediates) must be compatible with the catalysts in the desired order. In 
multicatalysis two or more catalyst species are present, therefore the 
opportunity for catalyst recovery and recycling is greatly reduced for mixed 
species; which would require subsequent separation and purification before 
reuse. This can be overcome with multifunctional catalysts that tether two or 
more catalysts together as a single species. 
1.4. Tandem taxonomy 
In the literature, many terms are used to describe the different multicatalytic 
processes and have unfortunately become interchangeable. Fogg and Santos 
attempted to clarify the different types of multicatalysis, with a more recent 
review by Patil expanding the definitions further.4, 5 Multicatalysis can be 
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subdivided into three main groups; cooperative catalysis, relay catalysis, and 
sequential catalysis (Figure 3). 
 
 
Figure 3 The definitions of the different multicatalytic processes. 
 
1.5. Cooperative Catalysis 
In cooperative catalysis, two catalysts, either separate or tethered, work 
together within the same catalytic cycle in order to catalyse a transformation 
(Figure 4).6, 7   
Multicatalysis
Sequential reactions 
with two 
mechanistically 
distinct processes
Orthogonal-Relay 
Catalysis
Two or more 
different catalysts
Cooperative Catalysis
Two catalysts that 
share the same 
catalytic cycle
Multifunctional 
Catalysis
Two orthogonal 
catalysts covalently 
tethered together as 
one species
Self-Relay Catalysis
One catalyst with 
two or more 
distinct reactions
Relay Catalysis
One or more catalysts 
that do not share 
catalytic cycles
Sequential Catalysis
Catalysts are added 
stepwise in one-pot
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Figure 4 Cooperative multicatalysis whereby catalysts A and B work together in the 
same catalytic cycle to carry out a transformation. 
 
One of the most famous examples of metal/metal cooperative multicatalysis is 
the Sonogashira coupling reaction, catalysed by a palladium catalyst 3 and a 
copper salt (Scheme 2).8 
 
Scheme 2 The Sonogashira coupling reaction; 1 (10 mmol), 2 (excess), 3 (0.5 
mol%), CuI (1.0 mol%), Et2NH (0.2 M), rt, N2, 6 h. 
  
Cooperative catalysis is useful to activate multiple functional groups in order 
to achieve transformations faster or allow previously inactive catalysts to 
function. Examples include imidazole,9 lanthanide,10, 11 cinchona/silver,12 
samarium/ mercaptan,13 palladium/copper,14 and ruthenium/palladium 
cooperative catalytic systems.15 Saicic used a proline organocatalyst with a 
palladium organometallic catalyst to generate 5- and 6-membered 
cycloalkanes via cooperative multicatalysis (Scheme 3).16 
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Scheme 3 A pyrrolidine/palladium cooperative multicatalysis process to generate a 
5-membered ring with the Tsuji-Trost reaction: 4 (0.16 mmol), Pd(PPh3)4 (5.0 mol%), 
6 (40 mol%), Et3N (1.0 eq), THF (0.3 M), rt, inert atmosphere, 30 min. 
 
1.6. Sequential Catalysis 
Sequential catalysis is a one-pot reaction with only a single catalyst present at 
the start of the reaction. The first reaction is carried out and when the end-point 
is reached, the second catalyst is added to the reaction. Further catalysts can 
be added to continue the sequence (Figure 5). 
 
Figure 5 Sequential multicatalysis, whereby the second catalyst is added to the 
reaction after the first catalysed transformation is complete. 
 
This type of multicatalysis is useful if the initial substrate can react with the 
subsequent catalysts, as undesired reactions can be avoided. However, 
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reaction monitoring must be put in place to identify the end-points; which can 
increase process time and cost. In addition, large-scale addition of a solid 
catalyst to a working reactor has practical limitations. Examples include a 
ruthenium/ytterbium,17 and a palladium/Brønsted acid/thiourea  sequential 
multicatalysis process.18 MacMillan has utilized sequential multicatalysis to 
carry out a metathesis/Mukaiyama-Michael addition/intramolecular aldol triple 
cascade, making five carbon-carbon bonds and four stereocentres in one-pot 
(Scheme 3).19  
 
 
Scheme 4 A sequential multicatalysis metathesis/Mukaiyama-Michael/aldol 
reaction. 
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1.7. Relay Catalysis 
Relay catalysis consists of one or more catalysts, present from the start of the 
reaction, with two or more distinct catalytic cycles. There are two types of relay 
catalysis: self-relay and orthogonal-relay. 
1.7.1. Self-relay 
In a self-relay multicatalysis process, only one catalyst is present in the 
reaction, which carries out different transformations on the initial substrate and 
the intermediate produced (Figure 6). 
 
 
Figure 6 Self-relay multicatalysis, whereby a single catalyst carries out two different 
sequential transformations, with two distinct catalytic cycles. 
 
Examples include: ruthenium catalysed C-H activation/Michael addition,20 
copper catalysed SNAr/denitrogenation/cyclisation,21 ruthenium catalysed 
metathesis/hydrogenation/hydrogen transfer,22 and gold catalysed 
addition/Petasis-Ferrier rearrangment using self-relay catalysis.23 Toste and 
Campbell utilized self-relay multicatalysis for an alkynylation/cyclization 
reaction sequence, with a gold triphenylphosphine catalyst (Scheme 5).24 
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Scheme 5 Self-relay multicatalysis of an alkynation/cyclization cascade for cyclic 
carbamimidates: imine (0.50 mmol), alkyne (0.60 mmol), p-TsHNCO (0.60 mmol), 
Ph3PAuCl (5.0 mol%), AgNTf2 (5.0 mol%), CHCl3 (0.2 M), 35 °C, 20 h. 
 
Problems can occur with substrates inserting into the wrong catalytic cycle and 
the reaction conditions must be balanced in order not to favour one catalytic 
transformation over the other. 
1.7.2. Orthogonal-relay 
In an orthogonal-relay catalysis process, two or more different catalysts are 
present in the reaction, which selectively react with a substrate in distinct 
catalytic cycles (Figure 7). 
 
Figure 7 Orthogonal-relay catalysis, whereby two different catalysts carry out 
sequential transformations with distinct catalytic cycles and both catalysts are 
present from the start. 
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Rovis has combined a chiral proline catalyst 24 and an NHC catalyst 25, to 
achieve a Michael addition/intramolecular crossed-benzoin orthogonal-relay 
system (Scheme 6).25  
 
 
Scheme 6 Proline and NHC catalysed Michael addition/crossed benzoin reaction in 
one-pot; proline (Ar = 3,5-(CF3)2-C6H3, 20 mol%), NHC (10 mol%), NaOAc (10 
mol%), CHCl3, 22 °C, 14 h. 
 
Examples include: a rhodium/palladium catalysed allylation/N-allylation 
sequence,26 an NHC/cinchonine catalysed oxidation/oxa-Michael addition 
sequence,27 a cobalt/ruthenium catalysed hydration/dehydrogenation 
sequence,28 and a ruthenium/proline catalysed oxidation/Michael 
addition/aldol reaction sequence.29 
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1.8. Multifunctional Catalysis 
In order to differentiate between multicatalysis and multifunctional catalysis 
(Figure 3), the following definition for multifunctional catalysis is described: a 
combination of auto-relay and orthogonal-relay catalysis, whereby a single 
molecular catalyst has two or more catalytic sites that have orthogonal 
chemical reactivities and are tethered together by a covalent bond or through 
a bridging ligand which is strongly bound to a metal centre (Figure 8).30  
 
 
Figure 8 A multifunctional catalyst, combing catalyst A with catalyst B via a covalent 
tether, which can carry out sequential reactions. 
 
Nature is by far the best example of combined catalysis, as many enzymes in 
the body work together to produce complex molecules within cellular systems. 
Enzymatic reactions do not require work-up or isolation, are very atom efficient 
and have mild reaction conditions. An example of an enzyme which carries out 
multiple reactions is Fatty Acid Synthase (FAS) (Figure 9).  
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Figure 9 The X-ray crystal structure of fungal FAS with enzymatic sites identified.31 
 
FAS is a dimer complex, which makes the enzyme more stable and allows 
intermediates to be transferred more easily from one site to the next by 
reducing the diffusion distance between catalysts. In addition, it is harder for 
intermediates to leave the enzyme complex and therefore minimises side 
reactions on route to palmitate 26 (Figure 10).32  
 
 
Figure 10 Palmitate 
 
FAS is a multifunctional enzyme used to make fatty acids in eukaryote cells. 
The three active domains on the enzyme are made up of several catalytic sites 
which are present on the polypeptide chain, which are required in sequence 
(Scheme 7). 
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Scheme 7 The catalytic cycle of FAS; i) Acetyl CoA and malonyl CoA bind to the 
acetyl transferase (AT) and malonyl transferase (MT). The acetyl group is 
transferred to the condensing enzyme (CE) and the malonyl group is transferred to 
the acyl carrier protein (ACP). ii) Addition of the acetyl group to the malonyl group 
occurs with loss of CO2. iii) The acetoacetyl group is reduced by the ketoacyl 
reductase (KR). iv) The butyryl group is translocated from ACP to CE. v) Another 
malonyl group binds to ACP and the cycle is repeated six times until palmitoyl-CE is 
formed. vi) Palmitoyl is translocated to thioesterase (TE). vii) Palmitoyl is hydrolysed 
by TE to 26 and released.32 
 
 
7 cycles
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ACP
ACP
ACP
ACPACP
ACPACP
CE
CE
CE
CE
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The disadvantages to multifunctional catalysis are: 
 The catalysts must be synthesised in advance; other multicatalysis 
processes simply combine catalysts in one-pot. 
 The catalysts must both be active under the same reaction conditions. 
 The substrate scope can be smaller than with the individual catalysts. 
 
The advantages to multifunctional catalysis are: 
 The catalysts can be easily recovered and recycled compared to mixed 
catalysts in one-pot.  
 The rate of the reaction can be increased, as the catalytic sites are in 
very close proximity to each other reducing the diffusion distance 
between catalysts. 
 Multifunctional catalysts often display a synergistic effect in contrast to 
the individual catalysts in one-pot. 
 Asymmetric transformations can also be enhanced with asymmetric 
catalysts as the close proximity of the catalysts helps to induce chirality 
of the substrates.30  
 
Schreiner demonstrated that lower catalyst and reagent loadings are a 
common benefit of multifunctional catalysis, with their organo-multifunctional 
oligopeptide/TEMPO catalyst 29 (Scheme 8).33 Compared to the analogous 
orthogonal-relay process (Scheme 9), the catalyst and reagent loadings were 
reduced by 92% and 63% respectively.34 
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Scheme 8 An organo-multifunctional catalyst to carry out catalytic desymmetrization 
and oxidation sequential reactions of 1,2-diols. 
 
 
Scheme 9 An orthogonal-relay multicatalysis process with separate TEMPO and 
oligopeptide catalysts to carry out catalytic desymmetrization and oxidation 
sequential reactions of 1,2-diols. 
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Peris has developed a series of organometallic multifunctional catalysts, which 
combined two different transition metals with a range of NHC bridging ligands 
(Figure 11). Peris displayed how difficult the design of multifunctional catalyst 
can be, by comparing bimetallic catalysts for the tandem cyclisation/alkylation 
reaction sequence towards alkylated indoles (Table 1).35 
 
 
Figure 11 Bimetallic complexes with mixtures of iridium(I)/iridium(III) and rhodium(I). 
 
The iridium(I)/iridium(III) bimetallic catalyst 34 gave the best activity and 
selectivity towards the bis-indole 41 (entry 3, Table 1). Catalyst 35 (entry 4, 
Table 1) gave poor activity and no selectivity, suggesting that the RhI(cod) 
fragment is responsible. However, the comparisons between the IrIIICp* 
fragment in catalysts 33, 34 and 35 (entries 2-4, Table 1) show contrasting 
results. Therefore, designing multifunctional catalysts requires mechanistic 
knowledge before producing an efficient catalyst system.  
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Table 1 1,2-Aminophenylethyl alcohol cyclisation/alkylation with 39 catalysed by 
bimetallic multifunctional catalysts.  
Entry Catalyst 40 (%)
a
41 (%)
a
1 32 22 73
2 33 11 73
3 34 10 86
4 35 15
b
15
b
5 36 38 57
6 37 17 41
 
a Conversions determined using 1H NMR; b Reaction time 20 h. 
 
The hetero-bimetallic complexes 35 and 42–46 were compared to the 
corresponding mixture of homo-bimetallic complexes (Figure 12).35-38 The 
combination of palladium and iridium complexes enhances the reactivity of the 
catalysts for a dehalogenation/hydrogenation reaction sequence; the 
multifunctional hetero-bimetallic catalysts, with the exception of 42, (entries 2-
5, Table 2) out perform a one-to-one mixture of the homo-bimetallic catalysts 
(entry 6, Table 2). 
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Figure 12 Hetero- and homo- bimetallic complexes reported by Peris for use in 
tandem catalysis. 
 
Table 2 Sequential dehalogenation/hydrogenation reactions catalysed by bimetallic 
complexes.  
 
Entry Catalyst 49 (%)
a
50 (%)
a
51 (%)
a
1 42 70 9 21
2 43 1 0 99
3 44 22 0 75
4 45 0 0 95
5 46 0 0 99
6 33 + 47 72 0 25
 
a Yields determined using GC. 
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A Suzuki-Miyaura/hydrogenation reaction sequence has also been carried out 
with the multifunctional catalysts; both hetero-bimetallic catalysts convert the 
starting material to product, however the yields are low (entries 1 and 2, Table 
3), and a one-to-one mixture of the homo-bimetallic catalysts only produced a 
5% yield (entry 3, Table 3). The yield with catalyst 46 was increased to 88% 
by extending the reaction time to 7 hours (entry 4, Table 3).  
 
Table 3 Sequential Suzuki-Miyaura/hydrogenation reactions catalysed by bimetallic 
complexes. 
Entry Catalyst 49 (%)
a
50 (%)
a
51 (%)
a
52 (%)
a
53 (%)
a
1 43 10 0 5 52 31
2 46 0 0 0 58 28
3 33 + 47 0 0 0 55 5
4 46 0 0 0 2
b
88
b
 
a Yields determined using GC; b Reaction time 7 hours. 
 
The palladium(II)/iridium(III) multifunctional catalyst 46 has catalysed a Suzuki-
Miyuara/α-alkylation reaction sequence and a nitroarene reduction/alcohol 
oxidation/coupling reaction sequence.39 An iridium(III)/platinum(II) 
multifunctional catalyst 54 has been utilized and shown to be more active than 
the mixed homo-bimetallic analogous reaction (Scheme 10).40 To date, there 
have been no reports of an organometallic/organo multifunctional catalyst 
system. 
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Scheme 10 1,2-Aminophenyl ethyl alcohol cyclisation/hydroalkoxylation/indole 
addition reaction sequence catalysed by a platinium(II)/iridium(III) multifunctional 
catalyst; alkyne addition after 12 hours, yield determined using GC.  
 
1.9. Hydrogen Transfer Reactions 
Transition metal catalysts have been intensively researched for 
carbonyl/imine/alkene reduction and alcohol/amine dehydrogenation through 
hydrogen transfer reactions. Hydrogen transfer is the abstraction of hydrogen 
from a hydrogen donor and subsequent addition of hydrogen to a hydrogen 
acceptor and vice versa (Scheme 11).41 
 
 
Scheme 11 Dehydrogenation of the hydrogen donor and hydrogenation of the 
hydrogen acceptor. 
 
Hydrogenation using a metal catalyst with gaseous hydrogen as the hydrogen 
source requires high pressures, high temperatures, flammable gases and 
expensive reactor set-ups. Although hydrogen gas is the most atom 
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economical method for hydrogenation reactions, using organic molecules as 
the hydrogen source is more efficient and greatly reduces the risk and cost of 
the reactions.42 In 1975, the first generation hydrogen transfer catalysts, such 
as [RuCl2(PPh3)3], gave low activity and required high temperatures (180 °C), 
with long reaction times.43 In 1991, the reactivity of [RuCl2(PPh3)3] was 
increased ten-thousand-fold with the addition of base, forming the highly 
reactive dihydro-ruthenium(II) species [H2Ru(PPh3)3], allowing the reaction to 
proceed at lower temperatures.44 
 
1.9.1. Transfer Hydrogenation 
The most common hydrogen donor system used for transfer hydrogenation 
reactions is iso-propanol, for the reduction of carbonyls and alkenes.45 The 
reverse hydrogen transfer reaction is a disadvantage, as it reduces the yield. 
However, acetone is the by-product of the reaction, which is highly volatile and 
can be easily removed to drive the equilibrium to the desired product. Transfer 
hydrogenation with a chiral catalyst, with either a chiral ligand or complex, can 
induce chirality into the products selectively. An efficient asymmetric catalyst 
is highly desirable, as many pharmaceutical molecules require specific chirality 
for selective activity with enzymes and biological receptor sites. Noyori showed 
that acetophenone 49 can be asymmetrically reduced with a chiral 
ruthenium(II) catalyst 57 to (S)-phenylethanol 51 (Scheme 12).46 
 
 
Scheme 12 Asymmetric reduction of acetophenone with a ruthenium(II) catalyst 57. 
 
Blacker has invented iridium(III) and rhodium(III) catalysts for the transfer 
hydrogenation of ketones (Scheme 13) and imines asymmetrically (Scheme 
14).47 In addition, asymmetric transfer hydrogenation of ketones in neat water, 
using CsDPEN iridium(III) catalysts was achieved (Scheme 15).48 Both 
enantiomers are accessible with the opposite ligand enantiomer. 
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Scheme 13 Asymmetric transfer hydrogenation of ketone 49 to alcohol 51 with high 
enantioselectivity using an iridium(III) catalyst 58; yield determined using GC. 
 
 
Scheme 14 An asymmetric transfer hydrogenation of imine 59 to amine 60 with high 
enantioselectivity using a rhodium(III) catalyst 61; yield determined using GC. 
 
 
Scheme 15 Ketone transfer hydrogenation in neat water with an iridium(III) catalyst 
62. Cs = camphor sulfonyl. 
 
Stradiotto achieved ketone transfer hydrogenation with zwitterionic 
ruthenium(II) catalyst 63 at very low catalyst loadings (0.05 mol%) with short 
reaction times (5 min), but without asymmetric induction.49  
 
Scheme 16 Ketone transfer hydrogenation with a zwitterionic ruthenium(II) catalyst. 
 
 
 
 27 
 
Mathey and Le Floch achieved ketone reduction (Scheme 17) with an 
extremely low catalyst loading (5 ×10-6 mol%).50 
 
Scheme 17 Ketone transfer hydrogenation with a phosphole ruthenium(II) complex 
at 5 ×10-6 mol% catalyst loading. 
 
A hydrogen donor system where the reverse reaction cannot occur can be 
achieved using a TEAF solution (2:5 triethylamine/formic acid), whereby formic 
acid is the source of hydrogen, producing gaseous carbon dioxide which 
makes the reaction essentially irreversible. However, the reaction scope is 
limited by the acidic nature of the conditions, which may degrade certain 
catalysts, substrates and/or reagents. Ikariya has utilized this system for the 
asymmetric reduction of ketones with an arene tethered catalyst 65 (Scheme 
18).51 
 
 
Scheme 18  Asymmetric reduction of a carbonyl with formic acid using a 
ruthenium(II) catalyst 65. 
 
Imines, which are protonated prior to reduction, can be also be reduced to 
amines asymmetrically with the TEAF system (Scheme 19).52  
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Scheme 19 Asymmetric reduction of a secondary imine with TEAF using a 
ruthenium(II) catalyst 66. 
 
1.9.2. Transfer Dehydrogenation 
A transfer dehydrogenation reaction is the abstraction of hydrogen from a 
substrate by the metal catalyst and its subsequent transfer to a hydrogen 
acceptor.53 Acetone is a commonly used hydrogen acceptor which produces 
iso-propanol as a by-product. As with transfer hydrogenation reactions, the 
reverse reaction with iso-propanol can result in lower product yields. Fujita and 
Yamaguchi carried out the transfer dehydrogenation of primary alcohols with 
acetone as the hydrogen acceptor (Scheme 20).54  
 
 
Scheme 20 The transfer dehydrogenation of 39 with acetone as the hydrogen 
acceptor using iridium(III) chloride dimer 36; yield determined using GC. 
  
Blacker, Marsden and Williams have prepared benzimidazoles by unlocking 
the reactivity of alcohols through transfer dehydrogenation with a 
ruthenium(II)/xantphos 71 catalyst. Crotonitrile was used as the hydrogen 
acceptor (Scheme 21).55 
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Scheme 21 Synthesis of a substituted benzimidazole from the dehydrogenation of a 
primary alcohol; yield determined using GC. 
 
Williams has combined the ruthenium(II) complex [Ru(PPh3)3COH2] and 
biphopshine ligand 71 in combination with a silica supported amine catalyst to 
carry out a transfer dehydrogenation reaction followed by a cross coupling of 
primary alcohols (Scheme 22).56  
 
Scheme 22 Synthesis of substituted α,β-unsaturated aldehydes. 
 
Transfer dehydrogenation of the alcohol substrate is necessary to generate 
electrophiles in order to achieve the cross-coupling. An excess of 
crotononitrile, the hydrogen acceptor, is required for the reaction, otherwise 
the reaction does not occur. Fujita and Yamaguchi carried out the acceptorless 
dehydrogenation of secondary alcohols, with the aim of improving atom 
economy, releasing hydrogen gas from the reaction (Scheme 23).57  
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Scheme 23 An acceptorless secondary alcohol dehydrogenation using an 
iridium(III) catalyst; yield determined using GC. 
 
1.9.3. Hydrogen Borrowing 
After a dehydrogenation reaction, the metal catalyst stores the abstracted 
hydrogen until a suitable hydrogen acceptor is available. However, the stored 
hydrogen can be returned to the substrate following an intermediate 
transformation. The catalyst effectively ‘borrows’ the hydrogen using hydrogen 
transfers.58 By dehydrogenating an alcohol substrate, unlocking a more 
reactive carbonyl functional group, intermediate transformations can be more 
easily performed.59 As both the hydrogen donor and the hydrogen acceptor 
are incorporated into the product, the reactions have excellent atom economy. 
Watanabe performed the catalysed N-alkylation of amines using a rhodium 
catalyst (Scheme 24).60 
 
 
Scheme 24 Substituted morpholine synthesis using hydrogen borrowing with 
intermediate imine formations. 
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Williams has utilized the hydrogen borrowing methodology for an indirect Wittig 
reaction (Scheme 25),61 and as a substitute for alkyl halides in the synthesis 
of Pheniramine 86 (Scheme 26) and Piribedil 90 (Scheme 27).62 
 
 
Scheme 25 Hydrogen borrowing and intermediate Wittig reaction to produce an 
alkane from an alcohol; 84 (1.0 mol%), 81 (1.1 eq), CH2CHSiMe3 (2.0 mol%), PhMe 
(1.0 M), 80 °C, 24 h. 
 
 
Scheme 26 Synthesis of antihistamine drug Pheniramine 87, using hydrogen 
borrowing with an intermediate imine formation. 
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Scheme 27 Synthesis of dopamine agonist drug Piribedil 91, using hydrogen 
borrowing with an intermediate imine formation. 
 
Zhao prepared a quinoline asymmetrically with a hydrogen borrowing method 
involving an intramolecular cyclisation step (Scheme 28).63 Taddei has 
coupled primary and secondary alcohols with a ruthenium(II) catalyst through 
an intermediate aldol elimination (Scheme 29).64 
 
 
Scheme 28 An asymmetric quinolone synthesis, using hydrogen borrowing with an 
intermediate intramolecular imine formation step. 
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Scheme 29 Cross-aldol elimination reaction between reduced primary and 
secondary alcohols with a final alkene transfer hydrogenation; yield determined 
using GC. 
 
Leonard, Blacker and Marsden reported the use of hydrogen borrowing 
methodologies with iridium(III) and ruthenium(II) catalysts to improve the 
synthesis of pharmaceutically relevant intermediates towards anithepatitis 
drug 99 (Scheme 30), muscarinic antagonist 100 (Scheme 31) and 
antiproliferative drug 101 (Scheme 32).65 The routes previously used alkyl 
halides or α-halo-carbonyls to achieve the desired intermediates, which are 
more hazardous and inefficient reagents. However, the use of hydrogen 
borrowing requires high temperatures, large catalyst loadings and often 
aromatic solvents; which may not transfer to large scale projects easily. 
 
 
Scheme 30 Improved route to intermediate 104 for the synthesis of anithepatitis 
drug 99. 
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Scheme 31 Improved route to intermediate 107 for the synthesis of muscarinic 
antagonist 100. 
 
Scheme 32 Improved route to intermediate 108 for the synthesis of antiproliferative 
drug 101. 
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1.10. Organocatalysis 
Many metal catalysts are strictly regulated in order to ensure that any metal 
contaminants in pharmaceutical drug products remain below toxic levels 
(Table 4).66 
 
Table 4 The concentration limits for human exposure to metal residues in 
pharmaceutical drug products.66 
Oral Exposure Parenteral Exposure
Class 1A:
Pt, Pd
Class 1B:
Ir, Rh, Ru, Os
Class 1C:
Mo, Ni, Cr, V
Class 2:
Cu, Mn
Class 3:
Fe, Zn
Classification
Concentration (ppm)
a
10 1
10 1
25 2.5
250 25
1300 130
 
a The concentration limits are based on the permitted daily exposure (μg/day) 
divided by the daily dose (g/day) for an assumed daily dose of 10 grams of the drug 
product. 
 
In order to remove impurities, extra scavenging and purification steps are 
added to syntheses; increasing plant time and costs at scale. An advantage 
for using organocatalysts is that the issue of metal contamination is avoided. 
However, the turnover numbers (TON) for these catalysts are low, so high 
catalyst loadings (10–30 mol%) are normally required for these reactions (cf. 
iridium/ruthenium catalysts; see 1.9.1). On the other hand, organocatalysts 
can be inexpensive compared to precious metal catalysts, which still makes 
them attractive. Primary and secondary amines are used as catalysts for a 
range of reactions, many of which use chiral amines to induce high 
enantioselectivity in the products. Stork showed that an amine can be used to 
catalyse the aldol reaction, where the amine forms an enamine, which raises 
the HOMO of the nucleophile making it more susceptible to electrophilic attack 
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(Scheme 33).67 Hayashi reported using chiral amines, such as amino acids L-
alanine 109, L-valine 110 and L-leucine 111, to give enantiomeric products 
(Scheme 34).68 Lu used amine catalysts for the Mannich reaction (Scheme 
35).69  
 
 
Scheme 33 Reaction mechanism for amine catalysed aldol reaction. 
 
 
Scheme 34 The aldol reaction of cyclohexanone 113 and p-nitrobenzaldehyde 112 
catalysed by L-alanine 109, L-valine 110 and L-leucine 111.  
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Scheme 35 Aminoacid catalysed Mannich reaction. 
 
Jacobsen reported an amine catalyst for Michael addition reactions to 
nitroalkenes (Scheme 36).70 
 
 
Scheme 36 Amine catalysed Michael addition reaction. 
 
N-Heterocyclic carbenes (NHCs) are a useful class of compounds, mainly 
used as ligands for organometallic reactions. However, the electronic and 
steric stability of these carbenes means they are excellent as organocatalysts, 
as they have dual modes of action; good electron acceptors and good electron 
donors.71, 72  NHCs are easily generated with a base (Scheme 37).  
 
 
Scheme 37 Activation of an NHC with a base; Y = CH, N; Z = NR, S; X = halide, 
BF4
–
, PF6
–
; R = alkyl, aryl. 
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The electronic and steric properties of NHCs can easily be tuned by altering 
the substituents on the heteroatoms and on the backbone of the ring. For 
organocatalysis, the nucleophilic strength of NHCs makes them useful 
catalysts for electrophilic addition to aldehyde groups. The electron 
withdrawing ability of NHCs can decrease the pKa of the ‘aldehyde’ proton, 
reversing the reactivity of the group and allowing umpolung reactions with 
electrophiles (Scheme 38).  
 
 
Scheme 38 Formation of an enamine type intermediate for attack onto electrophiles 
during NHC catalysis. 
 
The pKa of the C-2 position is important in catalysis, as deprotonation is 
essential for generating a carbene for an active catalyst (Figure 13). The more 
acidic the C-2 position, the milder the base required for the reactions. 
O’Donoghue and Smith have reported on the pKa values of triazolium, 
imidazolium and thiazolium salts (Figure 13).73  
 
 
Figure 13 The approximate pKas of the different types of NHC catalysts. 
  
1.10.1. Thiazolium Catalysts 
Thiamine pyrophosphate (TPP) 124 (Figure 14) is the catalytic cofactor used 
by the pyruvate dehydrogenase enzyme, which carries out the oxidative 
decarboxylation of pyruvate 125 (Scheme 39). 
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Figure 14 Thiamine pyrophosphate (TPP) 113. 
 
A key feature of the thiamine structure is a more acidic proton (pKa = 17.7) 
between the nitrogen and the sulfur of the thiazolium ring.74 Deprotonation 
generates a nucleophilic anion, which can then attack pyruvate 125.  
 
Scheme 39 The catalytic cycle for the decarboxylation of pyruvate 125 using TTP 
124, producing an -hydroxyketone 126; i) substrate binding; ii) decarboxylation; iii) 
benzoin condensation; iv) product release.  
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After decarboxylation, an activated intermediate is generated, due to the 
positive charge on the N-atom acting as an electron sink, which promotes a 
negative charge on the carbonyl carbon. The acetyl group is then transferred 
to a lipoamide molecule, generating a acetyllipoamide, which goes on to make 
acetyl CoA. In place of a lipoamide, addition of an aldehyde would generate 
an α-hydroxyketone.  
 
TPP is a cofactor for the transketolase enzyme (Scheme 40), which is the 
terminal catalyst in the fatty acid synthase complex. The thiazolium anion 
attacks the ketose substrate 127 and a retro-benzoin condensation reaction 
occurs, resulting in the loss of an aldehyde group. The activated glycoaldehyde 
Breslow intermediate carries out a benzoin condensation reaction with a 
suitable aldehyde to generate a new ketose product 128, which is then 
released.  
 
 
Scheme 40 Transketolase enzymatic cycle; i) substrate binding; ii) retro-benzoin 
condensation; iii) benzoin condensation; iv) product release. 
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The Buck reaction uses potassium cyanide (25 mol%) to catalyse the benzoin 
condensation in vitro.75 Ugai showed that the benzoin condensation can also 
be catalysed by thiazolium catalysts.76 Breslow achieved the benzoin 
condensation of benzaldehyde with a simple thiazolium catalyst whilst 
developing the mechanistic understanding of the reaction (Scheme 41).77 
Bode has used a thiazolium catalyst for an intramolecular benzoin 
condensation (Scheme 42).78 
 
 
Scheme 41 The benzoin condensation of 67 with a simple thiazolium catalyst 130; 
the yield was only qualitatively determined. 
 
Scheme 42 An intramolecular benzoin condensation catalysed by a thiazolium 
catalyst 133. 
 
1.10.2. Triazolium Catalysts 
O’Donaghue has investigated the acidity of the heterocyclic C-H of triazolium 
compounds (Figure 15), which are more acidic than analogous thiazolium and 
imidzolium heterocycles (Figure 13).73 
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Figure 15 The pKas (in parentheses) for a range of triazolium heterocycles; 
determined from the rate constants for deuterium exchange, in deuterium oxide at 
25 °C, and measured using 1H NMR. 
 
The structural variations of the triazolium catalysts help to account for the trend 
in the pKa values. A more electron withdrawing N-aryl substituent reduces the 
pKa of the triazolium catalyst (25<134<135). Incorporation of an oxygen atom 
in the aliphatic ring also reduces the pKa (134<136), whereas a silyl side chain 
causes an increase in pKa (137<138). Bode carried out a homo-benzoin 
condensation with a triazolium catalyst (Scheme 43).79  
 
 
Scheme 43  Triazolium catalysed homo-benzoin condensation. 
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O’Donoghue has carried out a cross-benzoin reaction which has produced 
three products (Scheme 44).80 
 
Scheme 44 A triazolium catalysed cross-benzoin condensation, producing a mixture 
of cross- and homo- coupled aldehydes; product ratio determined using 1H NMR 
spectroscopy. 
 
Zeitler and Connon showed that a cross-benzoin condensation can be 
catalysed by a triazolium catalyst (Scheme 45).81 Enders has used chiral 
triazoliums for asymmetric homo-benzoin condensations (Scheme 46).82 The 
Stetter reaction is another useful reaction between aldehydes and α,β-
unsaturated carbonyls that can be catalysed by triazolium catalysts (Scheme 
47).83 
 
 
Scheme 45 The triazolium catalysed cross-benzoin condensation. 
  
 
Scheme 46 Triazolium catalysed asymmetric benzoin condensation. 
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Scheme 47 Triazolium catalysed Stetter reaction. 
 
1.11. Summary 
The research reviewed in this chapter has covered multicatalysis, with a 
particular emphasis on multifunctional catalysis, organometallic catalysts for 
hydrogen transfer reactions and organocatalysed benzoin condensation 
reactions. The work shows potential for a multifunctional catalyst combining an 
NHC organocatalyst with an organometallic hydrogen transfer catalyst to 
achieve sequential reactions. 
  
 45 
 
1.12. Aims and Objectives 
The aim of this project was to design and synthesise novel ligands and 
iridium(III) complexes that combine organo and organometallic catalysts, and 
use these complexes to carry out multifunction catalysis for sequential 
reactions. 
 
The proposed multicatalytic cycle involves two hydrogen transfer reactions, 
that can be catalysed using an iridium(III) organometallic catalyst (see Chapter 
1.9), and a benzoin condensation, that can be catalysed using a thiazolium or 
triazolium organocatalyst (see Chapter 1.10). The proposed pathway is as 
follows (Scheme 48): 
i. The catalytic cycle begins with the transfer dehydrogenation of two 
primary alcohols by the organometallic catalyst. 
ii. The thiazolylidene catalyst attacks one of the resulting aldehydes. 
iii. The second aldehyde is attacked by the Breslow intermediate to form 
the α-hydroxyketone from the benzoin condensation. 
iv. Transfer hydrogenation of the -hydroxyketone produces the 1,2-diol. 
 
 
Scheme 48 Proposed multicatalytic cycle; i) transfer dehydrogenation, ii) Breslow 
intermediate formation, iii) benzoin condensation, iv) transfer hydrogenation. 
 
With this reaction sequence, it could also be possible to exploit hydrogen 
borrowing methodology; eliminating the need for hydrogen acceptors/donors 
(Scheme 49) (see Chapter 1.9.3).61 
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Scheme 49 Proposed catalytic cycle with hydrogen borrowing methodology; i) 
transfer dehydrogenation, ii) benzoin condensation, iii) transfer hydrogenation. 
 
With a successful system, the rates of catalysis will be compared against the 
rates for the separate catalysts and the scope of the reaction will be 
investigated. With different alcohols or amines, cross-benzoin products could 
be achieved. NHC organocatalysts are active catalysts for a wide range of 
reactions, therefore the reaction scope can be expanded; such as 
decarboxylation reactions of carboxylic acids and the Stetter reaction between 
α,β-unsaturated carbonyls and aldehydes.  
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2. Synthesis of Novel Thiazole and Triazole Iridium(III) 
Complexes 
2.1. Introduction 
The review of multicatalysis in Chapter 1 covered the use of organometallic 
catalysts, organocatalysts and combinations of the two within the same 
reaction creating a positive synergistic effect. There is an absence in the 
literature for the use of a multifunctional catalyst combining an organometallic 
catalyst and an organocatalyst in a single species. In this chapter, the design 
ideas behind the development of an organo/organometallic multifunctional 
catalyst and the synthetic routes to the complexes that fit the design objectives 
will be discussed.  
2.1.1. Functional Groups Targeted for Sequential Reactions  
Pharmaceutical molecules that contain a 1,2-diol, 1,2-ketoalcohol, 1,2-
aminoalcohol or a 1,2-ketoamine groups (Figure 16) can have synthetic routes 
that are long, use stoichiometric toxic reagents or expensive catalysts. A route 
to Formoterol, a long acting β2-agonist (LABA), involves the synthesis of an α-
haloketone, an asymmetric borohydride reduction, and two hydrogenations 
over precious metal catalysts (Scheme 50).84, 85 Another example of 1,2-diol 
formation from two alcohols involves a Wittig reaction and subsequent 
dihydroxylation with osmium tetroxide (Scheme 51).86, 87  
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Figure 16 Pharmaceuticals containg a 1,2-diol, 1,2-aminoalcohol or 1,2-ketoamine 
group. 
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Scheme 50 A 100 g scale synthetic route to long acting β2-agonist Formoterol. 
Conditions: i) Br2 (1.0 eq), (PhCO2)2 (1 mol%), CHCl3 (0.4 M), rt. ii) 152 (5 mol%), 
BH3•Me2S (0.7 eq), THF (0.3 M), 25 °C, 3 h. iii) PtO2 (2 mol%), H2, 45 psi, 
THF/Toluene (1:1, 0.7 M), 8 h. iv) HCO2H (2.0 eq), Ac2O (1.5 eq), 15 °C, 0.3 h.v) 
153 (0.95 eq), K2CO3 (2.5 eq), THF/MeOH (1:1, 0.3 M), 25 °C, 2 h. vi) neat, 120 °C, 
24 h. vii) Pd/C (10% Pd), H2, 45 psi, EtOH (0.5 M), 3 h. viii) fumaric acid (0.5 eq), 
reflux, 2 h. 
 
Both of these routes to 1,2-aminoalcohols are long, which increases yield 
losses between steps and overall reaction times, and use stoichiometric 
reagents which form large amounts of by-product; such as phosphine, boron 
and osmium waste.  
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Scheme 51 A synthetic route to D-ribo-phytosphingosine. Conditions; i) H2SO4, HBr. 
ii) PPh3 (1.1 eq), MeCN (0.3 M), reflux, 30 h. iii) DMSO (2.5 eq), oxalylchloride (1.2 
eq), Et3N (4.0 eq), DCM (0.3 M), –78 °C, 2 h. iv) LiHMDS (1 M in THF), THF (0.3 M), 
rt, 2 h. v) OsO4 (5 wt% in H2O, 0.1 eq), NMO (3.0 eq), acetone/H2O (9:1, 0.1 M), 0 
°C, 4 h. vi) AcOH (5.0 eq), DCM (0.3 M). vii) KOH (3.0 eq), EtOH (0.3 M), rt, 8 h. viii) 
Pd(OH)2 (20 wt%), H2, 100 psi, EtOH (0.3 M), rt. 
 
2.1.2. Design of the Multifunctional Catalyst 
To design a multifunctional catalyst, the reaction sequence has to be selected, 
so that the catalysts can be chosen for each step and then both catalysts can 
be connected together to form a single species. The simplest retrosynthetic 
disconnection of a 1,2-diol is the carbon-carbon bond, to give two aldehydes 
as synthetic equivalents (Scheme 52). 
 
 
Scheme 52 Retrosynthetic analysis of a 1,2-diol. 
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The chosen reaction sequence was the dehydrogenation of primary alcohols 
and the sequential benzoin condensation of the aldehyde intermediates to 
produce an α-hydroxyketone, which can undergo a further hydrogen transfer 
reaction to the generate a 1,2-diol. The overall transformation is a carbon-
carbon bond formed between two identical or different primary alcohols in a 
multicatalytic one-pot reaction (Scheme 53). 
 
 
Scheme 53 Outline of the reaction sequence, with each step catalysed by the same 
multifunctional catalyst. 
 
Aldehydes are good electrophiles and can easily form unwanted impurities 
during reactions. By generating the aldehydes in situ, impurity formation can 
be avoided; these occur during the work-up, isolation and purification stages 
of a synthesis. Thiazolium salts will catalyse the benzoin/acyloin condensation 
of two aldehydes to make 1,2-diols, or similarly an aldimine and aldehyde can 
be condensed to form 1,2-aminoalcohol.77,78 Enders has reported the use of 
organocatalysis to produce 1,2-ketoamines.88 Since the multifunctional 
catalyst has two active sites tethered in close proximity to each other, the 
diffusion distance between both sites is shorter; therefore the reactive 
aldehyde intermediates might be converted at a faster rate, limiting the number 
of unwanted side reactions. 
 
With the reaction sequence decided upon, the next step was to design the 
multifunctional catalyst. Three main factors have guided the design of the 
multifunctional complexes that are discussed in this chapter; tether length, 
organocatalyst acidity, and ligand coordination properties.   
1. To make a multifunctional catalyst, both catalysts must be covalently 
tethered together, or have a strong coordination to a metal.  The length and 
geometry of the tether will affect the rate of reaction and the ability of the 
two catalysts to interfere with each other’s catalytic cycle. Ideally, a short 
covalent tether would minimise the diffusion distance between catalytic 
sites and lead to improved kinetics. Since NHCs form strong carbene-metal 
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σ-bonds, if the tether were too flexible the carbene generated on the 
organocatalyst might prefer to coordinate to the metal centre and block 
both activities. Therefore, the organocatalyst should be prevented from 
binding to the metal centre by constraining the geometry (Scheme 54). 
 
 
Scheme 54 Inhibition of the organocatalyst via stong carbene-metal bond. 
 
A long, rigid tether would hold the carbene away from the metal, however 
this might encourage dimerization. The heterocycle might employ a donor 
atom to coordinate to the metal and geometrically prevent carbene-
coordination (Scheme 55). 
 
 
Scheme 55 The locked position of the organocatalyst, preventing carbene-metal 
bond formation. 
 
2. In order for the multifunctional catalyst to work, both catalysts must be able 
to exist in their activated states. To activate the organocatalyst, the thiazole 
ring must first be deprotonated to generate the active carbene species. This 
requires the pKa of the thiazole to be low enough to enable the use of a 
weak base. Thiazoles are weak acids (pKa ~28), however N-alkylated 
thiazolium species create an electron sink on the N-atom of the ring making 
the C-2 position acidic (pKa ~17–19). It was thought that coordinating the 
heterocycle to the metal centre via the N-donor atom would create a 
pseudo-thiazolium, or triazolium species, which should have an increased 
C-2 proton acidity (Figure 17). 
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Figure 17 Proposed design of the organocatalyst to increase the acidity of the ring;  
a) pseudo-thiazolium, and b) pseudo-triazolium. 
 
There are only a few examples of complexes that have thiazoles89-92 
(Figure 18) or triazoles93-95 (Figure 19) coordinated to iridium, ruthenium 
or rhodium metal centres via the heteroatom donors. 
 
 
Figure 18 Examples of iridium(III)89, ruthenium(II)90, 91 and rhodium(I)92 complexes 
that have 1,3-thiazole ligands coordinated to the metal via a N-donor. 
 
 
Figure 19 Examples of ruthenium(III)93 and ruthenium(II)94, 95 complexes that have a 
1,2,4-triazole ligand coordinated to the metal via a N-donor. 
 
3. In order for the iridium to be active, the number of labile and vacant sites 
on the metal centre of the organometallic catalyst could affect the rate of 
the hydrogen transfer reactions. If the complex was coordinatively and 
electronically saturated as an 18-electron species, a hemi-labile ligand 
would have to disassociate to allow the 16-electron species to accept 
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hydrogen from the substrate. Conversely, increasing the number of donor 
sites on the ligand will increase the chelate effect to the metal and improve 
the structural robustness of the multifunctional catalyst. Tridentate, 
bidentate and monodentate ligands have also been designed and 
synthesised in this chapter. 
 
2.2. Control Catalysts 
2.2.1. TsDPEN and CsDPEN Iridium(III) Complexes 
For comparison of catalytic activity, TsDPEN and CsDPEN iridium(III) 
complexes (R,R)-161 and (S,S,S)-62 were prepared with iridium(III) chloride 
dimer 36 (Scheme 56), as both are known in the literature for hydrogen transfer 
reactions with alcohols and aldehydes/ketones (see Chapter 1.9).47 
 
 
Scheme 56 The preparation of known iridium(III) complexes; a) (R,R)-161, and b) 
(S,S,S)-62.47 
 
2.2.2. Benzyl Tethered TsDPEN Iridium(III) Complex 
To use as a control study, to compare to the catalysis of a thiazole-tethered 
ligand, a non-coordinating benzene-tethered ligand was prepared following a 
literature procedure.96 Transforming the primary amine, which has been shown 
to be important in the bifunctional outer-sphere mechanism of the hydrogen 
transfer reaction (see Chapter 1.9), into a secondary amine could affect the 
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hydrogen transfer reactions. In addition, the presence of the benzene ring 
could influence the steric interactions of the reaction. The control ligand 164 
was prepared via the reductive amination of benzaldehyde 67 with (R,R)-
TsDPEN 162 (Scheme 57). 
 
 
Scheme 57 Synthesis of N-benzyl control ligand (R,R)-164. 
 
The intermediate was formed as a mixture of the imine and cyclic aminal 165, 
which was shown using 1H NMR to fully convert to the imine 166 over time 
(Scheme 58).  
 
 
Scheme 58 Conversion of cyclic aminal 165 to the imine 166. 
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Figure 20 Stacked 1H NMR spectra showing the conversion of intermediates over 
time; a) 1.5:1 mixture of aminal 165 and imine 166, b) 3.2:1 mixture of imine 166 
and aminal 165, c) amine ligand 164.  
 
In 2008, Wills prepared benzyl TsDPEN ligand 164,97 and in 2009 prepared a 
ruthenium(II) complex 167 from the ligand for the asymmetric transfer 
hydrogenation of acetophenone 49 (Figure 21).98 The analogous iridium(III) 
complex 168 was prepared from the iridium(III) chloride dimer 36 (Scheme 59). 
 
Figure 21 Wills’ ruthenium(II) complex 167 with ligand 164. 
 
 
Scheme 59 Preparation of benzyl tethered TsDPEN iridium(III) catalyst 168. 
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2.2.3. Thiazolium Control Catalyst 
A simple thiazolium compound was synthesised to use as a control catalyst for 
the benzoin condensation reaction and investigate the reaction conditions of 
the organocatalysis, from the neat reaction of 4-methyl-1,3-thiazole 169 and 
bromoethane (Scheme 60). 
 
 
Scheme 60 Synthesis of 4-methyl-3-ethylthiazolium bromide 130. 
 
2.3. Synthesis of Thiazole and Thiazolium Iridium(III) 
Complexes 
The synthesis of novel thiazole and thiazolium complexes is discussed in this 
section. The synthetic routes to the ligands designed were based on simple 
reactions in order to arrive at new ligands in a small number of steps. There 
are many catalyst systems reported in the literature that give high conversions 
and selectivities; however, if the synthesis of the ligand or catalyst is long and 
complicated the overall efficiency of the catalyst is reduced. Zhou reported an 
asymmetric catalyst 172 for the hydrogenation of ketimines in very high 
conversions and enantioselectivities (Scheme 61); however, the synthesis of 
the ligand required 13 steps and a resolution. 99 
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Scheme 61 The hydrogenation of ketimine 170 with Zhou’s expensive catalyst 172 
with high conversion and enantioselectivity. 
 
The preparation of 1,3-thiazoles synthesised from α-haloketones and 
thioformamides or thioalkylamides have been reported in the literature 
(Scheme 62).100-103 However, the use of α-haloketones (especially 
dichloroacetone 173) is often undesirable due to the high toxicity of these 
compounds. Using thioalkylamides is safer than thioformamides, however the 
C-2 position of the thiazole ring would be substituted, which would prevent 
carbene formation and organocatalysis.  
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Scheme 62 Examples of the reported synthetic routes to thiazole rings.   
 
A thiazole ring with an aldehyde substituent in the 4-position would create a 
single methylene unit tether from a simple reductive amination reaction with an 
existing amine ligand, such as TsDPEN 162. The 5-membered ring iridicycle 
would prevent carbene-metal bond formation (Figure 22). 
 
 
Figure 22 A 5-membered iridicycle highlighting the prevention of thiazolylidene 
coordinating to the metal centre. 
2.3.1. Synthesis of 1,3-Thiazole-4-carboxaldehyde 184 
As the most reactive position is the C-2 position, beginning a synthesis with a 
thiazole ring can be difficult. Therefore, commercially available thiazoles that 
are substituted on the 4- or 5-position, with the 2-position unsubstituted, 
formed the basis of the preparation of the thiazole ligands. Ethyl-4-
thiazolecarboxylate 183 was converted to 4-thiazolecarboxaldehyde 184 
through an ester reduction with DIBAL-H. With a standard acidic work-up, the 
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major product in the reaction was the alcohol 185, as a result of over-reduction. 
Jamison investigated the reduction of esters to aldehydes in continuous flow 
using 1.5 equivalents of DIBAL-H and a methanol quench,104 however using 
the same conditions in batch the over-reduction was still observed (entry 1, 
Table 5). 
 
Table 5 The selectivity of the reduction of ethyl-4-thiazolecarboxylate 183  to the 
product aldehyde 184 by varying the number of equivalents of DIBAL-H.  
 
 
a Distribution calculated from the integration of signals in the 1H NMR spectra. 
 
This suggests that there is an 83% excess of available hydrides for the 
reaction. As only a 50% excess is used in the reaction, it is proposed that 
DIBAL-H was transferring multiple hydrides (Scheme 63); one hydride from 
the Al-H bond and up to two hydrides from the methine C-H bonds of the iso-
butyl groups, generating iso-butene 186. In a similar example, Makio and Fujita 
demonstrate the reduction of imines with a TRIBAL reagent and observe iso-
butene 186 during the reaction.105 With 0.75 equivalents of DIBAL-H (entry 3, 
Table 5) only the aldehyde 184 is formed and with an isolated yield of 92%. 
 
Ester Aldehyde Alcohol 
1 1.50 0 17 83
2 0.95 0 25 75
3 0.33 93 7 0
4 0.50 14 86 0
5 0.75 0 100 0
Entry
DIBALH 
(x eq)
Product Distribution (%)
a
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Scheme 63 Mechanism of further hydride transfer over-reducing the ester 183 to 
the alcohol 185 and producing iso-butene 186. 
 
In 1987, Dondoni reported a route to 184 from inexpensive starting material 4-
bromo-2-(trimethylsilyl)-thiazole 187 (Scheme 64).106 After carrying out the 
reaction following Dondoni’s procedure, a low yield of the desired aldehyde 
was achieved (12% using 1H NMR) and this route was disregarded after two 
attempts. 
 
 
Scheme 64 The formylation of thiazole and subsequent TMS deprotection to 
aldehyde 184. 
 
2.3.2. Thiazole Tethered TsDPEN Iridium(III) Complex C.1 
The thiazole-tethered TsDPEN ligand L.1 was prepared from (R,R)-162 and 
184 via reductive amination reaction using sodium borohydride. As with the 
control ligand 164, the intermediate from the condensation reaction is a 
mixture of the imine 188 and the cyclic aminal 189, which fully converts over 
time to 188 (identified using 1H NMR, Figure 23). The imine 188 was then 
reduced to the desired ligand L.1 with sodium borohydride (Scheme 65). 
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Scheme 65 Synthesis of thiazole-TsDPEN ligand L.1. 
 
 
Figure 23 Stacked 1H NMR spectra showing the conversion of intermediates; a) 
mixture of cyclic aminal 189 and imine 188 (t= 0 h), and b) imine 188 (t= 16 h). 
 
In addition to the reductive amination route, L.1 was prepared with 4-
(chloromethyl)-1,3-thiazole hydrochloride 180 (Scheme 66). The yield of the 
SN2 reaction was lower than expected. This could be due to the solubility of 
the thiazolium salt in the reaction; however, an experiment with the salt 
separated into an organic layer before addition into a similar reaction also gave 
a low yield. The structure of ligand L.1 was determined by x-ray crystallography 
(Figure 24). 
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Scheme 66 The synthesis of thiazole ligand L.1 from thiazole hydrochloride 180. 
 
 
Figure 24 The x-ray crystal structure of thiazole tethered TsDPEN ligand L.1 with 
non-hydrogen atoms displayed as displacement ellipsoids, which are set at the 50% 
probability level. Hydrogen atoms have been removed for clarity. There are two 
molecules in the asymmetric unit cell, which differ in the direction of the tosyl group. 
 
With the novel thiazole ligand in hand, an iridium(III) complex C.1 was 
synthesised (Scheme 67). The target complex C.1 was prepared via ligand 
substitution of thiazole L.1 with 36; which was achieved by Blacker with 36 and 
analogous ligands.47 
 
 
Scheme 67 Preparation of target catalyst C.1. 
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The complex C.1 was identified using mass spectrometry; however, 1H NMR 
indicated two different species, C.1.1 and C.1.2, were present in a ratio of 3:1 
(Figure 25). 
 
 
Figure 25 1H NMR spectrum of C.1, showing two distinct sets of signals for C.1.1 
and C.1.2 in a ratio of 3:1 respectively. 
 
The reason behind the mixture of complexes could be that there are two 
diastereomeric complexes, as the 4-coordinate metal centre could be acting 
as a stereocentre. An optically impure batch of (R,R)-162 would result in 
diastereomers being produced in the reaction, therefore the specific rotation of 
the batch was measured and agrees with literature values ([α]D25 = –35°).107 
Another possibility is that the complex exists as two rotamers, with the 
tridentate ligand coordinating to the metal centre in two conformations. The 
energy of each of the rotamers will define the ratio in which they are present 
in the sample; there may also be conversion between them. However, as the 
ligand is tridentate, the chelating effect would make interconversion less likely. 
Molecular modelling of the two rotamers using DFT B3LYP/LANL2DZ 
suggests a ratio of complex C.1.1 to complex C.1.2 as 9:1 from the relative 
energies (E = 2.75 kcal mol-1) (Figure 26).  
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Figure 26 Molecular modelling of the two rotamers of the iridium(III) catalyst C.1.1 
and C.1.2 with a calculated ratio of 9:1 respectively using DFT B3LYP/LANL2DZ. 
 
2.3.3. Thiazole Tethered Iridium(III) Complex C.2 
The attempted preparation of thiazole tethered CsDPEN ligand L.2 was carried 
out in the same way as for the thiazole-tethered ligand L.1 (Scheme 68). 
 
 
Scheme 68 Synthesis of thiazole tethered ligand L.2. 
 
After the reduction of the imine intermediate, the ketone of the camphor group 
was found to have been reduced during the reaction. This was identified by 
C.1.1 C.1.2
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the absence of the characteristic signal (215 ppm) correlating to the highly 
strained ketone in the 13C {1H} NMR spectrum. The benzoin reaction could 
occur at the ketone,108 however the distance between the thiazole catalyst and 
the camphor group should prevent this. The reduction of the ketone group 
could produce two isomers; however, the iso-borneol will be the major product 
with the alcohol in the equatorial position, as this is the kinetic product of the 
irreversible reaction with axial attack from sodium borohydride opposite to the 
bulky gem-dimethyl group.109 The iridium(III) complex could theoretically 
reduce the ketone group via a transfer hydrogenation reaction, which has been 
discussed by Blacker to improve the enantioselectivity of transfer 
hydrogenation reactions; the camphor sulfonyl group is asymmetrically 
reduced increasing the chirality in the DPEN ligand.110 However, the 1H NMR 
spectra indicate that only the iso-borneol complex is formed. Catalyst C.2 was 
synthesised from the iridium(III) chloride dimer 36 (Scheme 69). 
 
 
Scheme 69 Preparation of catalyst C.2. 
 
The 1H NMR spectrum for this catalyst indicates only one species is present. 
As the three dimensional shape of ligand L.2 occupies a larger volume than 
the flat tosyl sidechain of L.1, the formation of one rotamer may be more 
selective over the other. In addition, the 1H NMR spectrum shows the alcohol 
is not deprotonated nor has it an O-donor to the metal centre. As with C.1, the 
amine group of C.2 is protonated. This was confirmed using narrow-band 
decoupling with 1H NMR spectroscopy, irradiating the broad signal at 9.6 ppm 
making the proton decouple with its neighbouring protons, causing the double 
doublets at 4.6 ppm and 4.2 ppm, corresponding to the methane and 
methylene groups either side of the amine group, to become doublets (Figure 
27). 
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Figure 27 a) 1H NMR spectrum of C.2, and b) narrowband decoupled spectrum of 
C.2 after proton signal at 9.6 ppm is irradiated. 
  
2.3.4. Thiazole Tethered CsDPEN Iridium(III) Complex C.3 
A second route to synthesise a thiazole tethered CsDPEN ligand from (S,S,S)-
163 was attempted with 180•HCl; avoiding the use of a reducing agent and 
therefore retaining the camphor ketone group (Scheme 70). The yield of the 
ligand L.3 was poor, as seen previously (2.3.2).  The ligand was complexed to 
iridium(III) chloride dimer 36 to produce the novel complex C.3 (Scheme 70). 
The ketone group of the camphor sidechain was shown to be intact, due to the 
characteristic signal (at 215 ppm) in the 13C {1H} NMR; which suggests that a 
transfer hydrogenation reaction is not occurring during the synthesis of 
complex C.2 (see Chapter 2.3.3). The molecular structure was determined 
using x-ray crystallography (Figure 28). Both complexes display a distorted 
octahedral geometry about the metal centre. 
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Scheme 70 The synthesis of novel ligand L.3 and complex C.3. 
 
 
 
Figure 28 The x-ray crystal structure of diastereomers (RIr)-C.3 (Ir1) and (SIr)-C.3 
(Ir2) with non-hydrogen atoms displayed as displacement ellipsoids, which are set at 
the 50% probability level. Hydrogen atoms have been removed for clarity. Both 
structures appear in the asymmetric unit. The centroid of the C(1)–C(5) ring is 
highlighted (green). 
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Table 6 The bond lengths (Å) and angles (˚) of the coordinating atoms of complex 
C.3; Cp*(1) and Cp*(2) correspond to the centroids of rings C(1)–C(5) and C(39)–
C(43) respectively (Figure 28). 
 
 
The crystal structure shows the complex has presented as diastereomers, due 
to the iridium acting as a chiral centre. Comparison of the N-Ir bond lengths 
(Table 6) indicates that the coordinated thiazole N-donor is the strongest of the 
three iridium bonds;this could be an indication that the metal centre is 
withdrawing more electron density from the thiazole ring, increasing the acidity 
of the C-2 proton. Aside from shorter N-Ir bond lengths (~0.3 Å), the 
measurements are of a similar order to that of the iridium(III) chloride dimer 
36.111 
2.3.5. 4-Methyl-Thiazole Tethered Ligands 
Another set of thiazole compounds were made with 5-formyl-4-methyl-1,3-
thiazole 190, so that the tether is in the 5-position; which does not allow 
tridentate coordination to the metal via the thiazole N-atom. Compounds 191 
and 192 were synthesised with (R,R)-162 and (S,S,S)-163 respectively 
(Scheme 71). 
 
Ir(1)-N(1) 2.081(10) N(1)-Ir(1)-N(2) 76.4(4)
Ir(1)-N(2) 2.157(10) N(1)-Ir(1)-N(3) 91.8(4)
Ir(1)-N(3) 2.118(11) N(2)-Ir(1)-N(3) 79.9(4)
Ir(1)-Cp*(1) 1.787 N(1)-Ir(1)-Cp*(1) 131.4
N(2)-Ir(1)-Cp*(1) 133.7
N(3)-Ir(1)-Cp*(1) 125.8
Ir(2)-N(4) 2.063(10) N(4)-Ir(2)-N(5) 78.9(4)
Ir(2)-N(5) 2.154(10) N(4)-Ir(2)-N(6) 84.2(4)
Ir(2)-N(6) 2.118(11) N(5)-Ir(2)-N(6) 78.2(4)
Ir(2)-Cp*(2) 1.786 N(4)-Ir(2)-Cp*(2) 130.8
N(5)-Ir(2)-Cp*(2) 133.0
N(6)-Ir(2)-Cp*(2) 131.2
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Scheme 71 The synthesis of 4-methlythiazole compounds 191 and 192. 
 
The preparation of the iridium(III) complexes with 4-methylthiazole compounds 
191 and 192 was unsuccessful (Scheme 72); there was neither 1H NMR or 
mass spectroscopic evidence for either complex. 
 
 
Scheme 72 Unsuccessful coordination of thiazole compounds 191 and 192 to 
iridium(III) chloride dimer 36. 
 
This was an interesting result, as formation of the complexes was being 
prevented by either the thiazole ring not being able to coordinate to the metal 
centre, or by the small alteration to the steric interactions of the ring; a single 
methyl group in the 4-position. This reinforced the initial design idea that 
coordinating the ring to the metal would improve the ligand coordination. 
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2.3.6. Thiazole Tethered Iridium(III) Complex C.4 
A novel complex C.4 was designed with only one donor site on the ligand to 
identify whether the thiazole is bound strongly to the metal centre; as indicated 
by the short bond length in the crystal structure of C.3 (Figure 28). Ligand L.4 
was made by the SN2 reaction of N-methylsulfonamide 193 and thiazole 
hydrochloride 180. The thiazole ligand L.4 was coordinated to iridium(III) 36 to 
give complex C.4 (Scheme 73). 
 
 
Scheme 73 The preparation of ligand L.4, via SN2 reaction from sulfonamide 193 
and thiazole 180•HCl, and monodentate thiazole iridium(III) complex C.4. 
 
The molecular structure of complex C.4 was determined using x-ray 
crystallography; which shows that the ligand L.4 is bound in a monodentate 
fashion through the N-atom of the thiazole (Figure 29). The complex displays 
a distorted octahedral geometry about the metal centre. 
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Figure 29 The x-ray cyrstal structure of complex C.4, with non-hydrogen atoms 
displayed as displacement ellipsoids, which are set at the 50% probability level. 
Hydrogen atoms have been removed for clarity. The centroid of the C(1)–C(5) ring is 
highlighted (green). 
 
Table 7 The bond lengths (Å) and angles (˚) of the coordinating atoms of complex 
C.4; Cp*(1) corresponds to the centroid of ring C(1)-C(5) (green, Figure 29). 
 
 
2.3.7. Thiazole Tethered Iridium(III) Complexes C.5 and C.6 
Two novel ligands were synthesised using p-toluenesulfonamide 194 and 
180•HCl. Both bidentate ligands L.5 and L.6 were synthesised in the same 
reaction and separated using column chromatography (Scheme 74). The yield 
of the bis-thiazole ligand L.6 was improved by increasing the equivalents of 
the thiazole starting material (Scheme 75).  
 
Ir(1)-Cl(1) 2.415(15) Cl(1)-Ir(1)-Cl(2) 88.07(6)
Ir(1)-Cl(2) 2.409(15) Cl(1)-Ir(1)-N(1) 90.73(13)
Ir(1)-N(1) 2.142(5) Cl(2)-Ir(1)-N(1) 85.25(13)
Ir(1)-Cp*(1) 1.767 N(1)-Ir(1)-Cp*(1) 129.31
Cl(1)-Ir(1)-Cp*(1) 126.58
Cl(2)-Ir(1)-Cp*(1) 123.72
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Scheme 74 Synthesis of mono- and bis-thiazole ligands L.5 and L.6. 
 
 
Scheme 75 Improved synthesis of bis-thiazole L.6. 
 
Initially, the synthesis was attempted with triethylamine as the base in the 
reaction. With p-toluenesulfonamide there was no conversion to the desired 
product, and only the triethyl[(1,3-thiazol-4-yl)methyl]azanium chloride salt 
195, which was analysed using 1H NMR and mass spectroscopy, was isolated 
(Scheme 76). In 1967, Lundina and Postovskii synthesised an analogous 
quaternary  ammonium salt 196 via a similar route (Scheme 77).112 
 
 
Scheme 76 The undesired synthesis of ammonium salt 195. 
 
 
Scheme 77 The synthesis of quaternary ammonium salt 196 as reported by Lundina 
and Postovskii. 
 
The ammonium chloride salt 195 was also identified from the reaction to make 
thiazole compound 197 with 10-camphorsulfonamide (S)-198. In addition, the 
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cyclic sulfonylimine (S)-199, from the intramolecular condensation of the 
sulfonamide (S)-198, was present in 89% yield (with respect to 198). The 
desired product was not observed using 1H NMR spectroscopy or LCMS 
(Scheme 78). 
 
 
Scheme 78 The undesired synthesis of ammonium salt 195 and cyclic sulfonylimine 
(S)-199. The yields were determined using 1H NMR spectroscopy. 
 
 
Scheme 79 The synthesis of bidentate complexes; a) C.5 and b) C.6. 
 
Both thiazole ligands L.5 and L.6 were coordinated to the iridium(III) dimer 36 
(Scheme 79). The 1H NMR spectra and the mass spectroscopic analysis for 
the mono-thiazole complex C.5 suggest that the thiazole compound has 
coordinated to the metal centre as a bidentate ligand; the sulfonamide N-H 
proton signal is absent. The bis-thiazole complex C.6 is more difficult to 
analyse using 1H NMR spectroscopy, however, the C-2 proton signal of the 
complex is broad when compared to the free ligand (Figure 30). Both rings 
must have the same bonding, as there is only one set of thiazole signals in the 
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1H NMR spectrum, which suggests that the ligand is bidentate. Also, the mass 
spectroscopic evidence for complex C.6 supports that the ligand is bound to 
the metal. 
 
 
Figure 30 Stacked 1H NMR spectra; a) bis-thiazole ligand L.6, b) bis-thiazole 
complex C.6. 
 
2.3.8. Thiazolium Ligands 
If the metal is not sufficiently electron poor, the pKa of the thiazole will not be 
low enough to allow deprotonation, and therefore will not be an active catalyst. 
Alkylating the thiazole ring at the N-atom would increase the acidity of the C-2 
position considerably (pKa ~17). Synthetic routes to compounds with 
thiazolium precursors is challenging, especially maintaining a C-2 position free 
from substitution; which is the most acidic and most reactive site on the ring.  
Alkylation of electron rich thiazoles are facile; however, 4-formyl-1,3-thiazole 
184 is electron poor, and very low yields of the novel thiazolium salt 200 were 
achieved using literature methods.113 With a large excess of iodomethane and 
heating at 80 °C, a reasonable yield was achieved (entry 5, Table 8). A second 
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novel thiazolium was prepared from a more electron rich thiazole 190 to 
produce thiazolium iodide 201 (Table 9). 1H NMR analysis of 201 in d4-
methanol showed that the hemiacetal 202 had formed with the solvent 
(Scheme 80). Therefore, the thiazolium aldehydes were analysed for NMR 
spectroscopy in d6-DMSO. 
 
Table 8 Methylation of electron poor thiazole 184 to novel thiazolium 200. 
 
 
 
Table 9 Methylation of a more electron rich thiazole 190 (cf. 184). 
 
 
 
Entry MeI (x eq) Time T (°C) Yield (%)
1 2.5 24 h rt 0
2 5.0 7 d rt 0
3 2.5 16 h 80 11
4 2.5 24 h 80 16
5 10.0 18 h 80 59
Entry MeI (x eq) Solvent Time (h) T (°C) Yield (%)
1 1.5 DCM 24 40 0
2 2.5 MeCN 24 rt 0
3 2.5 MeCN 18 80 18
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Scheme 80 Formation of hemiacetal 202 from 201 in d4-methanol in an NMR tube 
at room temperature. Ratio of proton to deuterium at the C-2 position is 1:1. 
 
With the thiazoliums prepared, reductive amination with amines (R,R)-162 and 
(S,S,S)-163 was attempted (Scheme 81). Both reactions were unsuccessful 
after the addition of sodium borohydride, suggesting that the thiazolium ring 
was reduced; due to the absence of downfield thiazole proton signals in the 1H 
NMR spectra. 
 
 
Scheme 81 Unsuccessful reductive amination of imine thiazolium iodides 203 and 
205 to 204 and 206 respectively. 
 
An alternative strategy to synthesise the thiazolium ligands 204 and 206 would 
be via an SN2 reaction with thiazolium salt 207. However, alkylation of thiazole 
180•HCl was unsuccessful, producing an insoluble black solid (Scheme 82).  
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Scheme 82 Attempted synthesis of thiazolium iodide 207. 
 
Thiazole ligand L.1 was stirred in iodomethane at reflux and in a microwave 
reactor at 110 °C in an attempt to methylate the thiazole N-atom (Scheme 83). 
However, the major product isolated was the eliminated iodomethylthiazolium 
salt 208. The desired product 209 was seen in the 1H NMR and LCMS spectra, 
but was not isolated from the mixture of other methylated products. 
 
 
Scheme 83 Attempted synthesis of thiazolium 209, forming thiazolium 208 as a side 
product. 
 
The bis-thiazole substituted ligand L.6 was alkylated at one of the thiazole N-
atoms using iodomethane to produce thiazole-thiazolium ligand L.7 (Scheme 
84). The thiazole/thiazolium ligand L.7 was complexed to iridium(III) dimer 36 
to produce thiazolium complex C.7.1. 
 
 
Scheme 84 Methylation of bis-thiazole L.6 to produce thiazolium iodide L.7.  
 
The thiazolium ligand L.7 was only soluble in d6-DMSO for NMR spectroscopy, 
therefore the complex C.7.1 was initially analysed in d6-DMSO. The 
crystallisation from the NMR sample yielded orange needles, which was 
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determined by x-ray crystallography to be an iridium(III) complex with two 
iodide ligands and a S-coordinated dimethylsulfoxide molecule (Figure 31). A 
similar structure [CpIrI2(d6-DMSO)] is known in the literature and was formed 
from the attempted analysis of [CpIrI2]2 in d6-DMSO.114 
  
 
Figure 31 X-ray crystal structure of [Cp*IrI2(d6-DMSO)] with non-hydrogen atoms 
displayed as displacement ellipsoids, which are set at the 50% probability level. 
Hydrogen atoms have been removed for clarity. The centroid of the C(1)–C(5) ring is 
highlighted (green). 
 
Table 10 The bond lengths (Å) and angles (°) of the coordinating atoms of 
[Cp*IrI2(d6-DMSO)]; Cp*(1) corresponds to the centroid of ring C(1)–C(5) (green, 
Figure 31). 
 
 
The structure indicates that the ligand was displaced by a molecule of 
dimethylsulfoxide and both chloride ligands were exchanged for iodides. The 
1H NMR spectrum of the original sample was collected again in d4-MeCN; as 
it was assumed the thiazolium iodide ligand would dissolve. As with the d6-
DMSO sample, the 1H NMR spectrum indicated the ligand L.7 was no longer 
coordinated to the metal centre. In CDCl3, in which the sample was surprisingly 
Ir(1)-I(1) 2.692(5) I(1)-Ir(1)-I(2) 92.61(17)
Ir(1)-I(2) 2.689(5) I(1)-Ir(1)-S(1) 89.20(4)
Ir(1)-S(1) 2.284(16) I(2)-Ir(1)-S(1) 89.26(4)
Ir(1)-Cp*(1) 1.828 I(1)-Ir(1)-Cp*(1) 123.93
I(2)-Ir(1)-Cp*(1) 121.83
S(1)-Ir(1)-Cp*(1) 129.30
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soluble (displaying another advantage of a multifunctional catalyst as 
coordination to the metal improved the solubility of the polar thiazolium in 
organic solvents), the thiazolium C-2 proton was shifted down field; which 
suggested complexed ligand (Figure 32). A suitable orange plate-like crystal 
was obtained from chloroform; the structure was determined using x-ray 
crystallography and found to exist with an anionic iridate(III) counter-complex 
(Scheme 85). Both complexes display a distorted octahedral geometry about 
the metal centres (Figure 33). 
 
Scheme 85 The synthesis of iridium(III)–iridate(III) complex C.7. 
 
  
Figure 32 Stacked 1H NMR spectra of thiazole-thiazolium complex C.7.1 in different 
solvents; a) d6-DMSO, b) d4-MeCN, and c) CDCl3. 
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Figure 33 The x-ray crystal structure of C.7.1 with four molecules of CDCl3 in the 
asymmetric unit. The compound was modelled as a mixture of halides with ratios of 
Cl1.6I0.4 (Ir1) and Cl1.95 I1.05 (Ir2). The distance between the centroids of thiazole (N1, 
S1, blue) and thiazolium (N3, S2, lilac) rings is 3.751 Å. Hydrogen atoms and 
solvent molecules have been removed for clarity.  
 
Table 11 The bond lengths (Å) and angles (˚) of the coordinating atoms of complex 
C.7. Cp*(1) and Cp*(2) corresponds to the centroids of rings C(1)–C(5) (green) and 
C(27)–C(31) (red) respectively (Figure 33). 
 
 
Ir(1)-Cl(1) 2.410(19) Cl(1)-Ir(1)-Cl(2) 89.3(3)
Ir(1)-Cl(2) 2.420(8) Cl(1)-Ir(1)-N(1) 93.10(17)
Ir(1)-N(1) 2.140(7) Cl(2)-Ir(1)-N(1) 85.5(4)
Ir(1)-Cp*(1) 1.758 N(1)-Ir(1)-Cp*(1) 126.35
Cl(1)-Ir(1)-Cp*(1) 124.93
Cl(2)-Ir(1)-Cp*(1) 125.8
Ir(2)-Cl(3) 2.462(2) Cl(3)-Ir(2)-Cl(4) 90.8(6)
Ir(2)-Cl(4) 2.417(9) Cl(3)-Ir(2)-Cl(5) 88.7(4)
Ir(2)-Cl(5) 2.411(9) Cl(4)-Ir(2)-Cl(5) 87.0(8)
Ir(2)-Cp*(2) 1.762 Cl(3)-Ir(2)-Cp*(2) 124.63
Cl(4)-Ir(2)-Cp*(2) 125.10
Cl(5)-Ir(2)-Cp*(2) 128.20
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Iridate(III) counter-complexes have been previously reported in the 
literature.115-118 The crystal structure of C.7.1 shows that some halide mixing 
has occurred. Substitution of chloride ligands by iodide anions at iridium(III) is 
well known in the literature.119 The orientation of the counter complex is 
directed at the proton of the C-2 position of the thiazolium ring; which could be 
explained by hydrogen bonding from the acidic proton to the halide ligands. 
The distance between the thiazole and thiazolium rings (3.751 Å) is within the 
constraints of face off-centred π-π stacking limits (3.3–3.8 Å).120   
 
A variable temperature 1H NMR experiment of complex C.7.1 from 213–323 K 
in CDCl3 presents differently in three main temperature ranges. In the high 
temperature region (313–323 K) the thiazole and thiazolium signals (>8 ppm) 
appear sharp, and the Cp* ligand appears as one peak (1.6 ppm). In the mid 
temperature region (263–303 K), the thiazole and thiazolium protons (>8 ppm) 
appear as broad signals, along with the aromatic, methyl and methylene 
protons. From 303 K to 263 K the Cp* ligand splits into five broad peaks, 
corresponding to each of the five methyl groups, indicating the ring has 
become less disordered. The low temperature region (253–213 K) shows the 
sharp thiazole and thiazolium proton signals (>8 ppm) have split into two sets. 
In addition, the methyl and methylene signals (4–5 ppm) have split into more 
resolved peaks with more complicated multiplicities. Rotamers could be the 
cause of the extra sets of peaks which are interconverting more slowly at the 
low temperature. In addition, the halide ligand scrambling could be the cause 
for the extra species observed. 
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Figure 34 Variable temperature 1H NMR experiment of thiazole-thiazolium 
iridium(III) complex C.7.1 in CDCl3 from 213–323 K.  
 
To avoid the halide mixing observed for complex C.7.1, analogous complex 
C.7.2 was synthesised using the iridium(III) diiodide dimer 210 (Scheme 86). 
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Scheme 86 The synthesis of thiazole-thiazolium iridium(III) complex C.7.2. 
2.3.9. Thiazole Tethered Pyridine Iridium(III) Complexes C.8 and C.9 
To increase the number of donor atoms in the ligand design, a pyridine 
sidechain was incorporated into the ligand structure. This will allow both 
thiazole rings to be methylated whilst maintaining a coordination site to the 
metal. Pyridine ligands on iridium are well known in the literature.121 The mono- 
and bis- thiazole ligands L.8 and L.9 were prepared with 5-methyl-2-
pyridinesulfonamide 211 and thiazole 180•HCl in the same reaction and then 
separated using column chromatography (Scheme 87). A suitable crystal was 
obtained for mono-thiazole ligand L.8 and the structure was determined by x-
ray crystallography (Figure 35).  
 
 
Scheme 87 The synthesis of mono-thiazole-pyridine and bis-thiazole-pyridine 
ligands L.8 and L.9 respectively. 
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Figure 35 The x-ray crystal structure of mono-thiazole-pyridine ligand L.8 with with 
non-hydrogen atoms displayed as displacement ellipsoids, which are set at the 50% 
probability level. Hydrogen atoms have been removed for clarity. The distance 
between the centroids of thiazole (green) and pyridine (red) rings is 3.589 Å. 
 
The distance between ring centroids of the thiazole and pyridine rings in ligand 
L.8 (3.589 Å) is within the constraints of face off-centred π-π stacking limits 
(3.3-3.8 Å).120 The shape of the ligand could help to define the shape of the 
metal complex, as all three N-donor atoms are directed towards the same 
point; suggesting the ligand will coordinate in a tridentate fashion. Both ligands 
L.8 and L.9 were complexed to iridium(III) dimer 36 (Scheme 88). 
 
 
Scheme 88 Synthesis of thiazole-pyridine complexes; a) C.8 and b) C.9 
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Analysis of both complexes C.8 and C.9 using 1H NMR spectroscopy indicates 
that the ligands are bound to the metal as at least bidentate ligands. However, 
geometry optimised UFF molecular models of both complexes show that both 
ligands are capable of binding as tridentate ligands (Figure 36). 
 
 
Figure 36 Molecular models of pyridine-thiazole complexes using a UFF model; a) 
C.8 and b) C.9 
 
 
Scheme 89 The synthesis of bis-thiazolium-pyridine ligand L.10. 
 
The bis-thiazole L.9 was alkylated with iodomethane to give bis-thiazolium 
L.10 (Scheme 89). The remaining yield was unreacted starting material. The 
1H NMR spectrum shows the product as the bis-thiazolium ligand; which was 
surprising as bis-thiazole ligand L.6 only alkylated once under the same 
conditions. With only a single alkylation, L.10 would have had two donor atoms 
to coordinate to the metal centre. The ligand L.10 can only bind as a 
monodentate ligand through the pyridine side-chain; however, two thiazole 
catalysts could improve the rate of the organocatalyzed benzoin condensation 
reaction. The bis-thiazole-pyridine ligand L.10 was complexed to iridium(III) 
dimer 36 to give complex C.10 (Scheme 90). 
a) b)
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Scheme 90 The synthesis of bis-thiazolium-pyridine iridium(III) complex C.10 and 
the decomposition to C.8 with an iodide counterion during recrystallization. 
 
The complex was recrystallized from dichloromethane and petrol to produce a 
suitable crystal for x-ray crystallography (Figure 37); however, the structure 
was not the desired bis-thiazolium complex C.10, but the structure expected 
for mono-thiazole complex C.8 (Scheme 88, a). Both complexes display a 
distorted octahedral geometry about the metal centre. There are two 
possibilities for the structure of the complex: either the batch of L.10 used was 
impure and the single crystal was recrystallized from the impurity, or a 
thiazolium molecule and a methyl group were eliminated from the complex via 
SN2 reactions with the iodide ions in solution.  During the attempted synthesis 
of thiazolium 209 from L.1 (Scheme 83), the eliminated iodomethyl-thiazolium 
208 was isolated in 23% yield, which supports the thiazolium elimination to 
make the crystal structure obtained for C.10. The NMR spectra for C.10 
suggested the complex had decomposed to a mixture of other species. 
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Figure 37 The x-ray crystal structure of [C.8]I with two enantiomers of the complex 
(RIr)-C.8 (Ir1) and (SIr)-C.8 (Ir2), two iodide counter ions, and two molecules of DCM 
in the asymmetric unit; with non-hydrogen atoms displayed as displacement 
ellipsoids, which are set at the 50% probability level. Hydrogen atoms and solvent 
molecules have been removed for clarity. The centroids of the C(11)-C(15) and 
C(31)-C(35) rings are highlighted red and green respectively. 
 
Table 12 The bond lengths (Å) and angles (°) of the coordinating atoms of complex 
C.8. Cp*(1) and Cp*(2) corresponds to the centroids of rings C(31)-C-(35) (green) 
and C(11)-C-(15) (red) respectively (Figure 37). 
 
Ir(1)-N(1) 2.088(7) N(1)-Ir(1)-N(2) 78.3(3)
Ir(1)-N(2) 2.089(7) N(1)-Ir(1)-N(3) 86.3(3)
Ir(1)-N(3) 2.120(7) N(2)-Ir(1)-N(3) 80.8(3)
Ir(1)-Cp*(1) 1.793 N(1)-Ir(1)-Cp*(1) 131.99
N(2)-Ir(1)-Cp*(1) 130.11
N(3)-Ir(1)-Cp*(1) 130.16
Ir(2)-N(4) 2.080(6) N(4)-Ir(2)-N(5) 78.8(3)
Ir(2)-N(5) 2.115(7) N(4)-Ir(2)-N(6) 79.9(3)
Ir(2)-N(6) 2.145(7) N(5)-Ir(2)-N(6) 81.4(3)
Ir(2)-Cp*(2) 1.787 N(4)-Ir(2)-Cp*(2) 133.32
N(5)-Ir(2)-Cp*(2) 128.64
N(6)-Ir(2)-Cp*(2) 134.03
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2.3.10. Rigid Tether for Thiazolium Iridium(III) Complexes  
An alternative ligand design is to use a rigid tether to the organocatalyst to lock 
the carbene away from the metal centre to prevent coordination of the 
thiazolium to the metal centre (Figure 38). However, the issue of intermolecular 
carbene-iridium(III) coordination is still possible. 
 
 
Figure 38 A new complex design that has a rigid tether to hold the thiazolium 
component away from the metal centre to avoid carbene coordinatinon. 
 
Based on the benzyl control ligand 164, a thiazole ligand with a rigid benzene 
tether 212 was designed (Figure 39).  
 
 
Figure 39 Design of a thiazole ligand 212 with a benzene tether to prevent 
intramolecular carben-metal binding. 
 
A straight forward route was attempted, from α,α'-dichloro-p-xylene 213 and 
either thiazole 169 or (R,R)-TsDPEN 162 (Scheme 91).  
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Scheme 91 Attempted synthesis of rigid benzene-tether components; a) 214 and b) 
215. 
 
The thiazolium 214 was not identified in the crude reaction mixture. Amine 215 
was identified using 1H NMR spectroscopy of the crude mixture as a trace 
product with many other side-products; however, the product was unable to be 
isolated. The focus of the project was shifted away from rigid covalent tethers; 
as intermolecular thiazolylidene-metal bond formation would be more 
prevalent.  
 
2.4. Triazole Ligands 
Triazolium organocatalysts are more acidic than the analogous thiazolium 
organocatalysts (pka ~16, see Chapter 1.10).73 Therefore, to increase the 
activity of the organocatalyst, novel triazole iridium(III) complexes have been 
synthesised.  
2.4.1. Triazol-1-yl TsDPEN Ligands 
An iridium complex 216 was designed with the triazolium ligand bound in a 6-
membered iridicycle to prevent carbene binding to the metal (Figure 40). 
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Figure 40 The design of a triazolium-iridium(III) multifunctional catalyst 216. 
 
The design only allows one donor atom from the ring to coordinate to the metal 
centre and prevents a carbene forming at the 5-position. A retrosynthetic route 
to the ligand was devised and the synthesis attempted (Scheme 92).  
 
 
Scheme 92 Retrosynthesis of the target triazolium ligand 217. 
 
The imide 218 was not commercially available, therefore the synthesis was 
attempted via two routes; a neat formic acid 219 condensation reaction with 
N-methylacetamide 220 that was reported as a decomposition product with 
palladium and DMF,122 and iso-propenyl acetate 221 acetylation reaction with 
N-methylformamide 222 that was reported in a patent (Scheme 93).123 
 
 
Scheme 93 The attempted synthetic routes to imide 218. 
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The synthesis of hydrazine 223 was also attempted based on three reported 
routes to similar compounds; however, all three routes were unsuccessful 
(Scheme 94).124-126 
 
 
Scheme 94 Attempted synthesis of hydrazine (R,R)-223. Conditions: i) 1. (R,R)-162 
(1.0 eq), KOH (0.67 eq), H2O, 2. H2NSO4H, H2O; ii) KOH (10 eq), H2NSO4H (2.0 eq), 
DMF, 50 °C, N2, 16 h; iii) KOtBu (15 eq), H2NSO4H (2.0 eq), MeOH, 0 °C, N2, 5 h. 
 
As the initial route was unsuccessful, an alternative route to a triazolium 
complex was undertaken. Starting from the commercially available 
aminoethanol (1S,2R)-224, the aziridine 225 was prepared via an 
intramolecular Mitsunobu reaction. The ring opening reaction with 1,2,4-
triazole 226 with potassium carbonate to make triazole 227 was unsuccessful 
and only starting material was recovered. Instead, the aziridine 225 was made 
more reactive by tosylating the N-atom. The product of the reaction was the 
ring opened 1-chloro-2-sulfonamide 228. This was useful, because not only 
has the tosyl sidechain added to the molecule, the chloride leaving group was 
now more reactive, making the SN2 reaction with 226 possible (Scheme 95). 
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Scheme 95 The synthetic route towards triazole (R,R)-L.11 via aziridine (R,R)-225 
and 1-chloro-2-sulfonamide (2S,1R)-228. 
 
The triazole ligand (R,R)-L.11 was coordinated to the iridium(III) dimer 36 
(Scheme 96). 1H NMR spectroscopic analysis of the complex shows two 
species, with a ratio of 1:1, that both have inequivalent triazole proton signals 
and both have the sulfonamide proton remaining. This suggests the two 
complex structures C.11.1 and C.11.2. Both complexes have the ligand bound 
in a monodentate fashion, as the sulfonamide proton signal is still present in 
the spectrum. This is different to the thiazole complexes that are bound through 
the sulfonamide N-atom under the same conditions. 
 
 
Scheme 96 The synthesis of triazole complexes C.11.1 and C.11.2. 
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2.4.2. Triazol-1-yl-2-ium Ligands 
The synthesis of the triazolium ligand (1S,2R)-229 was attempted from the ring 
opening reaction of aziridine (1S,2R)-225 with 1-methyl-1,2,4-triazole 230; 
which was prepared from 226 and iodomethane with base (Scheme 97).   
 
Scheme 97 The attempted synthetic route to triazolium chloride (1S,2R)-229. 
  
The reaction did not proceed to the product after five days at reflux, therefore 
the 2-methyl-1,2,4-triazolium iodide ligand L.12 was prepared from the 
alkylation of triazole ligand L.11 with iodomethane (Scheme 98). 
 
 
Scheme 98 The synthesis of triazolium iodide ligand L.12. 
 
The position of the positive charge of the triazolium can sit on either alkylated 
nitrogen atom of the ring (Figure 41). The triazolium ligand L.12 was 
complexed to iridium(III) dimer 210 to produce triazolylidene iridium(III) 
complex C.12 (Scheme 99). 
 
 
Figure 41 The resonance structures of triazolium ligand L.12 showing the two 
possible positions of the positive charge. 
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Scheme 99 The synthesis of triazolylidene iodide complex C.12. 
 
2.4.3. Triazol-4-yl TsDPEN ligands 
Herrmann and Kühn have developed a bis-triazolium ligand system for 
rhodium and platinum complexes as catalysts for alkene hydrogenation and 
hydrosilylation reactions respectively (Scheme 100).127-129  
 
 
Scheme 100 The synthetic route to bis-triazole ligand (R,R)-232, bis-triazolium 
(R,R)-233 and bis-triazolylidene platinum complex 234.129 
 
The bis-triazolylidene complexes were designed to coordinate to the metal as 
bidentate ligands; however, as triazoliums are well known organocatalysts for 
the benzoin reaction, the carbene position needs to remain unsubstituted for 
the organocatalysis to occur. A mono-triazole analogue of Herrmann and 
Kühn’s ligand L.13 was synthesised from (R,R)-162, formic hydrazide 231 and 
triethyl orthoformate (Scheme 101).     
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Scheme 101 The synthesis of triazole ligand (R,R)-L.13 with major side products 
imidazoline (R,R)-235 and N-formyl-TsDPEN (R,R)-236. 
 
The reaction was carried out in a sealed pressure tube as was used in the 
reported process. The reaction was lower yielding than expected and 
produced two major side products; imidazoline (R,R)-235 and N-formyl-
TsDPEN (R,R)-236. The reported yield for the bis-triazole compound 232 was 
60%, but side products of the reaction were not mentioned. The compounds 
(R,R)-235 and (R,R)-236 were separated using column chromatography, and 
the remaining pink crude oil was shown to contain the desired product (R,R)-
L.13. Recrystallisation of the crude oil from iso-propanol yielded the pure 
product (R,R)-L.13 as colourless crystals. In an attempt to improve the reaction 
conditions and yield of the product, the reaction was repeated in a microwave 
reactor; reducing the reaction time from 72 to 11 hours and improving the 
health and safety risks associated with a sealed high temperature reaction 
(Scheme 102).  
 
 
Scheme 102 The synthetic route (R,R)-L.13 using a microwave reactor. 
 
In this process, the yield of desired product L.13 remained low, however the 
formation of (R,R)-236 improved (27% to 60%) and there was no formation of 
imidazoline (R,R)-235. Formation of both (R,R)-L.13 and (R,R)-235 can be 
visualised from (R,R)-236; via reaction with (R,R)-231, and intramolecular 
condensation reactions respectively (Scheme 103). 
 97 
 
 
Scheme 103 Possible routes to (R,R)-L.13 and imidazoline (R,R)-235 from (R,R)-
236. 
 
To further improve the yield and selectivity for the triazole ligand (R,R)-L.13, 
increased equivalents of (R,R)-231 could be used; however, this reaction was 
not developed further. The molecular structure of (R,R)-L.13 was determined 
using x-ray crystallography (Figure 42). 
 
 
Figure 42 The x-ray crystal structure of (R,R)-L.13 with non-hydrogen atoms 
displayed as displacement ellipsoids, which are set at the 50% probability level. 
Hydrogen atoms have been removed for clarity. 
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The triazole ligand (R,R)-L.13 was complexed to the iridium(III) dimer 36 
(Scheme 104). 
 
 
Scheme 104 The synthesis of triazole iridium(III) complex C.13. 
 
The 1H NMR spectrum of complex C.13 shows that two species as present, 
with a ratio of 1.2:1.0. For both species, the ligand is bound to the metal centre 
as a monodentate ligand (analogous to C.11) through a triazole N-donor atom, 
because the sulfonamide proton signal is still present in the 1H NMR spectrum 
(Figure 43). The two sets of peaks have proton signals that have inequivalent 
triazole protons. As the triazole is symmetrical, only a single monodentate 
species should be possible with inequivalent signals; suggesting the ligand has 
bound in a different way to the metal centre. Possibilities for the second 
species (Figure 44) could be the ligand coordinated to two metal centres (a), 
or two ligands bound to a single metal centre (b); however, the integral for the 
Cp* signal does not allow for these structures. Another possibility could be the 
neutral (c) and ionic complexes (d). Rotamers could also be the cause for 
generating two different species with different inequivalent triazole protons (e 
and f).  
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Figure 43 Stacked 1H NMR spectra; a) triazole (R,R)-L.13, and b) triazole 
complex C.13. 
 
 
Figure 44 Possible monodentate structures of C.13 that would give different sets of 
inequivalent triazole proton singnals in the 1H NMR spectrum. 
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It is surprising neither triazole ligand (R,R)-L.11 or (R,R)-L.13 coordinate as 
bidentate ligands to the metal centre under the same conditions that were used 
for complexation of the thiazole ligands. More forcing conditions could form the 
bidentate complex as a single species. 
2.4.4. Triazol-4-yl-1-ium Ligands 
The triazole ligand (R,R)-L.13 was alkylated with iodomethane to produce the 
1-methyl-1,2,4-triazol-4-yl-1-ium iodide ligand (R,R)-L.14 (Scheme 105).  
 
 
Scheme 105 The synthesis of 1-methyl-1,2,4-triazol-4-yl-1-ium iodide ligand (R,R)-
L.14. 
 
As with ligand (R,R)-L.12 (Figure 41), the position of the positive charge of the 
triazolium can sit on either alkylated nitrogen of the ring (Figure 45). 
 
 
Figure 45 The resonance structures of triazolium ligand (R,R)-L.14 showing the two 
positions of the positive charge. 
 
The 1H NMR spectra of (R,R)-L.13 and (R,R)-L.14 show the effect that 
alkylation has on the chemical environment of the ring protons; both shifting 
downfield (Figure 46). The triazolium iodide (R,R)-L.14 was complexed to 
iridium(III) dimer 210 to give triazolylidene iridium(III) complex C.14 (Scheme 
106). 
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Scheme 106 The synthesis of triazolylidene iridium(III) complex C.14.  
 
The 1H NMR spectra of ligand (R,R)-L.14 and complex C.14 (Figure 46) 
suggests that the ligand is bound through the carbene; there is only one 
triazole C-H signal (at 8.6 ppm, spectrum b). Interestingly, the C-H of the DPEN 
backbone which is bound to the triazole N-atom has shifted downfield by 1.6 
ppm compared to the ligand (R,R)-L.13 once the carbene bond to the metal 
centre has been formed. 
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Figure 46 Stacked 1H NMR spectra; a) triazole (R,R)-L.13, b) triazolium iodide 
(R,R)-L.14, and c) triazolylidene complex C.14, with the backbone C-H signals 
indicated with arrows.  
 
A suitable crystal was obtained for the carbene complex C.14 and the structure 
was determined by x-ray crystallography (Figure 47). The complex displays a 
distorted octahedral geometry about the metal centre. The ligand is bound 
through the carbene only and not through the sulfonamide N-donor. It is 
surprising that the triazolium has been deprotonated under the reaction 
conditions, yet the sulfonamide proton remains. As with C.13, more forcing 
conditions could generate the 6-membered iridicycle. 
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Figure 47 The x-ray cyrstal structure of complex C.14, with two molecules of 
dichloromethane and water in the asymmetric unit. Non-hydrogen atoms displayed 
as displacement ellipsoids, which are set at the 50% probability level. Hydrogen 
atoms and solvent molecules have been removed for clarity. The centroid of the Cp* 
ring is highlighted (C26-C30, green). The distance between the centroids of triazole 
(C1-N3, blue) and tosyl (C18-C23, red) rings is 3.694 Å. 
 
Table 13 The bond lengths (Å) and angles (˚) of the coordinating atoms of complex 
C.14; Cp*(1) corresponds to the centroid of ring C(26)-C(30) (green, Figure 47). 
 
 
 
Ir(1)-I(1) 2.7275(12) I(1)-Ir(1)-I(2) 85.02(4)
Ir(1)-I(2) 2.7378(12) I(1)-Ir(1)-C(1) 96.2(4)
Ir(1)-C(1) 2.042(14) I(2)-Ir(1)-C(1) 92.2(4)
Ir(1)-Cp*(1) 1.837 I(1)-Ir(1)-Cp*(1) 123.07
I(2)-Ir(1)-Cp*(1) 122.38
C(1)-Ir(1)-Cp*(1) 126.10
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2.5. Summary 
Chapter 2 has covered the design considerations for a multifunctional catalyst 
to transform primary alcohols into 1,2-diols through three sequential reactions; 
transfer dehydrogenation, benzoin condensation, transfer hydrogenation. The 
synthesis of control catalysts, nine novel thiazole ligands and their 
corresponding iridium(III) complexes, and four novel triazole ligands and their 
corresponding complexes has been discussed. The different structural 
features included in the fourteen ligands are summarised in Table 14.  
 
Table 14 The different structural features of the novel thiazole and triazole ligands 
synthesied in Chapter 2. 
 
 
Thiazole ester reduction was achieved with 100% selectivity for the aldehyde 
product with 0.75 equivalents of reagent, avoiding over-reduction to the 
thiazole alcohol. It was found that the imine made between TsDPEN and an 
aldehyde forms an equilibrium with a cyclic aminal, of which only the imine is 
Rings Side Chains Backbones
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observed after 16 hours. An increased steric bulk around the thiazole N-atom 
decreased the coordinating ability of the ligand to the metal centre, resulting in 
no isolated complexes. 4-(Chloromethyl)-1,3-thiazole was used as a simple 
route to substituted thiazoles, whilst avoiding the use of reducing agents; 
however, the yields are typically low, except for the sulfonamide nucleophile to 
make L.5 and L.6. When triethylamine was used in the reactions with 4-
(chloromethyl)-1,3-thiazole or camphorsulfonamide the thiazole 
triethylammonium salt and the cyclic sulfonylimine products were formed 
preferentially.  
Thiazoles require high temperatures and a high concentration of alkylating 
agent to make thiazolium salts and still gave low yields. Thiazole aldehydes 
are more difficult to alkylate and are very reactive, even to weak nucleophiles. 
The thiazolium rings are completely reduced with sodium borohydride during 
an attempted reductive amination reaction. Alkylation of 4-(chloromethyl)-1,3-
thiazole was unsuccessful, leading to an insoluble black solid. Methylation of 
L.1 resulted in an iodide ion eliminating the diamine and forming 4-
(iodomethyl)-1,3-thiazolium iodide, which was isolated by filtration. Similarly, 
C.10 breaks down to C.8 with assumed loss of 4-(iodomethyl)-1,3-thiazolium 
iodide. Triazoles are easier to methylate, with much higher yields than the 
thiazoles. Synthesis of triazole L.11 required four steps from the 1,2-
aminoalcohol. Synthesis of L.13 is a single step to the ligand and produces a 
single isomer; however, the yield was low. The long reaction time was 
improved by using a microwave reactor, but the yield could be improved further 
by investigating the ratios of the reagents.  
Growing suitable single crystals for x-ray crystallography was challenging, as 
in most cases the complexes oiled out. Suitable single crystals were generally 
formed using vapour diffusion with either chloroform in hexane or acetone in 
pentane. The structures obtained presented the variety of the complexes 
prepared and that the thiazole and triazole N-atoms are strong donors to 
iridium(III) centres. The majority of the complexes were prepared in good 
yields and are air and water stable. Complex C.7.1 was more susceptible to 
ligand displacement (especially in DMSO) and complex C.10 was degraded 
via thiazolium elimination to complex C.8. The activity of the 14 novel 
complexes is discussed in Chapter 3. 
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3. Catalyst Testing 
3.1. Introduction 
This chapter discusses the catalyst testing of the thiazole and triazole 
iridium(III) complexes synthesised in Chapter 2. The results are discussed in 
four sections: 
1. Control reactions carried out with known catalysts to validate the target 
reaction sequence. 
2. The initial testing of the complexes C.1-C.6 and the optimisation of the 
transfer dehydrogenation reaction and the benzoin condensation 
catalyst tests. 
3. The comparison of all novel thiazole and triazole complexes under the 
same conditions. 
4. The testing of the scope of the reaction with substituted benzylic 
alcohols. 
 
3.2. Control Reactions 
3.2.1. Individual Catalyst Tests 
To validate the desired reaction sequence, each step of the sequence was 
carried out separately. The two catalytic components of the multifunctional 
complexes must be able to catalyse the hydrogen transfer and benzoin 
condensation reactions with the organometallic and organocatalysts 
respectively (Scheme 107). 
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Scheme 107 Proposed multicatalytic cycle; i) transfer dehydrogenation, ii) benzoin 
condensation, iii) transfer hydrogenation. 
 
3.2.1.1. Transfer Dehydrogenation of Benzyl Alcohol 
The first reaction of the multifunctional catalyst is the dehydrogenation of 
benzyl alcohol 39 to produce benzaldehyde 67. The iridium(III) chloride dimer 
36 was tested as a control for this reaction with acetone as the hydrogen 
acceptor (Scheme 108). Acetone was used as the hydrogen acceptor and 
potassium carbonate as the base in the reaction, following a procedure 
reported by Fujita.130 The yield was found to be lower than reported (87%), 
however, the reaction successfully converted 39 to 67.  
 
 
Scheme 108 The transfer dehydrogenation of benzyl alcohol 39 with catalyst 36. 
 
3.2.1.2. Benzoin Homo-Condensation of Benzaldehyde 
The organocatalysed benzoin condensation has been investigated with 67 
(Table 15). The experimental conditions chosen follow a modified procedure 
that was originally reported by Stetter and Kuhlmann (Scheme 109).131 4-
Methylthiazole 169 was used as a control catalyst; the unalkylated thiazole ring 
is unable to catalyse the reaction due to the poor electron withdrawing power 
of the N-atom in thiazole (entries 1 and 2). Thiazolium catalysts are necessary, 
as the positive charge on the N-atom acts as an electron sink and increases 
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the acidity of the catalyst. Thiamine hydrochloride 124 gave low yields with 
triethylamine (pKaH 10.8) as a base (entry 3 and 4). With potassium tert-
butoxide and potassium carbonate there was no conversion to benzoin 129 
(entries 5, 6). The thiazolium ring in 124 can be ring opened with a strongly 
alkaline solution (pH > 9.5), which could be the cause of no catalysis.132 N-
Ethyl-4-methylthiazolium bromide 130 achieved good conversion at 20 mol% 
catalyst loading (entry 8). Precious metal catalysts are often reported to reach 
full conversion in hydrogen transfer reactions with <1 mol% catalyst loadings;50 
the organo/organometallic multifunctional catalyst may require larger loadings 
to account for the organocatalysis step, therefore the catalyst tests with the 
multifunctional catalysts will be run at 5 mol% to give the organocatalysis a 
chance of working. An advantage of multifunctional catalysis can be a 
decrease in organocatalyst loading, as Schreiner reported a decrease in 
catalyst loading from 60 mol% to 5.0 mol% as a result of tethering the two 
catalysts.33  
 
 
Scheme 109 Benzoin condensation reaction of butyraldehyde with a thiamine 
analogue catalyst 240. 
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Table 15 The catalyst tests for the benzoin condensation of 67 to 129. 
 
 
a Reaction carried out in MeCN. 
  
3.2.1.3. Hydrogenation of Benzoin to Hydrobenzoin 
The final step in the reaction sequence of the multifunctional catalyst is the 
hydrogenation of benzoin 129 to give hydrobenzoin 237 (Scheme 110).133 This 
was achieved with 36 and (R,R)-162, with TEAF as the hydrogen donor, to 
produce 237 with 46% yield.  
 
 
Scheme 110 Hydrogenation of 129 with an iridium(III) catalyst. 
 
Both hydrogen transfer and benzoin condensation control reactions were 
successful, which shows that the desired reaction sequence with the chosen 
combination of catalysts is feasible. As both hydrogen transfers are designed 
Entry Catalyst
Catalyst Loading 
(x mol%)
Base
Base Loading     
(y mol%)
Time                 
(h)
Yield        
(%)
1 169 5 Et3N 30 24 0
2 169 20 DBU 30 24 0
3 124 5 Et3N 30 1.5 5
4 124 5 Et3N 30 1.5 13
5 124 5 KO
t
Bu 30 4 0
6 130 10 K2CO3 10 24 0
a
7 130 2 Et3N 60 5 0
8 130 20 Et3N 60 5 68
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to occur sequentially, hydrogen borrowing could be employed to remove the 
need for extra hydrogen acceptors/donors. 
Concerning the asymmetry of the reaction, only the final hydrogenation can 
influence the stereochemistry of the prochiral centre on 129, as racemisation 
of 129 through its enol form is possible (Scheme 111).134 Due to the close 
proximity of the thiazolium catalyst to the iridium metal centre, the 
multifunctional catalyst could hydrogenate the initial enantiomer formed 
directly after the benzoin condensation before it is able to racemise. This could 
be a very useful advantage of the catalyst design and allow the production of 
a specific enantiomer of 237. 
 
 
Scheme 111 The racemisation of 129 via the tautomer. 
 
3.2.2. One-pot Test 
An experiment to combine both separate catalysts in one-pot was carried out 
in order to compare the rate of reaction with the multifunctional catalysts. 
Schreiner and Peris have reported improvements in the rates of reaction with 
their multifunctional catalysts as compared to separate catalysts under the 
same conditions (see Chapter 1.8).33, 36 Orthogonal relay catalysis was 
attempted to perform the three sequential reactions in one-pot (Scheme 112). 
This resulted in 0% conversion of 39 to 67. The cause of no catalysis could be 
due to the iridium(III) catalyst being inhibited by the thiazolium catalyst 130. 
 
 
Scheme 112 Catalyst test with separate organo and organometallic components. 
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Sequential catalysis was attempted in order to support the idea of catalyst 
inhibition. Two parallel reactions in the absence of thiazolium were followed 
using GC. When the conversion to 67 was observed, a thiazole or thiazolium 
compound was added to the reaction (Figure 48). 
 
 
 
Figure 48 The conversion (%) of 67 against time (min) for the parallel 
dehydrogenation reactions of 39 with either thiazole 169 or thiazolium 130 added at 
30 minutes. Reactions followed using GC with decane as an internal standard. 
 
The mechanism for the inhibition of the iridium catalyst could be a strong 
coordination of the thiazolium carbene to the iridium centre. This would block 
the vacant sites required for an active 16-electron complex, therefore stopping 
the dehydrogenation of the alcohol substrate (Scheme 113). 
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Scheme 113 The proposed inhibited complex 240 preventing formation of the 
activated iridium catalyst 241. 
 
The result of the one-pot tests were disheartening; however, the design of the 
multifunctional catalyst prevents carbene-metal bonding using the N-atom as 
a ligand donor and therefore the observed inhibition should be prevented 
(Scheme 114). 
 
 
Scheme 114 Geometry restricted carbene-iridium bond formation. 
 
3.3. Transfer Dehydrogenation of Benzyl Alcohol 
This section discusses the testing of novel iridium(III) complexes presented in 
Chapter 2, optimisation of reaction conditions, and further catalyst 
development. The first step in the reaction sequence is the dehydrogenation 
of benzyl alcohol 39, however the formation of benzoin and related products 
were also assessed after each test. 
3.3.1. Initial Testing 
The conditions chosen to test the catalytic activity of the thiazole and triazole 
complexes C.1-C.14 were those typically used in the literature, with 39 as a 
comparable substrate.130, 135 Acetone is a good hydrogen acceptor and, used 
in excess as the solvent, is able to drive the equilibrium towards 67. The 
thiazole tethered complex C.1 was found to make only a trace of product 67 
and no derivatives 129 or 237 (Scheme 115). This may be because C.1 is 
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coordinatively saturated, requiring one of the tridentate coordination sites to 
show hemi-lability for abstraction of the hydride from 39. 
 
 
Scheme 115 Attempted catalytic sequence with iridium(III) complex C.1. 
 
The control tests showed that the transfer dehydrogenation worked well in the 
chosen reaction conditions and that a thiazole ring did not inhibit the catalyst. 
However, the result with C.1 suggested that the complex was inactive, where 
other tethered DPEN ligands have been successful.136 Complex C.2 was 
tested under similar conditions to produce 67 in 10% conversion (Scheme 
116). 
 
 
Scheme 116 The transfer dehydrogenation of 39 to 67 with novel catalyst C.2.  
 
This result indicated that the thiazole side chain was not the cause of inactivity, 
however, the yield was poor. Following a similar procedure by Fujita,130 
triethylamine was changed for potassium carbonate as the base in the reaction 
(Table 16). 
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Table 16 Catalyst tests with control and novel catalysts. 
 
 
a Conversion calculated from the corrected peak integrals using decane as an 
internal standard for GC at 24 hours. 
 
The yield was improved slightly using potassium carbonate and with a lower 
catalyst loading (entry 3). The conversion to 67 was almost as good as the 
control catalysts (entries 1 and 2). As the aim of the project was to carry out 
reactions in sequence, the benzaldehyde was expected to be used up as it 
was made, which would give a small concentration. However, the benzoin and 
hydrobenzoin products were not observed. Surprisingly, the aldehyde yield in 
the control reactions with the iridium(III) dimer and the iridium(III) complex 62 
were lower than seen previously (Scheme 108), and the cause was found to 
be an unwanted aldol side reaction. 
3.3.2. Aldol Reaction 
It is reported in transfer hydrogenation reactions that the acetone produced 
can react with the aldehyde substrate to make aldol products, especially with 
electrophilic substrates. In these reactions the aldol side-reaction has been 
avoided by slowly feeding in the aldehyde substrate to keep its concentration 
low, and relying on the faster rate of reduction compared to the aldol.137 In the 
case of transfer dehydrogenation, the acetone is in high concentration, 
increasing the chance of enolate formation. The enolate can attack the 
aldehyde product as it is formed. After re-analysis of the GC samples using an 
extended method and using GCMS to identify the compounds, the aldol 
reaction with acetone was shown to be occurring to produce the aldol products: 
Entry Catalyst
Conversion             
(%)
a
1 36 16
2 36 + (R ,R )-162 18
3 C.2 14
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4‐hydroxy‐4‐phenylbutan‐2‐one 242, benzylidene 243 and dibenzylidene 244 
(Figure 49). 
 
 
 
Figure 49 a) The conversion of 39 to 67 and the aldol reaction of 67 with acetone to 
give 242 and further products 243 and 244. b) Catalyst; 36. c) Catalyst; C.2. 
Samples quantified using GC with biphenyl as an internal standard. 
 
With catalyst 36, the rate of reaction is very fast, reaching 30% conversion 
after five minutes. Following the initial accumulation of 67 the aldol reaction 
begins, but after five hours 67 falls to below 10%. Once the aldol product 242 
is present in a high enough concentration, 243 is produced. 244 is present at 
4% after 24 hours. The reaction with catalyst C.2 showed a slower initial rate 
than 36, and did not reach equilibrium as quickly, as the substrate continued 
to decrease. A control reaction of 39 under the same conditions in the absence 
of catalyst showed only starting material after 24 hours. However, another 
control reaction with 67 as the substrate, also without catalyst, resulted in 
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formation of all the aldol products (Scheme 117), showing the aldol side-
reaction is not catalysed by C.2. 
 
 
Scheme 117 The aldol reaction in the absence of catalyst followed using GC with 
biphenyl as an internal standard. 
 
To see whether there are any other background reactions occurring, such as 
the Tishchenko138 or Cannizzaro139 reactions, an IR probe was used to follow 
a reaction of 67, 39 and potassium carbonate in acetonitrile in the absence of 
acetone (Figure 50). The reaction was heated to 50 °C and monitored for five 
hours, which resulted in no change to the presence of the benzaldehyde 
carbonyl stretch at 1702 cm-1. 
 
 
Figure 50 Overlayed IR spectra (time in minutes) with separate additions of 67 and 
39 at 0 and 30 minutes.  
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To prevent the aldol side reaction, the solvent was changed to acetonitrile; 
removing the ability to form 242, but also removing the hydrogen acceptor. As 
expected, the reaction in absence of acetone gave only 1% conversion to 67 
(entry 1, Table 17). Acetone was added back into the reaction in quantities 
stoichiometric with 39 to try to improve the conversion. Introducing one 
equivalent improves the conversion (entry 2), whilst five equivalents added 
over five hours (entry 3) resulted in a slight improvement to 7% conversion. 
Since acetone has a high vapour pressure, its loss from the reaction would 
increase the concentration of iso-propanol and drive the reverse reaction. The 
reactions were followed using GC (Figure 52), which shows that after four 
hours, the rate of conversion to 67 slows and even decreases at 24 hours. 
With the absence of side-products, this indicates that the dehydrogenation is 
in equilibrium with the reverse reaction under these conditions. Previously, 
complex C.1 was inactive in acetone. With acetonitrile as the solvent the 
complex gave 3% conversion (entry 4). Surprisingly, dehydrogenation of 39 to 
67 with catalyst C.3 (entry 5) gave a higher conversion than C.2. The only 
structural difference between the complexes is the bicyclic side chain; hydroxyl 
or ketone for C.2 and C.3 respectively. The activity of C.2 could be hindered 
due to competitive coordination of the hydroxyl group with the metal centre, 
which has been suggested is the reason behind an improvement in the 
enantioselectivity of other catalytic systems that use CsDPEN ligands.110 The 
mono- and bidentate thiazole complexes C.4–C.6 were prepared with the aim 
of improving the availability of the metal centre for catalysis by increasing the 
number of vacant/labile sites. All three complexes were able to turn-over, 
however the conversions were also poor (entries 6–8) (Figure 51).  
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Figure 51 Complexes C.1–C.7.1 
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Table 17 The conversions to 67 with varied acetone equivalents. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. b 5 equivalents added evenly over a period of 5 
hours. c Conversion calculated at 6 hours.d 0.5 mol% catalyst.  
 
 
Figure 52 Conversion (%) to 67 against reaction time (hours) with three different 
conditions (entries 1–3, Table 17). 
 
Entry Catalyst
Acetone                
(x eq)
Conversion             
(%)
a
1 C.2 0 1
2 C.2 1 5
3 C.2 5
b
7
c
4 C.1 1 3
5 C.3
d 2 12
6 C.4 1 5
7 C.5
d 2 3
8 C.6
d 2 5
9 C.7.1
d 2 4
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The benzoin products were not observed in any of the catalyst experiments. 
The cause of this could be due to the unsuccessful deprotonation at the 
thiazole C-2 position, as the acidity of this proton is dependent on the strength 
of the coordination of the thiazole N-donor to the iridium metal centre. If the 
metal has a poor electron withdrawing ability, the pKa of the thiazole will not be 
sufficiently decreased to allow the deprotonation and activation of the thiazole 
catalytic site, therefore the reaction will not occur. In order to correct this, 
alkylation of the N-atom of the thiazole would reduce the pKa of the C-2 position 
to ~17, which is more accessible with mild bases. The complexes C.1–C.7.1 
tested with 67 as the substrate in an attempt to produce 129 (Table 18). The 
iridium(III) complexes were unsuccessful in transforming 67 to 129. The bis-
thiazole ligand L.6 was alkylated on one of the thiazole rings to make 
thiazole/thiazolium ligand L.7; which was itself a successful organocatalyst for 
the benzoin condensation (entry 5). However, even though the thiazolium ring 
in C.7.1 is pointing away from the metal centre in the x-ray crystal structure, 
the iridium complex was not able to catalyse the reaction (entry 4). 
Intermolecular carbene-iridium bond formation could be the problem with the 
reaction, which would inhibit the organocatalyst. 
 
Table 18 Catalyst tests for the benzoin condensation of 67 to 129. 
 
 
 
Entry Catalyst
Catalyst Loading  
(x mol%)
Base           
(y eq)
Solvent
Temp      
(°C)
Yield     
(%)
1 C.4 1.0 K2CO3 (0.1) MeCN 40 0
2 C.1 5.0 Et3N (0.6) EtOH 70 0
3 C.1 5.0 Et3N (0.6)
i
PrOH 70 0
4 C.7.1 3.0 Et3N (5.0) MeCN 50 0
5 L.7 5.0 Et3N (2.0) MeCN 80 93
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3.3.3. Hexamethylacetone (HMA) 
Another way in which the aldol and reverse reactions can be avoided is using 
a hydrogen acceptor which cannot form the aldol products. Williams has used 
alkenes such as styrene and crotonitrile as successful hydrogen acceptors 
(Scheme 118);56, 140-142 however, Rovis has demonstrated that alkenes can be 
electrophiles for organocatalysed Stetter reactions between an alkene and an 
aldehyde (Scheme 119).143  
 
 
Scheme 118 The transfer dehydrogenation of benzyl alcohol 39 reported by 
Williams, with styene as the hydrogen acceptor.  
 
 
Scheme 119 The asymmetric Stetter reaction reported by Rovis with nitrostyrene 
246 and butraldehyde 239 using a chiral triazolium organocatalyst 245.  
 
HMA has a higher boiling point (152 °C) than acetone (56 °C), so higher 
reaction temperatures and reaction rates are accessible. Furthermore, with the 
absence of α-hydrogens, enolate formation is not possible; therefore the aldol 
reaction cannot occur. Even though at lab-scale it is 2000 times more 
expensive than acetone, HMA was tested to see if it was a viable hydrogen 
acceptor. Using C.3, the conversions were low (entries 1–3, Table 4), and even 
using it as a solvent failed to improve the conversion (entry 3). It may be that 
steric hindrance makes its reduction difficult, or the equilibrium favours the 
ketone over the alcohol. 
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Table 19 Catalyst tests with HMA as the hydrogen acceptor. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. 
 
3.3.4. Acetone Equivalents 
The transfer dehydrogenation reaction was investigated further to improve the 
conditions. The two main factors that were varied were the base loading and 
the number of acetone equivalents (Table 5). The type of base was also 
changed; a heterogeneous inorganic base (potassium carbonate) and a 
homogenous organic base (triethylamine). 
 
 
 
 
 
 
 
 
Entry
Catalyst Loading  
(x mol%)
HMA                   
(y eq)
Temperature          
(°C)
Conversion             
(%)
a
1 1.0 2.0 50 5
2 0.7 2.0 75 9
3 0.5 solvent 60 1
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Table 20 Catalyst tests with varied base, base loading and acetone equivalents. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. b MeCN (1 mL). c Conversion calculated at 4 hours. 
 
Starting from the previous results using 0.1 equivalents of potassium 
carbonate (entry 1), it was found that changing the base to triethylamine gave 
a slight improvement (entry 2). Further increasing the amount of triethylamine 
and acetone equivalents had little effect on the conversion (entries 3–5). Using 
potassium carbonate and increasing the amount of base and acetone showed 
a further improvement up to 30% conversion (entry 10). Repeating this 
reaction with potassium tert-butoxide, a stronger base, was detrimental (entry 
11). To see what affect an acid would have on the conversion, acetic acid was 
used instead of a base; however, the conversion was poor (entry 12). The 
experiments with increasing acetone (entries 6–10) were followed using GC 
(Figure 53). The initial rate of conversion in the reactions are fast for the first 
Entry Base
Base Loading       
(x eq)
Acetone        
(y eq)
Conversion             
(%)
a
1 K2CO3 0.1 5 8
b
2 Et3N 0.5 5 11
b
3 Et3N 1.0 10 8
4 Et3N 5.0 10 4
c
5 Et3N 1.0 20 12
6 K2CO3 1.0 10 11
7 K2CO3 1.0 20 26
8 K2CO3 1.0 30 24
9 K2CO3 1.0 40 25
10 K2CO3 1.0 50 30
11 KO
t
Bu 1.0 50 4
12 AcOH 1.0 50 3
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hour, then the rate slows and conversion decreases over time. With 50 
equivalents of acetone in acetonitrile, the conversion continues to increase 
after its initial peak at 2 hours, highlighting the need for a high acetone 
concentration. Pleasingly, no aldol side-products were observed during the 
reactions; the reverse reaction of 67 to 39, with iso-propanol as the hydrogen 
donor, occurs more quickly. This is surprising, as only 0.25 equivalents of iso-
propanol are present versus 50 equivalents of acetone. 
 
  
Figure 53 Conversion (%) against time (hours) for catalyst tests (entries 6–10, 
Table 20). 
 
3.3.5. Sodium Bisulfite Addition 
In an attempt to trap any 67 formed during the reaction, sodium bisulfite was 
added;144 ideally forming the bisulfite adduct 248 which would precipitate out 
of the reaction and drive the equilibrium in the forward reaction (Scheme 120). 
 
 
Scheme 120 Proposed adduct formation to drive the equilibrium to the aldehyde. 
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Direct addition of bisulfite to the reaction in acetonitrile led to no change, due 
to its insolubility. Consequently, the reaction was also investigated in a mixture 
with water, and compared with and without base (Table 21). 
 
 Table 21 Catalyst tests with sodium bisulfite to trap 67. 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. b The mass balance was less than 50% of the 
origional substrate concentration. 
 
The addition of water and/or sodium bisulfite to the reactions still allowed the 
transfer dehydrogenation to proceed; however, the conversions were low. The 
use of sodium bisulfite during the reaction was unsuccessful in improving the 
forward reaction.  
 
 
 
Entry
K2CO3             
(x eq)
MeCN         
(mL)
Water          
(mL)
NaHSO3          
(y eq)
Conversion 
(%)
a
1 0 2 0 0 9
2 1 2 0 1 16
3 0 2 0 1 9
4 0 1 1 0 8
5 0 1 1 1 9
6 1 1 1 0 12
b
7 1 1 1 1 13
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3.3.6. Substrate Addition 
To identify if catalyst deactivation was an issue, an experiment was conducted 
where the substrate was added in ten portions over 5 hours (Figure 54). The 
catalyst continued to turn-over after each addition. However, after the 
conversion reached 23% the reaction plateaued. 
 
 
 
Figure 54 Conversion (%) against time (hours) with 39 (0.1 eq) added every 30 
minutes for 5 hours.  
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3.3.7. Extra Catalyst Addition 
An experiment where a second portion of catalyst was added after 1.5 hours 
resulted in a decrease in conversion to 67; suggesting that the fresh catalyst 
was assisting the reverse reaction (Figure 55). From this experiment it seems 
that the catalyst is not deactivated, otherwise a further increase in conversion 
would be observed. 
 
 
 
Figure 55 Catalyst test with a second addition of catalyst (5 mol%) after 1.5 hours. 
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3.3.8. Reaction Equilibrium 
The equilibrium between the transfer dehydrogenation and hydrogenation 
reactions could be the reason for the poor turnover numbers observed with the 
thiazole iridium(III) complexes. Interestingly, the benzoin condensation 
reaction would remove 67 and drive the equilibrium to the product (Scheme 
121). An experiment starting with an equimolar mixture of 39 and 67 in the 
transfer dehydrogenation conditions resulted in only a small increase (5%) in 
the amount of 67 (Figure 56). 
 
 
Scheme 121 The equilibrium between 39 and 67, with the benzoin condensation 
driving the equilibrium. 
 
 
 
Figure 56 Catalyst test with a starting equimolar mixture of 39 and 67.  
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Physical techniques used in transfer hydrogenation reactions that exploit the 
high volatility of acetone, such as continuous distillation and membrane/mesh 
reactors using nitrogen to strip, have been shown to overcome the reverse 
reaction.145, 146 With its higher boiling point, removing iso-propanol in transfer 
dehydrogenation reactions is significantly more difficult. In an attempt to 
remove iso-propanol from the reaction, a distillation was set up to remove the 
solvent, acetone and iso-propanol. To maintain the acetone concentration and 
reaction volume, fresh acetone and solvent was added via syringe pump at a 
rate equal to distillation (Figure 57). The conversion did not exceed previous 
reactions; however, the temperature was higher and the concentrations of 
acetone or iso-propanol in the reaction were unknown. 
 
 
Scheme 122 The reaction conditions and experimental set-up of the distillation 
catalyst test. 
 
 
Figure 57 The distillation reaction was followed using GC with biphenyl as an 
internal standard. The distillation was stopped after four hours and the reaction was 
continued at 50 °C.  
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3.3.9. Inert Conditions 
The transfer dehydrogenation reaction was carried out previously in aerobic 
conditions in a round bottomed flask. To investigate whether atmospheric 
oxygen affects the catalytic activity, Schlenk reaction tubes and a strict 
nitrogen atmosphere were employed. A comparison of catalysts C.3, C.5 and 
C.6 with 50 equivalents of acetone in acetonitrile showed that C.3 still gave the 
highest conversion (entry 1, Table 22).  
 
Table 22 Comparison of catalysts C.3, C.5 and C.6 under a strict atmosphere of 
nitrogen. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. 
 
 
 
 
Entry Catalyst
Conversion 
(%)
a
1 C.3 21
2 C.5 7
3 C.6 11
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3.3.10. Slow Catalyst Addition 
The addition of catalyst to the reaction was investigated. In an experiment 
without base, the catalyst solution was prepared in a separate vessel to the 
reaction and added in four equal portions over four hours. The reaction was 
then repeated with base in the reaction vessel, but not pre-stirred with the 
catalyst. Then a reaction with only base in the catalyst solution and none in the 
main reaction vessel (Table 23). The experiment with base in the main reaction 
vessel gave the highest conversion (entry 2). The conversion is less than when 
all the catalyst was added at the start of the reaction; suggesting it is not 
deactivating, and that the equilibrium must be the main issue.  
Table 23 The catalyst and base addition catalyst tests with C.3. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. 
 
 
 
 
Entry Vessel 1 Vessel 2
Conversion             
(%)
a
1 – – 9
2 K2CO3 – 17
3 – K2CO3 13
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3.3.11. Further Optimisation 
After carrying out these reactions, the solubility of the potassium carbonate 
was considered problematic, as pre-stirring the catalyst in base and 
transferring it to the reaction still gave a 13% conversion to product. 
Triethylamine was soluble in this solvent combination and, since it was used 
successfully for the benzoin condensation (Table 15), would be a useful base 
in both sequential reactions. Using acetone as the solvent further improved the 
conversion (entry 4) without producing any aldol products as previously found 
using less strict inert conditions (Figure 49). Adding base from the start of the 
reaction gave a higher conversion than a delayed addition (entries 1 and 2). 
The reaction concentration was investigated and 63 mM of substrate in 
acetone was the optimal concentration (entry 6). Even at room temperature, 
the reaction reached 18% conversion (entry 7). The catalyst loading was then 
investigated, which showed that halving the amount of catalyst more than 
halved the conversion (entry 10), whilst doubling the amount had little effect 
(entry 11). With excess catalyst, dimer formation could become a process 
whereby the amount of active catalyst is decreased, resulting in a poorer yield.  
However, the solubility of the catalyst may have been a problem, as a further 
equivalent of base was required to make the reaction homogeneous. The 
repeat reaction (entry 9) gave a lower conversion than previously (entry 6), 
which shows that the catalyst may be more sensitive to the reaction conditions 
than previously thought. This could be due to the sensitivity of the catalyst to 
oxygen and/or water. The rate of reaction shows almost second order kinetics 
(Figure 58). 
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Table 24 Catalysts tests investigating the amount of acetone and catalyst loading. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. b Base added after 1 hour. c Reaction carried out at 
room temperature. d Reaction turned pale yellow with one equivalent of base, after 1 
hour a second equivalent of base added, reaction returned to a pink solution. 
 
 
Figure 58 The optimised catalyst test with C.3 follwed using GC, with biphenyl as an 
internal standard (entry 6, Table 24). 
 
 
Entry
Catalyst Loading (x 
mol%)
Acetone  (y 
mL)
Conversion 
(%)
a
1 5.0 2 47
b
2 5.0 2 51
3 5.0 4 62
4 5.0 4 18
c
5 5.0 6 58
6 5.0 4 48
7 2.5 4 22
8 10.0 4 47
d
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For comparison, the same reaction with 36 as the catalyst was carried out 
(Figure 59). The reaction was monitored using GC and the conversion reached 
77% after 24 hours. There was a very fast initial rate then the conversion 
plateaus. 
 
 
 
Figure 59 Catalyst control test with 36 with inert conditions. 
 
To investigate if adding acetonitrile would affect the reaction, an experiment 
was started in acetone and acetonitrile was added after 1.5 hours; the rate 
slowed and the conversion after 24 hours was 10% lower (Figure 60). 
Acetonitrile can coordinate to the metal centre and possibly block the vacant 
sites needed for catalysis to occur. 
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Figure 60 Transfer dehydrogenation of 39 without (39a/67a) and with (39b/67b) the 
addition of MeCN at 1.5 hours. 
 
An experiment was monitored using 1H NMR spectroscopy, carried out at room 
temperature without mixing (Figure 61). The conversion reached 6% after 24 
hours and the initial rate is three times faster than the second part of the 
reaction. This test again shows that the catalyst continues to turn-over at least 
for 24 hours.  
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Figure 61 Transfer dehydrogenation of 39 followed using 1H NMR in d6-acetone. 
 
3.3.12. Transfer Dehydrogenation Comparison of All Complexes 
To compare their activities, all of the thiazole, triazole and control complexes 
that were synthesised in Chapter 2 (Figure 63) were tested with the best 
conditions identified: Et3N (1.0 eq), acetone (63 mM), N2, 50 °C, 24 h. The 
reactions were carried out under a nitrogen atmosphere using a Radleys 
carousel reactor, which provides even heating and stirring for all the reactions 
(Figure 62).  
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Figure 62 Radleys carousel reactor with twelve reaction tubes. 
 
Each of the reactions were tested in duplicate and the 24 hour conversion was 
measured using both GC and 1H NMR spectroscopy (Figure 64). Overall, the 
duplicate results are in good agreement, and the conversion calculated from 
the GC data is marginally higher compared to the 1H NMR spectroscopy data. 
The control reaction with catalyst 36 gives the best conversion. The CsDPEN 
complex 62 performs moderately, and the TsDPEN and benzyl tethered 
complexes 161 and 168 perform poorly. Interestingly, complex C.3, which was 
used to improve the reaction conditions, performed three times less well than 
previously in a Schlenk tube. This could be due to a less strict nitrogen 
atmosphere in the carousel tubes. The best catalyst was the monodentate 
complex C.4, with a comparable conversion to 36. The bis-thiazole complex 
C.6 and triazole complexes C.11 and C.13 performed well, with conversions 
above 50%. A possible issue with the monodentate complexes is whether the 
ligand is being displaced and the catalyst 36 is responsible for the high 
conversion. However, the other monodentate complex C.7.2 performed badly. 
All thiazolium/triazolium complexes gave very low conversions, except for C.12 
(10%), and there were no other products observed in the reactions. 
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Figure 63 The control, thiazole and triazole complexes that were compared in the 
carousel reactions. 
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Figure 64 The average conversions of the duplicate catalyst tests for the transfer 
dehydrogenation of 39, analysed using GC (with biphenyl as an internal standard) 
and 1H NMR spectroscopy (with mesitylene as an external standard). The error bars  
are the standard deviation of the duplicate results. 
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3.3.13. Transfer Hydrogenation Comparison with All Complexes 
The thiazole, triazole and control complexes were also tested for the transfer 
hydrogenation of 67 with iso-propanol as the hydrogen donor (Figure 65). 
 
 
 
Figure 65 The average conversions of the duplicate catalyst tests for the transfer 
hydrogenation of 67, analysed using GC (with biphenyl as an internal standard) and 
1H NMR spectroscopy (with mesitylene as an external standard). The error bars are 
the standard deviation of the duplicate results. 
 
All the control catalysts and most of the novel catalysts transformed 67 to 39 
with high to quantitative conversions and the duplicates were in good 
agreement. Even the triazolium complex C.12 was successful compared to 
only 10% conversion in the transfer dehydrogenation reaction (Figure 64). 
Complexes C.1, C.7.2, C.9 and C.14 gave low conversions, as with the transfer 
dehydrogenation reaction.  These results indicate that the equilibrium between 
the hydrogen transfer reactions lies towards the primary alcohol, despite a 
large excess of the hydrogen acceptor in the reactions with acetone as a 
solvent. Benzoin was not observed in any of these reactions. 
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3.3.14. Transfer Dehydrogenation Catalyst Loading Comparison 
As complex C.4 gave the best results, the catalyst loading was investigated for 
the transfer dehydrogenation reaction (Table 25). As expected, the conversion 
decreased with catalyst loading. The reactions were followed using 1H NMR 
spectroscopy (Figure 66). 
 
Table 25 The catalyst tests with varied catalyst loadings. 
 
 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. 
 
Entry
Catalyst Loading      
(x mol%)
Conversion             
(%)
a
1 5.00 73
b
2 3.60 62
3 0.90 55
4 0.18 37
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Figure 66 The conversion caluclated from 1H NMR spectroscopy with mesitylene as 
an external standard of 39 to 67 with varied catalyst loading (mol%). The 5.00 mol% 
result was taken from a previous experiment (Figure 64).  
 
3.4. Transfer Dehydrogenation of Benzyl Alcohol Derivatives 
Having identified the best performing catalysts, a range of substituted benzylic 
alcohols were tested to look at the effect of increasing the electron donating or 
withdrawing power of the substituents on the ring (Scheme 123, Table 26). 
The conversion is higher for electron rich substrates (entries 1–3) and had a 
decreasing trend towards the electron poor alcohols with 1,3-dinitrobenzyl 
alcohol failing to give any product (entry 6); this trend follows that reported by 
Fujita.130 The conversions with C.13 were lower than C.4 and C.6, however 
the trend showed similar electronic effects. The results for the hydroxyl and 
methyl substrates were lower than expected, based on the conversion of 39. 
A secondary alcohol, 1-phenylethanol 51, was also tested and reached 
quantitative conversion with catalyst C.4 (entry 7). This result was interesting, 
as the extra methyl group is only a small steric difference, but the redox 
potential of primary alcohol oxidation is higher than secondary alcohols.147 The 
reverse reaction could be slower with acetophenone as it is less electrophilic 
than benzaldehyde, with the equilibrium in favour of the product.  
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Scheme 123 The catalysts and conditions used to test the varied benzylic alcohols 
248–254 in Table 26. 
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Table 26 Transfer dehydrogenation with catalysts C.4, C.6 and C.13. 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. b 0.17 M mesitylene in d6-acetone used as an external 
standard. c Substrate condensed with acetone; no oxidation product observed. 
 
C.4 C.6 C.13
1 99
b
97
b
60
b
2 97 97 69
3 89 84 45
4 78 69 60
5 50 40 13
6 0
b
0
b
0
b
7 100 - 52
8 0
c - -
9 0
c - -
Entry ProductSubstrate
Conversion (%)
a
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With catalyst C.13 the conversion only reaches 52% (entry 7); this is 
interesting, because C.13 has a chiral backbone, and since a racemic mixture 
of 1-phenylethanol was used, a selective catalyst would only give a 50% 
conversion. Two parallel reactions were carried out with the different 
enantiomers of the substrate and both reached the same conversion, 
suggesting the oxidation was not enantioselective (Scheme 124). The 
conversions were higher in these reactions as they were carried out in Schlenk 
tubes with a strict nitrogen atmosphere, again suggesting there is a possible 
sensitivity of the complexes to air or moisture. 
 
 
Scheme 124 Catalyst tests with the two enantiomers of 51, both reaching near 
quantative conversion with catalyst C.13 in Shlenk tubes. 
 
Benzylamine 253 and 1-phenethylamine 254 did not react as hoped, however, 
they did react with acetone to produce benzyl ketimines 260 and 261 (entries 
8 and 9). However, the same reactions were repeated without catalyst and 
shown to give the same conversions (Scheme 125). 
 
 
Scheme 125 Control test for the background reaction of substrates 253 and 254 
with acetone in the absence of a catalyst to produce imines 260 and 261 
respectively. 
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3.4.1. Transfer Dehydrogenation of 1-Phenylethanol 51 
For comparison against 39, the catalyst loading was investigated with 51 
(Table 27). With only 0.2 mol% of catalyst C.4, the reaction proceeded to 93% 
after 24 hours (entry 3). The reactions were followed using 1H NMR 
spectroscopy (Figure 67). The initial rates of the dehydrogenation reactions for 
both the production of 49 and 67 were plotted against the concentration of 
catalyst C.4 (Figure 68). The initial rates of reaction to make 49 were three 
times higher than for making 67 at low catalyst concentration. At higher 
concentrations of catalyst the rate of reaction is much lower for both products, 
again suggesting catalyst dimer formation could be limiting the rate of reaction.     
 
Table 27 The transfer dehydrogenation of 51 with catalyst C.4 with varied catalyst 
loadings. 
 
 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. b The average conversion of two results. 
 
Entry
Catalyst Loading      
(x mol%)
Conversion             
(%)
a
1 5.00 100
2 1.00 97
b
3 0.20 93
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Figure 67 The conversion caluclated from 1H NMR spectroscopy with mesitylene as 
an external standard of 51 to 49 with varied catalyst loading (mol%). 
 
 
Figure 68 The initial rate (mM.s-1) of the dehydrogenation reactions to produce 67 or 
49 against the concentration of catalyst C.4 used (mM). 
 
These results highlight how difficult the transfer dehydrogenation of 39 is in 
comparison to 51. The equilibrium must be responsible for the difference in 
conversion. Frustratingly, the benzoin condensation reaction requires an 
aldehyde substrate to work, meaning the multifunctional catalysis sequence 
cannot be carried out from 51. 
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3.5. Summary 
This chapter has discussed the testing of the novel complexes synthesised in 
Chapter 2 for the transfer dehydrogenation of benzyl alcohol. Control tests 
were carried out to validate the reaction sequence for multicatalysis, and the 
one-pot reaction showed that thiazolium compounds inhibit the transfer 
dehydrogenation of benzyl alcohol. The competition between the transfer 
dehydrogenation reaction and the aldol background reaction was investigated. 
The amount of acetone in the reactions was decreased to prevent the aldol 
reaction, however the conversion suffered. Experiments were conducted with 
increasing amounts acetone, which prevented the aldol reaction from 
occurring. The benzoin reaction was not successful with the iridium(III) 
complexes, even though the thiazole/thiazolium ligand L.7 was a good 
organocatalyst for the reaction.  
Hexamethylacetone was investigated as an alternative hydrogen acceptor, but 
performed poorly, even at higher temperatures. An experiment to trap the 
aldehyde product to drive the equilibrium to the aldehyde using sodium bisulfite 
was attempted, however the solubility of the salt prevented any adduct 
formation. The possibility of catalyst deactivation was negated with a substrate 
addition experiment showing a continually increasing concentration of 
aldehyde. Distillation to remove iso-propanol from the reaction was attempted, 
however the conversion was low.  
Switching the solvent back to acetone under strictly inert and dry conditions 
prevented the aldol reaction from occurring and increased the conversion to 
50% with C.3. Using soluble triethylamine improved the conversion over using 
potassium carbonate. Using the best conditions, all of the complexes prepared 
in Chapter 2 were compared against the control catalysts, and the highest 
conversion was found with monodentate thiazole complex C.4. A small 
substrate scoping set of reactions was carried out with the best three 
complexes and the more electron rich benzylic alcohols were found to be more 
easily oxidised. A secondary alcohol, which is unable to be used as a substrate 
for the organocatalyst, was also tested and found to give quantitative 
conversion; suggesting that the reverse reaction is slower than compared to 
benzaldehyde. Neither benzylamine nor 1-phenethylamine were converted to 
the desired imines (or dimers as expected), but reacted with acetone to form 
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benzyl ketimines. The catalyst loadings for the dehydrogenation of benzyl 
alcohol and 1-phenylethanol were investigated, with the conversion 
decreasing with catalyst loading. 1-Phenylethanol can reach 93% conversion 
with only 0.2 mol% of catalyst C.4. The initial rates of reaction for benzyl 
alcohol were found to be three times slower compared to 1-phenylethanol. At 
5 mol% catalyst loading, both substrates showed a slower initial rate.   
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4. Conclusions and Future Work 
The ability to use a single multifunctional catalyst to compress multiple steps 
into a single catalysed reaction is advantageous, and would improve the 
removal and recyclability of the catalyst from a reaction. There is an inherent 
challenge in creating a multifunctional catalyst, due to the nature of combining 
different catalysts that are aimed specifically at a selected reaction sequence, 
and the need to prevent intermediates reacting with the wrong active site. In 
addition, the substrate scope is narrowed, as only the substrates that can enter 
both catalytic cycles will give the desired products and both catalysts have to 
work in the same reaction conditions. There are very few examples of 
successful multifunctional catalysts in the literature, and those reported are 
made up of organo-organo-catalysts33 or metal-metal catalysts35. 
 
This project has developed an organo-organometallic multifunctional catalyst 
based on an iridium(III) hydrogen transfer catalysts and a thiazolium or 
triazolium benzoin condensation catalysts. A family of novel thiazole iridium(III) 
complexes and a family of triazole iridium(III) complexes were prepared and 
analysed using mass spectroscopy and NMR techniques, with x-ray crystal 
structures obtained where possible.  
 
The complexes were shown to be active for the dehydrogenation of benzyl 
alcohol to benzaldehyde, with monodentate thiazole complex C.4 performing 
on par with the control catalyst [Cp*IrCl2]2. However, the benzoin condensation 
was not catalysed by any of the complexes. The structural features of the early 
complexes were based on well-studied TsDPEN and CsDPEN organometallic 
catalysts, which are bidentate, and transformed into tridentate complexes with 
a tethered thiazole ring. These complexes are coordinatively and electronically 
saturated, and therefore catalyst activity requires one of the donors to 
dissociate to allow the dehydrogenation of the alcohol substrate. Following on 
from this design, monodentate and bidentate complexes were prepared with 
less steric encumbrance around the metal centre. However, the chelate 
strength of the ligands suffers with fewer donors. A pyridine side chain was 
then introduced to add another donor that could coordinate to the metal centre 
and allow a thiazolium to be available; however, the bis-thiazolium-pyridine 
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complex was unstable and decomposed. This highlighted the unfortunate 
leaving group ability of thiazoliums, as found during the synthesis of other 
thiazolium salts.  
 
X-ray crystallography confirmed that the thiazole ring coordinated to the metal 
centre as designed, which was hoped that the pKa of the thiazole would drop 
as electron density was donated to the metal centre. The acidity of the thiazole 
was believed to be one of the main reasons that the benzoin condensation 
reaction failed to work, therefore the ligand designs were focussed on 
thiazolium rings, which have a more accessible pKa. This was confirmed with 
a successful benzoin condensation using thiazolium ligand L.7. Unfortunately, 
the thiazolium-iridium(III) complexes were not organo-catalytically active. To 
further increase the acidity of the organocatalyst, triazole and triazolium 
complexes were made. The triazoliums both formed carbene complexes with 
the metal centre and therefore unable to catalyse the benzoin condensation. 
 
The transfer dehydrogenation reactions were investigated and the limited 
conversions were believed to be the result of an equilibrium that was heavily 
one-sided towards the substrate, and methods to push the equilibrium to the 
product were unsuccessful. The distillation set-up used to remove iso-propanol 
from the reaction using acetonitrile as the solvent, could be further developed 
with acetone as the solvent and allow addition of acetone only. This could help 
to drive off iso-propanol and stop the reverse reaction. Catalyst deactivation or 
dimerization could be a cause of low turn-over numbers, therefore improving 
the complex robustness or the steric bulk about the metal centre could 
increase the amount of active catalyst in the reactions. Kinetic modelling could 
be employed to investigate the mechanism of the dehydrogenation reaction 
with these complexes under these conditions. The results of the transfer 
hydrogenation tests were interesting, as the majority of the novel complexes 
reached quantitative conversions. This suggests the catalysts are able to turn-
over effectively under these conditions and demonstrated the difficulty faced 
with the equilibrium for the dehydrogenation reactions. 
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The substrate scope identified that the more electron rich benzylic alcohols 
were more easily oxidised. The amines tested in the substrate scope did not 
form imines as desired, but reacted with acetone to form ketimines. However, 
cyclic amines could be dehydrogenated more readily, as they should not react 
favourably with acetone in the reactions. 
 
Since the first step in the reaction sequence had been developed, the future 
work of this project would be the development of the benzoin condensation, 
possibly by designing a complex with a more defined steric bulk around the 
organocatalyst centre that would completely prevent carbene-iridium 
coordination or dimerization, which was believed to be a cause of inactivity.   
 
The organocatalyst has other reactivities that could be utilized with a working 
multifunctional catalyst for other reaction sequences. Decarboxylation 
reactions can be catalysed with TPP in enzyme reactions, which could be 
coupled with hydrogen transfer reactions to make aromatic aldehydes from α-
hydroxy-carboxylic acids. The aldehydes could then follow the benzoin 
condensation route and achieve a four-step reaction sequence. 
 
Enzymes have been developed by nature over time, and the ability of allosteric 
enzymes to alter their shape and conformation with specific receptors is yet to 
be adopted by organometallic catalysis. A carbene that is available at the 
centre of a catalyst could act as a receptor for aldehydes or ketones whilst a 
metal catalysed reaction occurs at another functional group on the substrate, 
perhaps aiding C-H activation for alkane dehydrogenation. 
 
Another route that could be ventured could be the combination of two 
immobilised catalysts, on either the same surface or separate surfaces, and 
conducting reactions in batch or continuous flow apparatus. This method could 
allow for the exchange and/or mixing of the types of catalyst required. 
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5. Experimental 
5.1. General Experimental 
All reagents were used as received from commercial suppliers. NMR spectra 
were recorded on a Bruker DX300 spectrometer operating at 300 MHz (1H 
NMR), or on a Bruker AVANCE III 300 operating at 300 MHz (1H NMR), or on 
a Bruker AVANCE III HD-400 spectrometer, operating at 400 MHz (1H NMR) 
and 101 MHz (13C NMR), or on a Bruker Avance 500 spectrometer operating 
at 500 MHz (1H NMR) and 126 MHz (13C NMR). High resolution mass spectra 
were recorded on a Bruker MaXis Impact ESI spectrometer or on an Agilent 
1200 LC and Bruker Daltonics HCT Ultra Ion Trap MS LCMS system. 
Elemental analyses were carried out in a Carlo Erba 1108 Elemental Analyzer. 
Melting point analysis was carried out on a Stuart Melting Point SMP30 and 
infra-red spectroscopy was carried out on a Bruker Platinum-ATR Alpha. 
Specific rotations were measured on a Schmidt & Haensch Polartronic H532. 
Gas chromatography was carried out with a HP6890 series GC system, with 
an FID detector and hydrogen flow gas. Gas chromatography mass 
spectrometry was carried out with a HP6890 series GC system with a HP5973 
mass selective detector and helium flow gas. A 30 m long, 320 m diameter 
HP-5 column was used for both GC and GCMS with an oven temperature of 
60 °C, a ramp of 15 °C/min to 140 °C and then 30 °C/min to 280 °C. 
Heterogeneous GC samples were filtered through a plug of celite prior to 
loading. HPLC data was obtained using an Agilent 1100 HPLC with a DAD and 
the data was processed with Chemstation software. X-ray measurements were 
carried out at 120K on an Agilent SuperNova diffractometer equipped with an 
Atlas CCD detector and connected to an Oxford Cryostream low temperature 
device using mirror monochromated Mo K  radiation ( = 0.7107 Å) or Cu K 
radiation ( = 1.54184 Å) from a Microfocus Mova X-ray source. Petrol refers 
to petroleum ether (40–60 °C). Assignment of NMR signals for novel 
compounds were aided with the following techniques: 13C {1H} DEPT135, 1H 
COSY, HMQC and HMBC. Carbon atoms are numbered to aid NMR 
assignment. All solvents in reactions carried out under nitrogen were collected 
from a solvent purification system and degassed prior to use. 
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5.2. Control Compounds 
5.2.1. Synthesis of Chloro[(R,R)-N-{(1,2-diphenyl-2-amino)-ethyl}-p-
toluenesulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) 161 
 
Following a modified procedure from Blacker and Mellor,47 triethylamine (39 
µL, 0.28 mmol, 4.00 eq) was added to a stirred solution of (R,R)-162 (50 mg, 
0.14 mmol, 2.00 eq) and 36 (54 mg, 0.07 mmol, 1.00 eq) in iso-propanol (5 
mL) and stirred at 40 °C for 16 hours. The solvent was removed from the brown 
solution to give a brown crystalline solid (60 mg, 0.08 mmol, 59%). mp; 130.3–
131.6 °C. ESIMS m/z = M+-Cl 693.2020, Theoretical Mass = 693.2127. 1H 
NMR (500 MHz, CDCl3)  7.40 (d, J = 8.1 Hz, 2H, CH-16/20), 7.22 – 7.06 (m, 
2H, CH-5/7), 6.92 – 6.78 (m, 8H, CH-Ph), 6.64 (d, J = 7.4 Hz, 2H, CH-10/14), 
4.52 – 4.31 (m, 2H, NH2), 4.30 (d, J = 10.8 Hz, 1H, CH-1), 3.68 (t, J = 10.8 Hz, 
1H, CH-2), 2.23 (s, 3H, CH3-21), 1.84 (s, 15H, CH3-22). 13C NMR {1H} (126 
MHz, CDCl3) ; 140.62 (C-15), 139.55 (C-18), 138.91 (C-9), 138.69 (C-3), 
128.76 (C-10/14), 128.61 (C-5/7), 128.50 (C-6), 128.44 (C-16/20), 127.87 (C-
17/19), 127.13 (C-4/8), 127.03 (C-11/13), 126.54 (C-12), 85.59 (C-22), 74.09 
(C-2), 69.58 (C-1), 21.23 (C-21), 8.76 (C-22). IR (cm-1): 3226, 3028, 2978, 
2914, 2603, 2497, 1598, 1475, 1445, 1331, 1159. Spectral data is consistent 
with the literature.148 
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5.2.2. Synthesis of Chloro[(S,S,S)-N-{(1,2-diphenyl-2-amino)-ethyl}-
camphorsulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) 62 
 
Following a modified procedure form Blacker and Mellor,47 Triethylamine (33 
µL, 0.24 mmol, 4.00 eq) was added to a stirred solution (S,S,S)-163 (50 mg, 
0.12 mmol, 2.00 eq) and 36 (47 mg, 0.06 mmol, 1.00 eq) in iso-propanol (5 
mL) and stirred at 40 °C for 16 hours. The solvent was removed from the brown 
solution to give a brown crystalline solid (91 mg, 0.11 mmol, 96%). mp; 164.4–
167.5 °C. ESIMS m/z = M+-Cl 753.2569, Theoretical Mass = 753.2696.  1H 
NMR (500 MHz, CDCl3)  7.26 – 7.07 (m, 10H, CH-Ph), 5.17 (s, 1H, NH), 4.86 
(d, J = 9.8 Hz, 1H, CH-1), 4.77 (s, 1H, CH-2), 3.35 (d, J = 14.7 Hz, 1H, CHH-
3), 2.69 (d, J = 14.7 Hz, 1H, CHH-3), 2.36 – 2.20 (m, 2H, CH-6/9), 2.03 (t, J = 
4.3 Hz, 1H, CH-7), 1.99 – 1.91 (m, 2H, CH-6/8), 1.57 – 1.43 (m, 16H, CH3-25, 
CH-8), 0.85 (s, 3H, CH3-12), 0.74 (s, 3H, CH3-11). 13C NMR {1H} (126 MHz, 
CDCl3) ; 215.96 (C-5), 139.08 (C-19), 133.00 (C-13), 128.82 (C-21/23), 
128.71 (C-22), 128.53 (C-20/24), 128.44 (C-14/18), 127.91 (C-16), 127.74 (C-
15/17), 85.27 (C-25), 63.00 (C-1), 62.34 (C-2), 58.49 (C-4), 51.06 (C-3), 48.58 
(C-10), 42.83 (C-6), 42.56 (C-7), 27.00 (C-8), 24.73 (C-9), 19.73 (C-11), 19.38 
(C-12), 9.03 (C-25). IR (cm-1): 3470, 3216, 3062, 2958, 2916, 1742, 1576, 
1495, 1454, 1376, 1143. The complex is known, but the spectral data has not 
been reported in the literature.48 
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5.2.3. Synthesis of (R,R)-N-{1,2-diphenyl-2-[(phenyl)methanimine]-ethyl}-
p-toluenesulfonamide 166 
 
67 (300 L, 3.00 mmol, 1.1 eq) was added to a solution of (R,R)-162 (1 g, 2.73 
mmol, 1 eq) in toluene (10 mL) and stirred at reflux under nitrogen for 2 hours. 
The solvent was removed from the yellow solution to give a pale yellow solid 
(1.15 g, 2.53 mmol, 93% yield). ESIMS m/z = M++H 455.1802, Theoretical 
Mass = 455.1788. 1H NMR (500 MHz, CDCl3) : 7.82 (d, J = 7.5 Hz, 2H, CH-
23/27), 7.71 (d, J = 8.2 Hz, 2H, CH-Ph), 7.43 (t, J = 7.7 Hz, 2H, CH-Ph), 7.38 
– 7.34 (m, 1H, CH-Ph), 7.27 (d, J = 8.1 Hz, 2H, CH-Ph), 7.20 – 7.15 (m, 1H, 
CH-Ph), 7.13 (m, 5H, CH-Ph), 7.01 – 6.95 (m, 2H, CH-Ph), 6.88 (d, J = 7.5 Hz, 
2H, CH-Ph), 6.19 (s, 1H, CH-1), 4.59 (d, J = 7.8 Hz, 1H, CH-2), 4.18 (d, J = 
7.8 Hz, 1H, CH-3), 4.04 (br s, 1H, S-NH), 2.44 (s, 3H, CH3-28). 
 
5.2.4. Synthesis of (R,R)-N-{1,2-diphenyl-2-(benzylamino)-ethyl}-p-
toluenesulfonamide 164  
 
This compound is known in the literature. 67 (600 L, 6.00 mmol, 1.10 eq) was 
added to a solution of (R,R)-162 (2.0 g, 5.45 mmol, 1.00 eq) in EtOH (20 mL) 
and stirred at reflux (82 °C) under nitrogen. The reaction was followed by TLC 
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until the imine was formed after 2 hours. The reaction was cooled to room 
temperature, diluted with EtOH (20 mL) and NaBH4 (311 mg, 8.72 mmol, 1.60 
eq) was slowly added. The reaction was stirred for 16 hours, quenched with 
water (30 mL) and the organics were extracted with ethyl acetate (2 x 40 mL). 
The organic layer was dried with MgSO4 and the solvent was removed in vacuo 
to give a colourless solid. The solid was recrystallized from ethyl acetate and 
petrol to give the product as colourless fine needles (1.87 g, 4.10 mmol, 75%). 
Rf = 0.62 (ethyl acetate/petrol, 1:3), mp; 126.3–127.2 °C (Lit. 136–138 °C). 
ESIMS m/z = M++H 457.1986, Theoretical Mass = 457.1944. 1H NMR (300 
MHz; CDCl3) : 7.36 (d, J = 8.3 Hz, 2H, CH-23/27), 7.27 (t, J = 6.9 Hz, 3H, CH-
Ph), 7.22 – 7.11 (m, 5H, CH-Ph), 7.09 – 6.87 (m, 9H, CH-Ph), 6.17 (br s, 1H, 
S-NH), 4.31 (d, J = 7.7 Hz, 1H, CH-3), 3.68 (d, J = 7.7 Hz, 1H, CH-2), 3.62 (d, 
J = 13.2 Hz, 1H, CHH-1), 3.41 (d, J = 13.2 Hz, 1H, CHH-1), 2.31 (s, 3H, CH3-
28), 1.68 (br s, 1H, amine-NH).13C NMR {1H} (126 MHz, CDCl3) ; 142.72 (C0-
Ph), 140.77 (C0-Ph), 139.38 (C0-Ph), 138.91 (C0-Ph), 138.27 (C0-Ph), 129.10 
(C-Ph), 128.48 (C-Ph), 128.43 (C-Ph), 128.04 (C-Ph), 127.95 (C-Ph), 127.62 
(C-p-Ph), 127.56 (C-Ph), 127.51 (C-Ph), 127.32 (C-p-Ph), 127.18 (C-p-Ph), 
127.11 (C-Ph), 66.81 (C-2), 63.09 (C-3), 50.88 (C-1), 21.43 (C-28). IR (cm-1); 
3246, 3060, 3026, 2926, 2846, 2815, 1600, 1489, 1456, 1433, 1322, 1156. 
Spectral data is consistent with the literature.97  
 
5.2.5. Synthesis of [(R,R)-N-{1,2-diphenyl-2-(benzylamino)-ethyl}-p-
toluenesulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) 168 
 
Following a modified procedure from Wills,98 triethylamine (14 L, 0.10 mmol, 
2.00 eq) was added to a red solution of 164 (23 mg, 0.05 mmol, 1.00 eq) and 
36 (20 mg, 0.03 mmol, 0.50 eq, 1.00 eq Ir) in iso-propanol (1 mL) and stirred 
at 40 °C for 16 hours. The solvent was removed from the deep red solution in 
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vacuo to give a dark red powder. The powder was washed with water (1 mL) 
and dried in vacuo to give the product as a dark red powder (33 mg, 0.04 mmol, 
84%). mp; 110.3–113.9 °C. ESIMS: m/z = M++H 783.2590, Theoretical Mass 
= 783.2591. 1H NMR (500 MHz, CDCl3)  7.58 (d, J = 7.2 Hz, 2H, CH-23/27), 
7.30 – 7.19 (m, 6H, CH-Ph), 7.10 – 7.05 (m, 4H, CH-Ph), 7.00 – 6.95 (m, 1H, 
CH-Ph), 6.86 (t, J = 7.6 Hz, 2H, CH-Ph), 6.76 (d, J = 8.0 Hz, 2H, CH-24/26), 
6.43 (d, J = 7.5 Hz, 2H, CH-Ph), 5.00 (d, J = 16.3 Hz, 1H, CH-3), 4.29 (s, 1H, 
CHH-1), 3.98 (d, J = 16.3 Hz, 1H, CH-2), 3.57 (s, 1H, CHH-1), 2.23 (s, 3H, 
CH3-28), 1.82 (s, 15H, CH3-29). 13C NMR {1H} (126 MHz, CDCl3) ; 145.69 
(C0-Ph), 142.78 (C0-Ph), 140.88 (C0-Ph), 140.19 (C0-Ph), 140.01 (C0-Ph), 
128.41 (C-p-Ph), 128.27 (C-Ph), 128.00 (C-Ph), 127.89 (C-Ph), 127.33 (C-Ph), 
127.28 (C-p-Ph), 127.08 (C-Ph), 127.04 (C-Ph), 126.62 (C-Ph), 126.15 (C-p-
Ph), 125.91 (C-Ph), 86.29 (C-3), 85.54 (C-29), 64.27 (C-2), 45.92 (C-1), 25.35 
(C-28), 8.71 (C-29). IR (cm-1); 3058, 3026, 2978, 2917, 2603, 2496, 1600, 
1489, 1478, 1444, 1278, 1189. 
 
5.2.6. Synthesis of 3-Ethyl-4-methyl-1,3-thiazol-3-ium bromide 130 
 
169 (5.0 mL, 55.0 mmol, 1.00 eq) was added to 1-bromoethane (4.5 mL, 60.0 
mmol, 1.09 eq) and stirred at reflux under nitrogen for 20 hours. The white 
slurry was washed with EtOH (10 mL) to give a colourless solid, which was 
recrystallized in methanol to give 130 as colourless cubic crystals (2.77 g, 13.3 
mmol, 24%). HPLC; 99% (tR = 5.688 min). mp; 172.3–174.4 °C (Lit. 170–171 
°C).77 ESIMS: m/z =M+-Br 128.0535, Theoretical Mass = 128.0534. 1H NMR 
(300 MHz; d6-DMSO) : 10.17 (d, J = 2.0 Hz, 1H, CH-1), 8.04 (d, J = 2.0 Hz, 
1H, CH-2), 4.47 (q, J = 7.3 Hz, 2H, CH2-5), 2.56 (s, 3H, CH3-4), 1.46 (t, J = 7.3 
Hz, 3H, CH3-6). 13C NMR {1H} (126 MHz, d6-DMSO) ; 158.62 (C-1), 145.74 
(C-3), 121.89 (C-2), 47.86 (C-5), 14.51 (C-4), 12.59 (C-6). IR (cm-1): 3045.28, 
2976.36, 2957.18, 2873.38, 1580.79. Spectral data is consistent with the 
literature.149 
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5.3. Thiazole Compounds 
5.3.1. Synthesis of 1,3-Thiazole-4-carboxaldehyde 184 
 
5.3.1.1. Method 1 
General procedure for the synthesis of 184; DIBALH (1.0 M in DCM, x eq) was 
added dropwise to 183 (1.00 g, 6.36 mmol, 1.00 eq) in DCM (40 mL) under 
nitrogen at –78 °C and stirred for 2 hours. The reaction was quenched slowly 
with MeOH (30 mL), and stirred for 3 hours at room temperature. The solvent 
was removed in vacuo to give a crude solid, which was washed with ethyl 
acetate (20 mL) to give the products described (Table 28). The product (entry 
3) was recrystallized from DCM and petrol to give colourless needles (663 mg, 
5.86 mmol, 92%). 
 
Table 28 The selectivity of the reduction of ethyl-4-thiazolecarboxylate 183  to the 
product aldehyde 184 by varying the number of equivalents of DIBAL-H. 
Ester Aldehyde Alcohol 
1 1.50 0 17 83
2 0.95 0 25 75
3 0.33 93 7 0
4 0.50 14 86 0
5 0.75 0 100 0
Entry
DIBALH 
(eq)
Product Distribution (%)
a
 
 
5.3.1.2. Method 2 
nBuLi (1.6 M in hexanes, 4.0 mL, 6.35 mmol, 1.50 eq) was added dropwise to 
a solution of 4-bromo-2-(trimethylsilyl)-1,3-thiazole (725 L, 4.23 mmol, 1.00 
eq) in dry THF (25 mL) at –78 °C under nitrogen and stirred for 0.5 hours. 4-
Formylmorpholine (636 L, 6.35 mmol, 1.00 eq) in THF (5 mL) was added 
dropwise and stirred at –78 °C under nitrogen for 1 hour. HCl (1 M, 10 mL, 10 
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mmol, 2.36 eq) was added dropwise and stirred for 16 hours whilst the reaction 
was allowed to warm to room temperature. The brown solution was washed 
with DCM (10 mL) and extracted with brine (30 mL). The solvent was removed 
in vacuo from the organic layer to give a brown solid (crude mass 553 mg, 0% 
yield). 1H NMR gave trace conversion only. 
5.3.1.3. Analytical Data 
mp; 62.4–63.3 °C (Lit. 59–61 °C)150. LCMS: m/z = M++H 114.0, Theoretical 
Mass = 114.0. 1H NMR (300 MHz, CDCl3)  10.13 (s, 1H, CH-4), 9.18 (d, J = 
0.8 Hz, 1H, CH-1), 8.07 (s, J = 0.8 Hz, 1H, CH-2). 13C NMR {1H} (126 MHz, 
CDCl3) ; 184.83 (C-4), 155.72 (C-3), 154.01 (C-1), 126.66 (C-2). IR (cm-1); 
3074, 2860, 2799, 2727, 2699, 1682. Spectral data is consistent with the 
literature.150 
 
5.3.2. Synthesis of (R,R)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-yl)methan 
imine]-ethyl}-p-toluenesulfonamide 188 
 
184 (100 mg, 0.88 mmol, 1.10 eq) and (R,R)-162 (294 mg, 0.80 mmol, 1.00 
eq) were stirred at reflux in ethanol (5 mL) for 2 hours. The homogenous yellow 
solution was cooled to room temperature and the solvent was removed in 
vacuo to give yellow powder (370 mg, 0.80 mmol 91% yield). ESIMS: m/z = 
M+ 462.2270, Theoretical Mass = 462.1304. 1H NMR (300 MHz, CDCl3) ; 8.91 
(d, J = 2.0 Hz, 1H, CH-1), 7.72 (d, J = 2.0 Hz, 1H, CH-2), 7.50 (d, J = 8.3 Hz, 
2H, CH-20/24), 7.27 – 7.17 (m, 8H, CH-Ph), 7.15 (d, J = 8.3 Hz, 2H, CH-21/23), 
7.05 (m, 2H, CH-Ph), 6.15 (s, 1H, CH-4), 4.71 (d, J = 6.8 Hz, 1H, CH-5), 4.49 
(d, J = 6.8 Hz, 1H, CH-6), 2.41 (s, 3H, CH3-25), 2.23 (br s, 1H, S-NH). 13C 
NMR {1H} (126 MHz, CDCl3) ; 153.41 (C-1), 148.61 (C-3), 143.70 (C-22), 
139.25 (C0-Ph), 138.21 (C0-Ph), 134.80 (C-19), 129.49 (C-Ph), 128.57 (C-Ph), 
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128.33 (C-Ph), 127.84 (C-Ph), 127.74 (C-Ph), 127.64 (C-Ph), 127.41 (C-Ph), 
126.92 (C-Ph), 117.99 (C-2), 74.89 (C-4), 71.51 (C-6), 69.97 (C-5), 21.57 (C-
25). 
5.3.3. Synthesis of (R,R)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-
amino]-ethyl}-p-toluenesulfonamide L.1 
 
5.3.3.1. Method 1 
184 (250 mg, 2.21 mmol, 1.00 eq) and (R,R)-162 (811 mg, 2.21 mmol, 1.00 
eq) were stirred in ethanol (10 mL) at reflux for 4 hours. The reaction to 188 
was complete by TLC. NaBH4 (126 mg, 3.32 mmol, 1.5 eq) was added to the 
yellow solution and stirred for 16 hours at room temperature. The solvent was 
removed in vacuo from the cloudy solution and the solid was dissolved in DCM 
(2 x 10 mL) and extracted with brine (2 x 20 mL). The organic layers were 
combined, dried with MgSO4, filtered and the solvent was removed in vacuo to 
give a yellow amorphous solid. The product was purified with column 
chromatography (ethyl acetate/petrol, 1:2) and recrystallized from ethyl 
acetate in petrol to give the product as colourless needles (830 mg, 1.79 mmol, 
81% yield). 
5.3.3.2. Method 2 
(R,R)-162 (2.16 g, 5.88 mmol, 1.00 eq), 180•HCl (1.00g, 5.88 mmol, 1.00 eq) 
and K2CO3 (812 mg, 5.88 mmol, 1.00 eq) were stirred in ethanol (50 mL) at 
reflux for 48 hours. The solvent was removed in vacuo to give a yellow solid, 
which was transferred to a separating funnel with DCM (10 mL). The organics 
were washed with DCM (2 x 40 mL) and extracted with a saturated solution of 
NaHCO3 (2 x 50 mL). The organic layers were combined, dried with MgSO4, 
filtered and the solvent was removed in vacuo to give a yellow amorphous 
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solid. The product was purified with column chromatography (ethyl 
acetate/petrol, 1:2) and recrystallized from ethyl acetate in petrol to give the 
product as colourless needles (806 mg, 1.74 mmol, 30%). 
5.3.3.3. Analytical Data 
Rf = 0.40 (ethyl acetate/petrol, 1:3), mp; 142–145 °C. ESIMS m/z = M++H 
464.1463, Theoretical Mass = 464.1461. Anal. Calcd for C25H25N3O2S2: C, 
64.77; H, 5.43; N, 9.06; S, 13.84. Found: C, 63.75; H, 5.40; N, 8.80; S, 14.00. 
1H NMR (500 MHz, CDCl3)  8.66 (d, J = 1.7 Hz, 1H, CH-1), 7.30 (d, J = 8.0 
Hz, 2H, CH-20/24), 7.08 – 7.05 (m, 3H, CH-9–11), 7.02 – 6.88 (m, 8H, CH-
2/Ph), 6.86 (d, J = 7.6 Hz, 2H, CH-15/17), 6.13 (s, 1H, S-NH), 4.27 (d, J = 7.4 
Hz, 1H, CH-6), 3.72 (d, J = 14.3 Hz, 1H, CH-4), 3.67 (d, J = 7.4 Hz, 1H, CH-
5), 3.58 (d, J = 14.3 Hz, 1H, CH-4), 2.26 (s, 3H, CH-25), 2.00 (br s, 1H, amine-
NH).13C NMR {1H} (126 MHz, CDCl3) ; 155.95 (C-3), 152.93 (C-1), 142.70 (C-
22), 138.85 (C-13), 138.38 (C-7), 137.14 (C-19), 129.12 (C-21/23), 128.38 (C-
8/12), 127.97 (C-14/18), 127.61 (C-9/11), 127.59 (C-10), 127.46 (C-15/17), 
127.31 (C-16), 127.09 (C-20/24), 114.36 (C-2), 67.16 (C-5), 63.10 (C-6), 46.85 
(C-4), 21.43 (C-25). IR (cm-1); 3304, 2957, 2935, 2872, 2854, 1613, 1583, 
1511, 1454, 1437, 1248, 1148. X-ray crystal data for this compound can be 
found in the appendix. 
5.3.4. Synthesis of [(R,R)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-
amino]-ethyl}-p-toluenesulfonamide](η5-pentamethylcyclopenta 
dienyl)iridium(III) chloride C.1 
 
Triethylamine (70 L, 0.50 mmol, 4.00 eq) was added to a solution of (R,R)-
L.1 (116 mg, 0.25 mmol, 1.00 eq) and 36 (100 mg, 0.13 mmol, 0.50 eq, 1.00 
eq Ir) in iso-propanol (5 mL) and stirred at room temperature for 18 hours. The 
solvent was removed in vacuo to give a light brown powder, which was 
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recrystallized in DCM and petrol to give brown microcrystals (108 mg, 0.14 
mmol, 55% yield). mp; 203.7–206.2 °C. ESIMS: m/z = M+ 790.2096, 
Theoretical Mass = 790.2113. 1H NMR (500 MHz, CDCl3) 9.53 (br s, 1H, 
amine-NH), 9.32 (d, J = 1.9 Hz, 1H, CH-1), 7.50 (s, 1H, CH-2), 7.39 (d, J = 7.6 
Hz, 2H, CH-20/24), 7.24 – 7.14 (m, 3H, CH-15–17), 7.07 (d, J = 8.1 Hz, 2H, 
CH-21/23), 6.75 – 6.56 (m, 7H, CH-9–12/14/18), 4.59 (d, J = 12.2 Hz, 1H, CH-
6), 4.53 (dd, J = 12.2, 3.3 Hz, 1H, CH-5), 4.42 (d, J = 17.0 Hz, 1H, CH-4), 4.19 
(d, J = 17.0 Hz, 1H, CH-4), 2.13 (s, 3H, CH3-25), 2.02 (s, 15H, CH3-26).13C 
NMR {1H} (126 MHz, CDCl3) ; 159.48 (C-3), 155.62 (C-1), 140.45 (C-19), 
140.03 (C-22), 137.70 (C-13), 132.36 (C-7), 131.28 (C-20/24), 128.79 (C-
15/18), 128.25 (C-Ph), 128.11 (C-16), 128.03 (C-Ph), 127.41 (C-Ph), 127.08 
(C-21/23), 126.45 (C-10), 112.29 (C-2), 88.42 (C-26), 79.96 (C-6), 64.19 (C-
5), 47.32 (C-4), 21.03 (C-25), 9.68 (C-26). IR (cm-1); 3376, 3029, 2977, 2916, 
2529, 2495, 1600, 1489, 1267, 1133. 
 
5.3.5. Synthesis of (R,R)-N-{1,2-diphenyl-2-[(3-methyl-1,3-thiazol-3-ium-
4-ylmethyl)-amino]-ethyl}-p-toluenesulfonamide iodide 209 and N-
Methyl-4-(iodomethyl)-1,3-thiazol-3-ium iodide 208 
(R,R)-L.1 (100 mg, 0.21 mmol, 1.00 eq) was stirred in iodomethane (4 mL) at 
110 °C in a microwave for 3 hours. The precipitate was filtered from the 
solution and washed with DCM (5 mL) to give 208 as a spectroscopically pure 
orange powder (18 mg, 0.05 mmol, 23%). 
5.3.5.1. Analytical Data for N-Methyl-4-(iodomethyl)-1,3-thiazol-3-ium 
iodide 208 
 
mp; 175.6–177.3 °C. ESIMS m/z = M+-I 239.9347, Theoretical Mass = 
239.9344. 1H NMR (500 MHz, d6-DMSO) 10.12 (d, J = 2.4 Hz, 1H, CH-1), 
8.30 (d, J = 2.6 Hz, 1H, CH-2), 4.81 (s, 2H, CH2-4), 4.15 (s, 3H, CH3-5). 13C 
NMR {1H} (126 MHz, d6-DMSO) ; 161.88 (C-1), 146.31 (C-3), 123.97 (C-2), 
39.60 (C-5), –9.20 (C-4). IR (cm-1): 3073, 3005, 2848, 1563, 1456.  
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5.3.6. Synthesis of (S,S,S,R)-C-(7,7-Dimethyl-2-hydroxy-bicyclo[2.2.1] 
hept-1-yl)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-amino]-ethyl}-
methanesulfonamide L.2 
 
(S,S,S)-163 (189 mg, 0.44 mmol, 1.00 eq) and 184 (50 mg, 0.44 mmol, 1.00 
eq) were dissolved in ethanol (10 mL) and stirred at reflux for 20 hours. The 
reaction was allowed to cool to room temperature and NaBH4 (42 mg, 1.10 
mmol, 2.5 eq) was added and stirred at room temperature for 20 hours. The 
solvent was removed in vacuo to give an orange amorphous solid, which was 
dissolved in DCM (50 mL) and extracted with an aqueous HCl solution (2 M, 
50 mL). The organic layer was neutralized with a saturated aqueous solution 
of NaHCO3 (50 mL) and the organics extracted with DCM (50 mL), dried with 
MgSO4, filtered and the solvent was removed in vacuo to give an orange solid. 
The product was purified with column chromatography (ethyl acetate/petrol, 
1:1) and recrystallized from ethyl acetate and petrol to give the product as a 
colourless powder (118 mg, 0.36 mmol, 82% yield). Rf = 0.57 (ethyl 
acetate/petrol, 1:1). mp; 73.3–75.1 °C. ESIMS: m/z = M++H 526.2192, 
Theoretical Mass = 526.2193.  1H NMR (500 MHz, CDCl3)  8.73 (s, 1H, CH-
1), 7.37 – 7.12 (m, 10H, CH-Ph), 7.00 (s, 1H, CH-2), 6.22 (br s, 1H, S-NH), 
4.59 (d, J = 7.3 Hz, 1H, CH-6), 3.97 – 3.92 (m, 2H, CH-5/9), 3.87 (d, J = 14.3 
Hz, 1H, CHH-4), 3.70 (d, J = 14.3 Hz, 1H, CHH-4), 2.99 (br s, 1H, OH), 2.63 
(d, J = 13.9 Hz, 1H, CHH-7), 2.21 (d, J = 13.9 Hz, 1H, CHH-7), 2.10 (br s, 1H, 
amine-NH), 1.74 – 1.57 (m, 4H, CH-10–12), 1.56 – 1.48 (m, 1H, CHH-13), 1.46 
– 1.31 (m, 1H, CHH-13), 1.11 – 0.92 (m, 1H, CH-12), 0.72 (s, 3H, CH3-15), 
0.56 (s, 3H, CH3-16). 13C NMR {1H} (126 MHz, CDCl3) ; 155.80 (C-3), 153.11 
(C-1), 139.13 (C-16), 138.86 (C-22), 128.64 (C-Ph), 128.08 (C-p-Ph), 128.02 
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(C-p-Ph), 127.78 (C-Ph), 127.53 (C-Ph), 114.57 (C-2), 76.24 (C-9), 66.42 (C-
5), 63.37 (C-6), 53.24 (C-7), 50.17 (C-8), 48.43 (C-14), 46.70 (C-4), 44.29 (C-
11), 38.79 (C-10), 30.31 (C-13), 27.34 (C-12), 20.33 (C-16), 19.47 (C-15). IR 
(cm-1); 3515, 3264, 3063, 2951, 2879, 1467, 1444, 1311, 1133. 
 
5.3.7. Synthesis of [(S,S,S,R)-C-(7,7-Dimethyl-2-hydroxy-bicyclo[2.2.1] 
hept-1-yl)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-amino]-ethyl}-
methanesulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) 
chloride C.2 
 
Triethylamine (70 L, 0.50 mmol, 4.00 eq) was added to a yellow solution of 
L.2 (132 mg, 0.25 mmol, 1.00 eq) and 36 (100 mg, 0.13 mmol, 1.00 eq) in iso-
propanol (5 mL) and stirred at room temperature for 16 hours. The solvent was 
removed in vacuo to give a dark brown powder (164 mg, 0.19 mmol, 77% 
yield). mp; 171.6–175.8 °C. ESIMS; m/z = M+-Cl 852.2587, Theoretical Mass 
= 852.2845.  1H NMR (500 MHz, CDCl3)  9.77 (s, 1H, NH), 9.29 (d, J = 2.0 
Hz, 1H, CH-1), 7.47 (d, J = 7.5 Hz, 2H, CH-23/27), 7.36 (s, 1H, CH-2), 7.28 – 
7.23 (m, 2H, CH-24/26), 7.25 – 7.12 (m, 5H, CH-Ph), 7.11 – 7.06 (m, 1H, CH-
19), 4.67 (dd, J = 12.5, 4.0 Hz, 1H, CH-5), 4.53 (d, J = 12.5 Hz, 1H, CH-6), 
4.28 (dd, J = 17.8, 7.4 Hz, 1H, CHH-4), 4.11 (d, J = 17.8 Hz, 1H, CHH-4), 3.81 
(s, 1H, CH-9), 3.29 (d, J = 2.4 Hz, 1H, OH), 1.98 (s, 15H, CH3-28), 1.94 (s, 2H, 
CH2-7), 1.58 – 1.44 (m, 6H, CH-10–13),  0.97 (t, J = 8.3 Hz, 1H, CHH-10), 0.51 
(s, 3H, CH3-16), 0.46 (s, 3H, CH3-15). 13C NMR {1H} (126 MHz, CDCl3) ; 
158.48 (C-3), 156.00 (C-1), 139.62 (C-22), 132.24 (C-16), 131.38 (C-23/27), 
128.94 (C-25), 128.78 (C-Ph), 128.57 (C-Ph), 128.34 (C-24/26), 128.06 (C-
19), 113.05 (C-2), 88.18 (C-28), 79.04 (C-5), 76.08 (C-9), 64.39 (C-6), 57.37 
(C-7), 51.33 (C-8), 48.10 (C-14), 47.64 (C-4), 44.33 (C-11), 38.43 (C-13), 
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31.58 (C-12), 27.36 (C-10), 20.31 (C-16), 19.39 (C-15), 9.98 (C-28). IR (cm-1); 
3445, 3031, 2928, 2878, 2602, 2495, 1476, 1453, 1291, 1106. 
 
5.3.8. Synthesis of (S,S,S)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-
amino]-ethyl}-camphorsulfonamide L.3 
 
180•HCl (500 mg, 2.94 mmol, 1.00 eq), (S,S,S)-163 (1.26 g, 2.94 mmol, 1.00 
eq) and K2CO3 (812 mg, 5.88 mmol, 2.00 eq) were stirred in acetonitrile (15 
mL) at reflux for 48 hours. The reaction was cooled to room temperature, 
washed with DCM (25 mL x 3) and extracted with a saturated solution of 
NaHCO3 (25 mL x 3). The combined organics were extracted with brine (2 x 
20 mL) and the organic layer was dried with MgSO4 and filtered. The solvent 
was removed in vacuo to give a pale yellow amorphous solid, which was 
purified using column chromatography (ethyl acetate/petrol, 2:1) to give a 
colourless amorphous solid. The solid was recrystallized from 2% ethyl acetate 
in petrol solution to give the product as colourless needles (550 mg, 1.06 mmol, 
36%). Rf = 0.63 (petrol:ethyl acetate, 1:2). mp; 68.4–72.1 °C. ESIMS m/z = M+ 
524.2105, Theoretical Mass = 524.2036. 1H NMR (500 MHz, CDCl3)  8.72 
(d, J = 1.9 Hz, 1H, CH-1), 7.29 – 7.17 (m, 10H, CH-Ph), 7.02 (d, J = 1.9 Hz, 
1H, CH-2), 6.33 (d, J = 3.7 Hz, 1H, S-NH), 4.70 (dd, J = 6.9, 4.3 Hz, 1H, CH-
6), 3.91 (d, J = 7.2 Hz, 1H, CH-8), 3.84 (d, J = 14.2 Hz, 1H, CHH-4), 3.69 (d, J 
= 14.2 Hz, 1H, CHH-4), 3.01 (d, J = 15.0 Hz, 1H, CHH-7), 2.46 (d, J = 15.0 Hz, 
1H, CHH-7), 2.35 – 2.26 (m, 2H, CH-11/12), 2.03 (t, J = 4.4 Hz, 1H, CHH-10), 
1.99 – 1.89 (m, 1H, CHH-13), 1.84 (d, J = 18.4 Hz, 1H, CHH-10), 1.66 – 1.59 
(m, 2H, CHH-20, amine-NH), 1.35 – 1.26 (m, 1H, CHH-13), 0.93 (s, 3H, CH3-
15), 0.73 (s, 3H, CH3-16). 13C NMR {1H} (126 MHz, CDCl3) ; 155.9 (C-3), 
152.86 (C-1), 139.48 (C-23), 139.34 (C-17), 128.53 (C-21/19), 128.40 (C-
25/27), 127.88 (C-18/22), 127.78 (C-20), 127.67 (C-26), 127.38 (C-24/28), 
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114.40 (C-2), 67.03 (C-4), 63.32 (C-6), 58.58 (C-8), 50.10 (C-7), 46.85 (C-14), 
42.73 (C-10), 42.70 (C-11), 26.92 (C-13), 25.29 (C-12), 19.81 (C-15), 19.62 
(C-16). IR (cm-1): 3265, 3063, 3029, 2957, 1741, 1602, 1494, 1454, 1321, 
1145. 
 
5.3.9. Synthesis of [(S,S,S)-N-{1,2-diphenyl-2-[(1,3-thiazol-4-ylmethyl)-
amino]-ethyl}-camphorsulfonamide](η5-pentamethylcyclo 
pentadienyl)iridium(III) chloride C.3 
 
Triethylamine (30 L, 0.21 mmol, 4.00 eq) was added to a solution of L.3 (56 
mg, 0.11 mmol, 2.00 eq) and 36 (42 mg, 0.05 mmol, 1.00 eq) in iso-propanol 
(2 mL) at room temperature for 24 hours. The solvent was removed in vacuo 
from the deep red solution to give dark red microcrystals (83 mg, 0.10 mmol, 
89%). mp; 207.2–211.1 °C. ESIMS m/z = M+-Cl 850.2400, Theoretical Mass = 
850.2688.  1H NMR (500 MHz, CDCl3)  9.59 (s, 1H, NH), 9.26 (d, J = 2.2 Hz, 
1H, CH-1), 7.46 (d, J = 7.5 Hz, 2H, CH-17/21), 7.38 (s, 1H, CH-2), 7.24 (t, J = 
7.5 Hz, 2H, CH-18/20), 7.20 – 7.09 (m, 5H, CH-Ph), 7.05 (t, J = 7.1 Hz, 1H, 
CH-19), 4.66 (dd, J = 12.5, 5.5 Hz, 1H, CH-5), 4.58 (d, J = 12.5 Hz, 1H, CH-
6), 4.24 (dd, J = 17.3, 5.5 Hz, 1H, CHH-4), 4.09 (d, J = 17.3 Hz, 1H, CHH-4), 
2.23 – 2.16 (m, 2H, CH-7/10), 2.13 – 2.04 (m, 2H, CH2-13), 1.96 (s, 15H, CH3-
28), 1.92 (s, 1H, CHH-7), 1.89 (t, J = 4.4 Hz, 1H, CH-11), 1.86 – 1.78 (m, 2H, 
CH2-12), 1.66 (d, J = 18.8 Hz, 1H, CHH-10), 0.98 (s, 3H, CH3-16), 0.71 (s, 3H, 
CH3-15). 13C NMR {1H} (126 MHz, CDCl3) ; 215.20 (C-9), 158.97 (C-3), 
155.97 (C-1), 139.48 (C-22), 132.41 (C-16), 131.35 (C-17/21), 129.12 (C-
23/27), 128.98 (C-19), 128.39 (C-24/26), 128.33 (C-18/20), 127.71 (C-25), 
112.18 (C-2), 88.12 (C-28), 79.03 (C-5), 64.33 (C-6), 59.45 (C-8), 53.57 (C-7), 
47.54 (C-4), 47.01 (C-14), 43.51 (C-11), 42.61 (C-10), 26.58 (C-12), 26.39 (C-
13), 19.97 (C-16), 19.82 (C-15), 9.93 (C-28). IR (cm-1): 3360, 3030, 2956, 
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2919, 1738, 1625, 1493, 1452, 1280, 1117. X-ray crystal data for this 
compound can be found in the appendix. 
 
5.3.10. Synthesis of (R,R)-N-{1,2-diphenyl-2-[(4-methyl-1,3-thiazol-5-
ylmethyl)-amino]-ethyl}-p-toluenesulfonamide 191 
 
190 (100 mg, 0.79 mmol, 1.00 eq) and (R,R)-162 (289 mg, 0.79 mmol, 1.00 
eq) were stirred in ethanol (5 mL) at reflux for 16 hours. The formation of the 
imine was complete by 1H NMR. The reaction was cooled to room temperature 
and NaBH4 (76 mg, 1.97 mmol, 2.50 eq) was added and stirred for 48 hours. 
The solvent was removed in vacuo and the yellow solid was dissolved in DCM 
(5 mL) and transferred to a separating funnel. The organic layer was washed 
with DCM (2 x 10 mL) and extracted with brine (2 x 10 mL). The organic layers 
were combined, dried with MgSO4, filtered and the solvent was removed in 
vacuo to give a pale yellow solid. The solid was purified by recrystallisation 
from ethyl acetate and petrol to give the product as colourless microcrystals 
(284 mg, 0.60 mmol, 75%). mp; 157.9–160.2 °C. ESIMS m/z = M++H 
478.1634, Theoretical Mass = 478.1617. 1H NMR (500 MHz, CDCl3)  8.63 
(s, 1H, CH-1), 7.36 (d, J = 8.2 Hz, 1H, CH-21/25), 7.19 – 7.14 (m, 3H, CH-10–
12), 7.06 (t, J = 7.2 Hz, 1H, CH-17), 7.04 – 6.98 (m, 4H, CH-16/18/22/24), 6.97 
– 6.92 (m, 1H, CH-9/13), 6.87 (d, J = 7.0 Hz, 1H, CH-15/19), 5.90 (s, 1H, S-
NH), 4.32 (d, J = 7.9 Hz, 1H, CH-7), 3.75 (d, J = 14.3 Hz, 1H, CHH-5), 3.68 (d, 
J = 7.9 Hz, 1H, CH-6), 3.59 (d, J = 14.3 Hz, 1H, CHH-5), 2.32 (s, 3H, CH3-26), 
2.13 (s, 3H, CH3-4), 1.82 (br s, 1H, amine-NH). 13C NMR {1H} (126 MHz, 
CDCl3) ; 150.77 (C-1), 149.51 (C-2), 142.84 (C-23), 138.26 (C-8), 137.92 (C-
14), 136.97 (C-20), 130.14 (C-3), 129.13 (C-22/24), 128.53 (C-10/12), 128.02 
(C-16/18), 127.88 (C-17), 127.58 (C-9/13), 127.43 (C-11/15/19), 127.10 (C-
21/25), 66.44 (C-6), 63.00 (C-7), 42.17 (C-5), 21.43 (C-26), 14.91 (C-4). IR 
(cm-1): 3214, 3067, 3029, 2925, 2850, 1600, 1554, 1493, 1331, 1152. 
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5.3.11. Synthesis of (S,S,S)-C-(7,7-Dimethyl-2-hydroxy-
bicyclo[2.2.1]hept-1-yl)-N-{1,2-diphenyl-2-[(4-methyl-1,3-thiazol-5-
ylmethyl)-amino]-ethyl}-methanesulfonamide 192 
 
190 (50 mg, 0.39 mmol, 1.00 eq) and (S,S,S)-163 (168 mg, 0.39 mmol, 1.00 
eq) were dissolved in ethanol (5 mL) and stirred at reflux for 18 hours. The 
formation of the imine was complete by 1H NMR. The reaction was cooled to 
room temperature and NaBH4 (37 mg, 0.98 mmol, 2.5 eq) was added and 
stirred for 16 hours. The solvent was removed in vacuo and the white solid was 
dissolved in DCM (5 mL) and water (5 mL) and transferred to a separating 
funnel. The organic layer was washed with DCM (2 x 10 mL) and extracted 
with brine (2 x 10 mL). The organic layers were combined, dried with MgSO4, 
filtered and the solvent was removed in vacuo to give an off-white solid. The 
solid was purified by recrystallisation from ethyl acetate and petrol to give the 
product as colourless microcrystals (143 mg, 0.26 mmol, 67%). mp; 78.6–80.8 
°C. ESIMS m/z = M++H 540.2361, Theoretical Mass = 540.2349. 1H NMR (500 
MHz, CDCl3)  8.64 (s, 1H, CH-1), 7.33 – 7.09 (m, 10H, CH-Ph), 5.97 (s, 1H, 
S-NH), 4.56 (d, J = 7.3 Hz, 1H, CH-7), 3.98 – 3.91 (m, 1H, CH-10), 3.87 – 3.78 
(m, 2H, CH-5/6), 3.65 (d, J = 14.3 Hz, 1H, CHH-5), 2.60 (d, J = 13.9 Hz, 1H, 
CHH-8), 2.24 (d, J = 13.9 Hz, 1H, CHH-8), 2.16 (s, 4H, CH3-4/OH), 1.69 – 1.49 
(m, 5H, CH-11–14), 1.40 – 1.32 (m, 1H, CHH-11), 1.09 – 0.96 (m, 1H, CHH-
14), 0.70 (s, 3H, CH3-17), 0.57 (s, 3H, CH3-16). 13C NMR {1H} (126 MHz, 
CDCl3) ; 150.90 (C-1), 149.66 (C-2), 138.47 (C-18), 138.34 (C-24), 130.08 
(C-3), 128.76 (C-m-Ph), 128.70 (C-m-Ph), 128.27 (C-p-Ph), 128.24 (C-p-Ph), 
127.71 (C-19/23), 127.63 (C-25/29), 76.24 (C-10), 65.64 (C-6), 63.17 (C-7), 
53.42 (C-8), 50.17 (C-9), 48.44 (C-15), 44.28 (C-12), 42.02 (C-5), 38.76 (C-
13), 30.28 (C-11), 27.34 (C-14), 20.34 (C-16), 19.42 (C-17), 14.95 (C-4). IR 
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(cm-1): 3520, 3262, 3062, 3029, 2952, 2878, 1629, 1602, 1541, 1494, 1454, 
1314, 1139. 
5.3.12. Synthesis of N-methyl-N-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide L.4 
 
194 (111 mg, 0.60 mmol, 2.00 eq) and NaOH (24 mg, 0.60 mmol, 2.00 eq) 
were dissolved in ethanol (10 mL) and stirred at room temperature for 1 hour. 
180•HCl (51 mg, 0.30 mmol, 1.00 eq) was added and the reaction was stirred 
at reflux for 16 hours. The reaction was cooled to room temperature and the 
solvent was removed in vacuo. The crude material was washed with brine (2 
x 10 mL) and extracted with DCM (2 x 10 mL). The organics were collected 
and the solvent was removed in vacuo to give a white solid. The product was 
purified by column chromatography (ethyl acetate/petrol, 1:1) and 
recrystallized from ethyl acetate and petrol to give colourless needles (50 mg, 
0.18 mmol, 59%). 
HPLC: 99% (tR = 15.417 min). Rf  = 0.21 (ethyl acetate/petrol, 1:1). mp; 77.7–
81.3 °C. ESIMS m/z = M++H 283.0568, Theoretical Mass = 283.0569. 1H NMR 
(500 MHz, CDCl3)  8.73 (d, J = 2.0 Hz, 1H, CH-1), 7.70 (d, J = 8.4 Hz, 2H, 
CH-7/11), 7.33 (s, 1H, CH-2), 7.32 (d, J = 8.4 Hz, 2H, CH-8/10), 4.42 (s, 2H, 
CH2-4), 2.79 (s, 3H, CH3-5), 2.44 (s, 3H, CH3-12). 13C NMR {1H} (126 MHz, 
CDCl3) ; 153.01 (C-1), 152.90 (C-3), 143.50 (C-6), 134.63 (C-9), 129.72 (C-
8/10), 127.49 (C-7/11), 116.45 (C-2), 50.07 (C-4), 35.33 (C-5), 21.52 (C-12). 
IR (cm-1): 3100, 3056, 2922, 2856, 1600, 1522, 1489, 1329, 1157.  
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5.3.13. Synthesis of Dichloro[N-methyl-N-(1,3-thiazol-4-ylmethyl)-p-
toluenesulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) C.4 
 
L.4 (25 mg, 0.09 mmol, 2.00 eq) and 36 (35 mg, 0.04 mmol, 1.00 eq) were 
stirred in DCM (5 mL) at room temperature for 16 hours. The solvent was 
removed in vacuo to give a yellow powder. Recrystallization from chloroform 
and hexane gave the product as yellow plates (53 mg, 0.08 mmol, 91%). mp; 
229.6–232.2 °C. ESIMS m/z = M+-Cl 645.0968, Theoretical Mass = 645.0988. 
1H NMR (500 MHz, CDCl3)  9.38 (br s, 1H, CH-1), 7.72 (d, J = 8.1 Hz, 2H, 
CH-7/11), 7.54 (s, 1H, CH-2), 7.36 (d, J = 8.1 Hz, 2H, CH-8/10), 4.84 (s, 2H, 
CH2-4 ), 2.83 (s, 3H, CH3-5), 2.47 (s, 3H, CH3-12), 1.56 (s, 15H, CH3-13). 13C 
NMR {1H} (126 MHz, CDCl3) ; 158.23 (br, C-1), 154.79 (C-3), 143.90 (C-6), 
134.82 (C-9), 129.94 (C-8/10), 127.28 (C-9/11), 117.12 (C-2), 86.08 (C-13), 
50.81 (C-4), 35.64 (C-5), 21.57 (C-12), 8.98 (C-13). IR (cm-1): 3122, 3089, 
2967, 2922, 1600, 1533, 1444, 1373, 1160. X-ray crystal data for this 
compound can be found in the appendix. 
 
5.3.14. Synthesis of N-(1,3-thiazol-4-ylmethyl)-p-toluenesulfonamide L.5 
and N,N-bis-(1,3-thiazol-4-ylmethyl)-p-toluenesulfonamide L.6 
Following a modified procedure from Caldwell;103 194 (402 mg, 2.35 mmol, 
2.00 eq), 180•HCl (200 mg, 1.18 mmol, 1.00 eq) and K2CO3 (650 mg, 4.71 
mmol, 4.00 eq) were stirred at reflux in acetonitrile (10 mL) for 24 hours. The 
white homogeneous solution was washed with ether (3 x 40 mL) and extracted 
with water (3 x 40 mL). The combined organics were dried with MgSO4, filtered 
and the solvent was removed in vacuo to give a pale yellow solid. Both title 
compounds were separated and purified using column chromatography 
(petrol:ethyl acetate, 1:1) and recrystallized from ethyl acetate and petrol. 
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5.3.14.1. Analytical Data for N-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide L.5 
 
Product isolated as colourless plates (155 mg, 0.58 mmol, 49 %). Rf = 0.42 
(petrol:ethyl acetate, 1:1). mp; 123.9–124.7 °C. ESIMS m/z = M+ 269.0470, 
Theoretical Mass = 269.0412.  1H NMR (500 MHz, CDCl3)  8.69 (d, J = 1.9 
Hz, 1H, CH-1), 7.68 (d, J = 8.2 Hz, 2H, CH-6/10), 7.23 (d, J = 8.2 Hz, 2H, CH-
7/9), 7.10 (d, J = 1.9 Hz, 1H, CH-2), 5.59 (t, J = 6.0 Hz, 1H, NH), 4.32 (d, J = 
6.0 Hz, 2H, CH2-4), 2.40 (s, 3H, CH3-11). 13C NMR {1H} (126 MHz, CDCl3) ; 
153.49 (C-1), 152.41 (C-3), 143.44 (C-5), 136.89 (C-8), 129.62 (C-6/10), 
127.14 (C-7/9), 115.67 (C-2), 43.02 (C-4), 21.50 (C-11). IR (cm-1): 3062, 2849, 
1599, 1523, 1308, 1146. 
5.3.14.2. Analytical Data for N,N-bis-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide L.6 
 
Product isolated as colourless plates (61 mg, 0.17 mmol, 29%). Rf = 0.23 
(petrol:ethyl acetate, 1:1). mp; 133.3–135.5 °C. ESIMS m/z = M+ 366.0451, 
Theoretical Mass = 366.0399.  1H NMR (500 MHz, CDCl3)  8.66 (d, J = 2.0 
Hz, 2H, CH-1/1′), 7.64 (d, J = 8.3 Hz, 2H, CH-6/10), 7.27 – 7.23 (m, 4H, CH-
2/2′/7/9), 4.68 (s, 4H, CH2-4/4′), 2.40 (s, 3H, CH3-11). 13C NMR {1H} (126 MHz, 
CDCl3) ; 152.87 (C-3/3′), 152.82 (C-1/1′), 143.23 (C-5), 137.06 (C-8), 129.50 
(C-6/10), 127.29 (C-7/9), 116.92 (C-2/2′), 47.05 (C-4/4′), 21.51 (C-11). IR (cm-
1): 3109, 3067, 2971, 2921, 2857, 1601, 1525, 1498, 1338, 1160. 
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5.3.15. Synthesis of N,N-bis-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide L.6 
194 (101 mg, 0.59 mmol, 1.00 eq), 180•HCl (200 mg, 1.18 mmol, 2.00 eq) and 
K2CO3 (324 mg, 2.35 mmol, 4.00 eq) were stirred at reflux in acetonitrile (5mL) 
for 16 hours. The reaction was cooled to room temperature and the solvent 
was removed in vacuo. The white solid was washed with DCM (2 x 10 mL) and 
extracted with brine (2 x 10 mL). The combined organics were dried with 
MgSO4, filtered and the solvent removed in vacuo to give a white powder (181 
mg, 0.44 mmol, 84%) (see 5.3.14.2 for analytical data). 
 
5.3.16. Attempted synthesis of N-(1,3-thiazol-4-ylmethyl)-p-
toluenesulfonamide L.5 
 
Triethylamine (163 L, 1.18 mmol, 2.00 eq) was added to a solution of  
194 (101 mg, 0.59 mmol, 1.00 eq) and 180•HCl (100 mg, 0.59 mmol, 1.00 eq) 
in acetonitrile (5 mL). The reaction was stirred at reflux for 16 hours. The 
solvent was removed in vacuo to give a white solid. 1H NMR shows the product 
of the SN2 reaction of the 180•HCl with triethylamine to give salt 195. 
5.3.16.1. Analytical Data for triethyl[(1,3-thiazol-4-yl)methyl]azanium 
chloride 195 
 
LCMS: M+ = 199.1, Theoretical Mass = 199.1. 1H NMR (500 MHz, CDCl3) 
8.82 (d, J = 1.9 Hz, 1H, CH-1), 8.33 (d, J = 1.9 Hz, 1H, CH-2), 4.80 (s, 2H, 
CH2-4), 3.35 (q, J = 7.2 Hz, 6H, CH2-Et), 1.37 (t, J = 7.2 Hz, 9H, CH3-Et). 
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5.3.17. Attempted synthesis of (S)-N-(1,3-thiazol-4-ylmethyl) 
camphorsulfonamide 197 
 
Triethylamine (163 L, 1.18 mmol, 2.00 eq) was added to a solution of  
10-camphorsulfonamide (136 mg, 0.59 mmol, 1.00 eq) and 180•HCl (100 mg, 
0.59 mmol, 1.00 eq) in acetonitrile (5 mL). The reaction was stirred at reflux for 
16 hours. The solvent was removed in vacuo to give a white solid. 1H NMR 
shows the intramolecular reaction of the starting material to the sulfonyl imine 
(S)-199 and the product of the SN2 reaction of the 180•HCl with triethylamine 
to give salt 195 (see 5.3.16.1 for analytical data). 
5.3.17.1. Analytical Data for (S)-Camphorsulfonylimine 199  
 
1H NMR (500 MHz, CDCl3) 3.18 (d, J = 13.3 Hz, 1H), 2.97 (d, J = 13.3 Hz, 
1H), 2.77 (ddd, J = 19.1, 4.7, 2.4 Hz, 1H), 2.44 (ddd, J = 19.1, 4.7, 2.4 Hz, 1H), 
2.26 (t, J = 4.3 Hz, 1H), 2.15 (d, J = 4.3 Hz, 1H), 1.79 (t, J = 9.1 Hz, 1H), 1.52 
– 1.43 (m, 2H), 1.09 (s, 3H), 0.87 (s, 3H). Spectral data is consistent with the 
literature.151 
5.3.18. Synthesis of Chloro[N-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) C.5 
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L.5 (30 mg, 0.11 mmol, 2.00 eq) and 36 (45 mg, 0.06 mmol, 1.00 eq) were 
stirred in DCM (5 mL) at 40 °C for 16 hours. The solvent was removed in vacuo 
to give a yellow powder. The powder was washed with DCM (10 mL) and 
extracted with water (10 mL). The solvent was removed to give the product as 
a yellow powder (65 mg, 0.10 mmol, 94%). mp; 209.5–212.3 °C. ESIMS m/z 
= M+-Cl 595.1022, Theoretical Mass = 595.1065.  1H NMR (500 MHz, CDCl3) 
8.80 (d, J = 2.0 Hz, 1H, CH-1), 7.89 (d, J = 8.1 Hz, 2H, CH-6/10), 7.11 (d, J 
= 8.1 Hz, 2H, CH-7/9), 7.02 (d, J = 2.0 Hz, 1H, CH-2), 4.25 (s, 2H, CH2-4), 2.30 
(s, 3H, CH3-11), 1.76 (s, 15H, CH3-12). 13C NMR {1H} (126 MHz, CDCl3) ; 
159.59 (C-3), 151.70 (C-1), 140.51 (C-8), 139.97 (C-5), 128.75 (C-7/9), 128.26 
(C-6/10), 110.70 (C-2), 86.50 (C-12), 49.99 (C-4), 21.33 (C-11), 9.59 (C-12). 
IR (cm-1): 3059, 2978, 2914, 2822, 2603, 2497, 1598, 1548, 1475, 1268, 1132.  
5.3.19. Synthesis of Chloro[N,N-bis-(1,3-thiazol-4-ylmethyl)-p-toluene 
sulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) chloride 
C.6  
 
Triethylamine (11 μL, 0.08 mmol, 2.00 eq) was added to a stirred solution of 
L.6 (30 mg, 0.08 mmol, 2.00 eq) and 36 (33 mg, 0.04 mmol, 1.00 eq) were 
stirred in DCM (5 mL) and stirred at 40 °C under nitrogen for 16 hours. The 
solvent was removed in vacuo to give a yellow powder. The powder was 
washed with DCM (10 mL) and extracted with water (10 mL). The solvent was 
removed in vacuo to give the product as a yellow powder (25 mg, 0.07 mmol, 
86%). mp; 208.1–210.3 °C. ESIMS m/z = M+-Cl2 346.5559, Theoretical Mass 
= 346.5565.  1H NMR (500 MHz, CDCl3) ; 9.00 (br s, 2H, CH-1/1′), 7.70 (d, J 
= 7.7 Hz, 2H, CH-6/10), 7.29-7.27 (m, 4H, CH-2/2′/7/9), 4.90 (br s, 4H, CH2-
4/4′), 2.43 (s, 3H, CH3-11), 1.50 (s, 15H, CH3-12). 13C NMR {1H} (126 MHz, 
CDCl3) ; 159.37 (1/1′), 145.22 (C-3/3′), 141.17 (C-8), 136.96 (C-5), 129.76 
(7/9), 127.30 (8/10), 116.89 (C-2/2′), 86.11 (C-12), 50.18 (C-4/4′), 21.57 (C-
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11), 8.96 (C-12). IR (cm-1): 3093, 2963, 2916, 1596, 1490, 1448, 1408, 1378, 
1155. 
5.3.20. Synthesis of 3-Methyl-4-formyl-1,3-thiazol-3-ium iodide 200 
 
The general procedure for the synthesis of 200; Iodomethane (x eq) was added 
to a stirred solution of 184 (100 mg, 0.88 mmol, 1.00 eq) in acetonitrile (5 mL) 
and stirred under nitrogen. The solvent was removed in vacuo and the crude 
solid was washed with DCM (10 mL) and the precipitate filtered out to give the 
product as a spectroscopically pure orange powder in the yields described 
(Table 29). 
 
Table 29 Methylation of electron poor thiazole 184 to novel thiazolium 200. 
Entry MeI (x eq) Time T (°C) Yield (%)
1 2.5 24 h rt 0
2 5.0 7 d rt 0
3 2.5 16 h 80 11
4 2.5 24 h 80 16
5 10.0 18 h 80 59
 
 
5.3.20.1. Analytical Data 
mp; 149.6–150.8 °C. ESIMS m/z = M+(+H2O)(-I) 146.0068, Theoretical Mass 
= 146.1824. 1H NMR (500 MHz, d6-DMSO)  10.25 (d, J = 2.5 Hz, 1H, CH-1), 
10.01 (s, 1H, CH-4), 9.17 (d, J = 2.5 Hz, 1H, CH-2), 4.37 (s, 3H, CH3-5). 13C 
NMR {1H} (126 MHz, d6-DMSO) ; 180.85 (C-4), 163.52 (C-1), 142.97 (C-3), 
137.79 (C-2), 41.73 (C-5). IR (cm-1): 3088, 2933, 2856, 1698. 
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5.3.21. Synthesis of 3,4-Dimethyl-5-formyl-1,3-thiazol-3-ium iodide 201 
 
The general procedure for the synthesis of 201; Iodomethane (x eq) was added 
to a stirred solution of (200 mg, 1.57 mmol, 1.00 eq) in solvent (5 mL) and 
stirred under nitrogen. The reaction was quenched with ethanol (1 mL) and the 
solvent was removed in vacuo. The brown solid was washed with DCM (10 
mL) and the yellow precipitate was filtered to give a yellow solid in the yields 
described (Table 30). 
 
Table 30 Methylation of a more electron rich thiazole 190 (cf. 184). 
Entry MeI (x eq) Solvent Time (h) T (°C) Yield (%)
1 1.5 DCM 24 40 0
2 2.5 MeCN 24 rt 0
3 2.5 MeCN 18 80 18
 
 
5.3.21.1. Analytical Data 
HPLC: 98% (tR = 6.752 min). mp; 72.1–74.1 °C. ESIMS m/z = M++MeOH 
174.0583, Theoretical Mass = 174.0589. 1H NMR (500 MHz, d6-DMSO) 
10.36 (s, 1H, CH-1), 10.21 (s, 1H, CH-4), 4.16 (s, 3H, CH3-6), 2.84 (s, 3H, 
CH3-5). 13C NMR {1H} (126 MHz, d6-DMSO) ; 183.87 (C-4), 163.97 (C-1), 
153.33 (C-2), 134.61 (C-3), 40.16 (C-6), 12.22 (C-5). IR (cm-1): 3100, 3044, 
2999, 1652. 
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5.3.22. Synthesis of N-(3-methyl-1,3-thiazol-3-ium-4-ylmethyl)-N-(1,3-
thiazol-4-ylmethyl)-p-toluenesulfonamide iodide L.7 
 
L.6 (100 mg, 0.27 mmol, 1.00 eq) was stirred in iodomethane (5 mL) at room 
temperature for 7 days. The solvent was removed in vacuo and recrystallized 
in chloroform, and the precipitate filtered to give the product as a yellow powder 
(95 mg, 0.19 mmol, 70%). HPLC; 87% (tR = 8.072 min). mp; 182.0–183.9 °C. 
ESIMS m/z = M+-I 380.0592, Theoretical Mass = 380.0561. 1H NMR (500 MHz, 
d6-DMSO)   10.04 (d, J = 1.9 Hz, 1H, CH-1), 8.86 (d, J = 1.4 Hz, 1H, CH-6), 
8.04 (d, J = 1.9 Hz, 1H, CH-2), 7.78 (d, J = 8.2 Hz, 2H, CH-11/15), 7.51 – 7.42 
(m, 3H, CH-7/12/14), 4.75 (s, 2H, CH2-5), 4.48 (s, 2H, CH2-9), 4.16 (s, 3H, 
CH3-4), 2.44 (s, 3H, CH3-16). 13C NMR {1H} (126 MHz, CDCl3) ; 160.90 (C-
1), 154.55 (C-6), 151.60 (C-8), 144.14 (C-3), 143.99 (C-13), 134.45 (C-10), 
130.00 (C-12/14), 127.27 (C-11/15), 125.71 (C-2), 117.84 (C-7), 47.54 (C-9), 
44.94 (C-5), 39.92 (C-4), 21.02 (C-16). IR (cm-1): 3116, 3085, 3065, 2969, 
1600, 1579, 1336, 1158. 
 
5.3.23. Synthesis of Dichloro[N-(3-methyl-1,3-thiazol-3-ium-4-ylmethyl)-
N-(1,3-thiazol-4-ylmethyl)-p-toluenesulfonamide](η5-pentamethyl 
cyclopentadienyl)iridium(III) dichloroiodoiridate(III) C.7.1 
 
L.7 (15 mg, 0.03 mmol, 1.00 eq) and 36 (24 mg, 0.03 mmol, 1.00 eq) were 
stirred in acetonitrile (2 mL) at room temperature for 16 hours. The solvent was 
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removed from the orange solution in vacuo to give an orange powder, which 
was recrystallized from chloroform and petrol to give orange needles (23 mg, 
0.02 mmol, 66%). ESIMS m/z = 496.1106 [M+-C11H13N2S2O2 + MeCN], 
Theoretical Mass = 496.1398, m/z = 455.0757 [M+-C11H13N2S2O2], Theoretical 
Mass = 455.1133, m/z = 367.2219 [IrL.7ClI]2+, Theoretical Mass = 367.4462.  
1H NMR (500 MHz, CDCl3)  11.29 (s, 1H, CH-1), 8.81 (br s, 1H, CH-6), 7.96 
(s, 1H, CH-2), 7.67 (d, J = 7.9 Hz, 2H, CH-11/15), 7.35 (d, J = 7.9 Hz, 2H, CH-
12/14), 7.32 (s, 1H, CH-7), 4.77 (s, 2H, CH2-5), 4.60 (br s, 2H, CH2-9), 4.36 (s, 
3H, CH3-4), 2.46 (s, 3H, CH3-16), 1.77 – 1.51 (m, 30H, CH3-17/18). 13C NMR 
{1H} (126 MHz, CDCl3) ; 164.65 (C-1), 155.40 (br, C-6)151.34 (C-8), 144.73 
(C-13), 143.38 (C-3), 134.57 (C-10), 130.24 (C-12/14), 127.36 (C-11/15), 
125.33 (C-2), 118.96 (C-7), 85.56 (br, C-17/18), 47.37 (C-9), 44.70 (C-5), 
40.98 (C-4), 21.65 (C-16), 9.39 (br, C-17/18). X-ray crystal data for this 
compound can be found in the appendix. 
 
5.3.24. Synthesis of Diiodo[N-(3-methyl-1,3-thiazol-3-ium-4-ylmethyl)-N-
(1,3-thiazol-4-ylmethyl)-p-toluenesulfonamide](η5-pentamethyl 
cyclopentadienyl)iridium(III) C.7.2 
 
L.7 (30 mg, 0.06 mmol, 2.00 eq) and 210 (34mg, 0.03 mmol, 1.00 eq) were 
stirred in DCM (5 mL) at 40 °C under nitrogen for 16 hours. The solvent was 
removed from the dark red solution in vacuo and the red solid was 
recrystallized from chloroform and pentane to give the product as red needles 
(41 mg, 0.04 mmol, 63%). mp; 175.7–182.8 °C. ESIMS m/z = 496.0098 [Cp*IrI 
+ MeCN], Theoretical Mass = 496.1398, m/z = 454.9843 [Cp*IrI], Theoretical 
Mass = 455.1133, m/z = 380.0575 [L.7], Theoretical Mass = 380.0561.  1H 
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NMR (500 MHz, CDCl3)  10.95 (d, J = 2.4 Hz, 1H, CH-1), 8.60 (s, 1H, CH-6), 
7.83 (d, J = 2.4 Hz, 1H, CH-2), 7.57 (d, J = 8.3 Hz, 2H, CH-11/15), 7.26 (d, J 
= 8.3 Hz, 2H, CH-12/14), 7.19 (s, 1H, CH-7), 4.66 (s, 2H, CH2-5), 4.41 (s, 2H, 
CH2-9), 4.29 (s, 3H, CH3-4), 2.38 (s, 3H, CH3-16), 1.84 (s, 15H, CH3-17). 13C 
NMR {1H} (126 MHz, CDCl3) ; 162.39 (C-1), 155.89 (C-6), 150.76 (C-8), 
144.70 (C-13), 144.22 (C-3), 134.70 (C-10), 130.20 (C-12/14), 127.36 (C-
11/15), 124.45 (C-2), 118.51 (C-7), 88.86 (C-17), 47.18 (C-9), 44.75 (C-5), 
41.16 (C-4), 21.65 (C-16), 10.76 (C-17). IR (cm-1): 3111, 3088, 3064, 2967, 
2905, 1599, 1578, 1449, 1331, 1155. 
 
5.3.25. Synthesis of N-(1,3-Thiazol-4-ylmethyl)-5-methylpyridine-2-
sulfonamide L.8 and N,N-bis-(1,3-Thiazol-4-ylmethyl)-5-
methylpyridine-2-sulfonamide L.9 
211 (100 mg, 0.58 mmol, 1.00 eq), 180•HCl (200 mg, 1.16 mmol, 2.00 eq) and 
K2CO3 (160 mg. 1.16 mmol, 2.00 eq) were stirred in acetonitrile (5 mL) at 80 
°C for 16 hours. The reaction was cooled to room temperature and the solvent 
was removed in vacuo. The white solid was washed with DCM (2 x 20 mL) and 
extracted with a saturated aqueous solution of NaHCO3 (2 x 20 mL). The 
combined organics were wash with brine (20 mL), dried with MgSO4 and 
filtered. The solvent was removed in vacuo to give a white solid, from which 
the two title compounds were isolated and purified using column 
chromatography (ethyl acetate/petrol, 1:1) and recrystallized from ethyl 
acetate and petrol. 
 
5.3.25.1. Analytical Data for N-(1,3-Thiazol-4-ylmethyl)-5-methylpyridine-
2-sulfonamide L.8 
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Product isolated as colourless blocks (34 mg, 0.13 mmol, 22%). Rf: 0.29 (ethyl 
acetate/petrol, 3:1). HPLC; 96% (tR = 7.355 min). mp; 180.1–185.9 °C. ESIMS 
m/z = M++H 270.0369, Theoretical Mass = 270.0365.  1H NMR (500 MHz, d6-
DMSO)  8.98 (d, J = 1.9 Hz, 1H, CH-1), 8.54 (d, J = 1.6 Hz, 1H, CH-9), 8.39 
(t, J = 5.1 Hz, 1H, NH), 7.85 (dd, J = 8.0, 1.6 Hz, 1H, CH-7), 7.80 (d, J = 8.0 
Hz, 1H, CH-6), 7.43 (d, J = 1.9 Hz, 1H, CH-2), 4.30 (d, J = 5.1 Hz, 2H, CH2-4), 
2.40 (s, 3H, CH3-10). 13C NMR {1H} (126 MHz, d6-DMSO) ; 155.26 (C-5), 
154.01 (C-1), 153.72 (C-3), 150.04 (C-9), 138.31 (C-7), 136.92 (C-8), 121.18 
(C-6), 115.95 (C-2), 42.93 (C-4), 17.84 (C-10). IR (cm-1): 3105, 3082, 3025, 
2822, 1459, 1416, 1314, 1132. X-ray crystal data for this compound can be 
found in the appendix. 
 
5.3.25.2. Analytical Data for N,N-bis-(1,3-Thiazol-4-ylmethyl)-5-
methylpyridine-2-sulfonamide L.9 
 
Product isolated as colourless needles (24 mg, 0.07 mmol, 11%). Rf: 0.16 
(ethyl acetate/petrol, 3:1). HPLC; 86% (tR = 8.392 min). mp; 172.1–176.2 °C. 
ESIMS m/z = M++H 367.0384, Theoretical Mass = 367.0352.  1H NMR (500 
MHz, d6-DMSO)  8.93 (d, J = 1.8 Hz, 2H, CH-1/1′), 8.44 (s, 1H, CH-9), 7.78 
(d, J = 7.6 Hz, 1H, CH-7), 7.71 (d, J = 7.6 Hz, 1H, CH-6), 7.45 (d, J = 1.8 Hz, 
2H, CH-2/2′), 4.72 (s, 4H, CH2-4/4′), 2.38 (s, 3H, CH3-10). 13C NMR {1H} (126 
MHz, d6-DMSO) ; 154.87 (C-5), 154.15 (C-1/1′), 152.03 (C-3/3′), 150.01 (C-
9), 138.09 (C-7), 136.99 (C-8), 121.60 (C-6), 117.50 (C-2/2′), 47.31 (C-4/4′), 
17.86 (C-10). IR (cm-1): 3108, 3067, 3023, 2821, 1458, 1414, 1315, 1169. 
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5.3.26. Synthesis of [N-(1,3-Thiazol-4-ylmethyl)-5-methylpyridine-2-
sulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) chloride 
C.8 
 
Triethylamine (13 L, 0.09 mmol, 1.00 eq) was added to a stirred solution of 
L.8 (25 mg, 0.09 mmol, 2.00 eq) and 36 (37 mg, 0.05 mmol, 1.00 eq) in DCM 
(3 mL) and stirred at 40 °C for 24 hours. The solvent was removed from the 
orange solution in vacuo to give the product as orange crystals (50 mg, 0.08, 
88%). mp; 168.0–176.5 °C. ESIMS m/z = M+-Cl 596.0951, Theoretical Mass = 
596.1017.  1H NMR (500 MHz, CDCl3)  11.21 (s, 1H, CH-1), 9.83 (s, 1H, CH-
9), 7.69 (d, J = 7.5 Hz, 1H, CH-7), 7.60 (d, J = 7.5 Hz, 1H, CH-6), 7.04 (s, 1H, 
CH-2), 4.81 (d, J = 17.3 Hz, 1H, CHH-4), 4.22 (dd, J = 17.3, 1.6 Hz, 1H, CHH-
4), 2.60 (s, 3H, CH3-10), 2.17 (s, 15H, CH3-11). 13C NMR {1H} (126 MHz, 
CDCl3) ; 160.23 (C-1), 158.45 (C-3), 155.22 (C-5), 154.61 (C-9), 141.39 (C-
7), 141.28 (C-8), 121.23 (C-6), 111.26 (C-2), 89.92 (C-11), 51.64 (C-4), 18.53 
(C-10), 9.23 (C-11). IR (cm-1): 2978, 2946, 2916, 2739, 2531, 1632, 1475, 
1444, 1332, 1171. X-ray crystal data for this compound, which was collected 
from a single crystal in the preparation of C.10, can be found in the appendix. 
 
5.3.27. Synthesis of [N,N-bis-(1,3-Thiazol-4-ylmethyl)-5-methylpyridine-
2-sulfonamide](η5-pentamethylcyclopentadienyl)iridium(III) 
dichloride C.9 
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L.9 (41 mg, 0.11 mmol, 2.00 eq) and 36 (45 mg, 0.06 mmol, 1.00 eq) were 
stirred in DCM (3 mL) at 40 °C for 24 hours. The solvent was removed from 
the yellow solution in vacuo to give the product as yellow crystals (77 mg, 0.10 
mmol, 96%). mp; 172.9–185.2 °C. ESIMS m/z = 596.0971 [M+-C4H4NSCl2], 
Theoretical Mass = 596.1017, m/z = 367.0362 [L.9+H], Theoretical Mass = 
367.0352. 1H NMR (500 MHz, CDCl3)  9.09 (br s, 2H, CH-1/1′), 8.43 (s, 1H, 
CH-9), 7.92 (d, J = 7.9 Hz, 1H, CH-7), 7.68 (d, J = 7.9 Hz, 1H, CH-6), 7.45 (s, 
2H, CH-2/2′), 5.09 (br s, 4H, CH2-4/4′), 2.45 (s, 3H, CH3-10), 1.56 (s, 15H, CH3-
11). 13C NMR {1H} (126 MHz, CDCl3) ; 161.26 (br, C-1/1′), 155.19 (C-3/3′), 
155.00 (C-5), 150.18 (C-9), 138.21 (C-6), 137.48 (C-8), 122.91 (C-7), 117.65 
(C-2/2′), 86.06 (C-11), 49.91 (br, C-4/4′), 18.59 (C-10), 9.03 (C-11). IR (cm-1): 
2978, 2946, 2882, 2603, 2531, 2497, 1572, 1475, 1444, 1335, 1168. 
 
 
5.3.28. Synthesis of N-bis-(3-Methyl-1,3-thiazol-3-ium-4-ylmethyl) 
-5-methylpyridine-2-sulfonamide diiodide L.10 
 
L.9 (43 mg, 0.12 mmol, 1.00 eq) was stirred in iodomethane (2 mL, excess) at 
40 °C for 16 hours. The solvent was removed in vacuo and washed with DCM, 
and the yellow precipitate filtered and dried in air to give the product as yellow 
crystals (32 mg, 0.06 mmol, 53%). ESIMS m/z = 395.1023 [M+-HI2], 
Theoretical Mass = 395.0670.  1H NMR (500 MHz, d6-DMSO)  10.07 (s, 2H, 
CH-1/1′), 8.69 (s, 1H, CH-10), 8.07 – 8.01 (m, 3H, CH-2/2′/8), 7.98 (d, J = 8.0 
Hz, 1H, CH-7), 4.92 (s, 4H, CH2-5/5′), 4.19 (s, 6H, CH3-3/3′), 2.48 (s, 3H, CH3-
11). 13C NMR {1H} (101 MHz, d6-DMSO) ; 161.95 (C-1/1′), 152.83 (C-6), 
151.40 (C-10), 144.72 (C-4/4′), 139.77 (C-8), 139.43 (C-9), 125.28 (C-2/2′), 
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123.26 (C-7), 46.23 (C-5/5′), 40.56 (C-3/3′), 18.52 (C-11). IR (cm-1): 2981, 
2959, 2904, 1573, 1455, 1370, 1158. 
 
5.3.29. Synthesis of Diiodo[N,N-bis-(3-methyl-1,3-thiazol-3-ium-4-
ylmethyl)-5-methylpyridine-2-sulfonamide](η5-pentamethylcyclo 
pentadienyl)iridium(III) diiodide  C.10 
 
L.10 (16 mg, 0.02 mmol, 1.00 eq) and 210 (12 mg, 0.01 mmol, 1.00 eq) in 
DCM (2 mL) and stirred at 40 °C for 16 hours. The solvent was removed from 
the red solution in vacuo to give a red powder, which was recrystallized in 
acetone and pentane to the give the product as a red crystalline powder (17 
mg, 0.01 mmol, 69%). mp; 192.5–195.7 °C. ESIMS m/z = 596.0962 [M+-
C6H10NSI2], Theoretical Mass = 596.1017, m/z = 496.0102 [Cp*IrI + MeCN], 
Theoretical Mass = 496.1398, m/z = 454.9847 [Cp*IrI], Theoretical Mass = 
455.1133, m/z = 381.0515 [L.10-CH3], Theoretical Mass = 381.0514, m/z = 
284.0518 [L.10-C5H7NS], Theoretical Mass = 284.0527, m/z = 198.0378 
[L.10], Theoretical mass, 198.0374. The complex decomposed before suitable 
NMR spectra could be collected. 
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5.4. Triazole Compounds 
5.4.1. Synthesis of (R,R)-2,3-Diphenylaziridine 225 
 
5.4.1.1. Method 1 
Following a procedure by Fang,152 DIAD (506 µL, 2.57 mmol, 1.10 eq) was 
added to a solution triphenylphosphine (737 mg, 2.81 mmol, 1.20 eq) in THF 
(5 mL) at room temperature under nitrogen with vigorous stirring for 20 
minutes. A solution of (1S,2R)-224 (500 mg, 2.34 mmol, 1.00 eq) and 
triethylamine (971 µL, 7.02 mmol, 3.00 eq) in THF (7.5 mL) was added and 
stirred at room temperature for 20 hours. The solvent was removed in vacuo 
to give a yellow oil, which was then directly purified using column 
chromatography (ethyl acetate/petrol, 1:3) to give the product as a white solid 
(356 mg, 1.82 mmol, 78%). 
5.4.1.2. Method 2 
DIAD (506 µL, 2.57 mmol, 1.10 eq) and triethylamine (971 µL, 7.02 mmol, 3.00 
eq) were added to a stirred solution of triphenylphosphine (737 mg, 2.81 mmol, 
1.20 eq) and (1S,2R)-224 (500 mg, 2.34 mmol, 1.00 eq) in THF (15 mL) under 
nitrogen at room temperature with vigorous stirring for 20 minutes. The dark 
yellow solution was then stirred at room temperature for 20 hours. The solvent 
was removed in vacuo to give a viscous yellow oil, which was then directly 
purified using column chromatography (ethyl acetate/petrol, 1:3) to give the 
product as a colourless oil. The product was recrystallized from ethyl acetate 
to give a white solid (367 mg, 1.88 mmol, 80%). 
5.4.1.3. Analytical Data 
Rf: 0.83 (ethyl acetate/petrol, 1:3). mp; 49.8–50.6 °C (Lit. 56–58 °C). ESIMS 
m/z = M++H 196.1123, Theoretical Mass = 196.1121.  1H NMR (500 MHz, 
CDCl3)  7.38 – 7.32 (m, 4H, CH-Ph), 7.30 – 7.24 (m, 6H, CH-Ph), 3.10 (s, 
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2H, CH-1/1′), 1.49 (s, 1H, NH). 13C NMR {1H} (126 MHz, CDCl3) ; 139.68 (C-
2/2′), 128.64 (C-4/4′/6/6′), 127.34 (C-3/3′/7/7′), 125.52 (C-5/5′), 43.81 (C-1/1′). 
IR (cm-1): 3257, 3216, 3058, 3032, 2982, 1601, 1599, 1490, 1449. Spectral 
data is consistent with the literature.153 
 
5.4.2. Synthesis of 1-Methyl-1,2,4-triazole 230 
 
Iodomethane (448 µL, 7.2 mmol, 1.00 eq) was added to a solution of 226 (500 
mg, 7.2 mmol, 1.00 eq) and K2CO3 (1.49 g, 10.8 mmol, 1.50 eq) in acetonitrile 
(40 mL) and stirred at 45 °C for 2 days. The reaction was cooled to room 
temperature and the solvent was removed in vacuo to give a white solid. The 
solid was washed with DCM and the white precipitate was filtered out to give 
a colourless solution. The solvent was removed in vacuo to give the product 
as a colourless oil (444 mg, 5.34 mmol, 74%). % (tR = min). ESIMS m/z = M++H 
84.0660, Theoretical Mass = 84.0556.  1H NMR (500 MHz, CDCl3)  8.09 (s, 
1H, CH-1), 7.93 (s, 1H, CH-2), 3.95 (s, 3H, CH3-3). IR (cm-1): 3111, 2948, 
1674, 1513. Spectral data is consistent with the literature.154 
 
5.4.3. Synthesis of N-(2S,1R)-(2-Chloro-1,2-diphenylethyl)-p-toluene 
sulfonamide 228 
 
Following a modified procedure from Mattay,155 a solution p-toluenesulfonyl 
chloride (259 mg, 1.36 mmol, 2.00 eq) in THF (2.5 mL) was slowly added to a 
stirred solution of (R,R)-225 (132 mg, 0.68 mmol, 1.00 eq) and pyridine (550 
µL, 6.80 mmol, 10.0 eq) in THF (2.5 mL) at 60 °C under nitrogen and stirred 
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for 16 hours. The bright yellow opaque solution was poured directly into a slurry 
of ice and water (100 mL) and stirred for 10 minutes. The mixture was washed 
with DCM (2 x 50 mL) and extracted with brine (2 x 50 mL). The organics were 
collected, dried with MgSO4, filtered and the solvent was removed in vacuo to 
give a yellow oil. The product was purified with column chromatography (ethyl 
acetate/petrol, 1:3) to give a white solid (73 mg, 0.19 mmol, 28%). HPLC; 86% 
(tR = 10.606 min). Rf: 0.44 (ethyl acetate/petrol, 1:3). mp; 120.1–121.7 °C (Lit. 
122–123 °C).156 ESIMS m/z = M+ 408.0795, Theoretical Mass = 408.0801. 1H 
NMR (500 MHz, CDCl3)  7.49 (d, J = 8.3 Hz, 2H, CH-16/20), 7.32 – 7.26 (m, 
1H, CH-6), 7.23 (t, J = 7.2 Hz, 2H, CH-5/7), 7.17 (t, J = 7.4 Hz, 1H, CH-12), 
7.11 – 7.05 (m, 4H, CH-11/13/17/19), 7.00 (d, J = 7.2 Hz, 2H, CH-4/8), 6.81 
(d, J = 7.3 Hz, 2H, CH-10/14), 5.20 (d, J = 5.0 Hz, 1H, CH-2), 5.18 (d, J = 8.3 
Hz, 1H, NH), 4.81 (dd, J = 8.3, 5.0 Hz, 1H, CH-1), 2.34 (s, 1H, CH3-21). 13C 
NMR {1H} (126 MHz, CDCl3) ; 143.30 (C-18), 137.20 (C-15), 136.40 (C-3), 
135.30 (C-9), 129.34 (C-17/19), 128.80 (C-6), 128.34 (C-11/13), 128.17 (C-
5/7), 128.01 (C-12), 127.92 (C-10/14), 127.76 (C-4/8), 127.06 (C-16/20), 66.64 
(C-2), 63.21 (C-1), 21.44 (C-21). IR (cm-1): 3278, 3064, 3032, 2983, 1598, 
1495, 1457, 1437, 1326, 1168. Spectral data is consistent with the literature.157 
 
5.4.4. Synthesis of (R,R)-N-{1,2-Diphenyl-2-(1,2,4-triazol-1-yl)-ethyl}-p- 
toluenesulfonamide L.11 
 
(2S,1R)-228 (73 mg, 0.19 mmol, 1.00 eq), 1,2,4-triazole (26 mg, 0.38 mmol, 
2.00 eq) and K2CO3 (52 mg, 0.38 mmol, 2.00 eq) were refluxed in acetonitrile 
(10 mL) for 18 hours. The reaction was cooled to room temperature and the 
solvent was removed in vacuo to give a white solid. The solid was transferred 
to a separating funnel, washed with DCM (10 mL), and extracted with a 
saturated aqueous solution of NaHCO3 (10 mL). The organics were collected, 
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dried with MgSO4, filtered and the solvent was removed in vacuo to give a 
white powder (76 mg, 0.18 mmol, 96%). mp; 216.4–219.8 °C. ESIMS m/z = 
M++H 419.1545, Theoretical Mass = 419.1536.  1H NMR (500 MHz, d6-DMSO) 
 8.49 (d, J = 10.9 Hz, 1H, NH), 8.36 (s, 1H, CH-1), 7.77 (s, 1H, CH-2), 7.65 
(dd, J = 7.0, 2.3 Hz, 2H, CH-18/22), 7.40 – 7.31 (m, 3H, CH-19/21/p-Ph), 7.17 
(d, J = 8.2 Hz, 2H, CH-Ph), 7.11 – 7.06 (m, 2H, CH-Ph), 7.02 – 6.96 (m, 5H, 
CH-Ph), 5.73 (d, J = 10.9 Hz, 1H, CH-3), 5.29 (t, J = 10.9 Hz, 1H, CH-4), 2.25 
(s, 3H, CH3-23). 13C NMR {1H} (101 MHz, d6-DMSO) ; 161.02 (C-1/2), 142.13 
(C-20), 139.96 (C-5), 138.95 (C-17), 138.91 (C-11), 129.27 (C-19/21), 128.31 
(C-7/9), 127.97 (C-Ph), 127.82 (C-Ph), 127.79 (C-Ph), 127.36 (C-8), 127.12 
(C-14), 126.56 (C-18/22), 62.49 (C-4), 56.54 (C-3), 21.30 (C-23). IR (cm-1): 
3147, 3108, 2898, 1595, 1510, 492, 1454, 1323, 1151.  
 
5.4.5. Synthesis of Dichloro[(R,R)-N-{1,2-diphenyl-2-(1,2,4-triazol-1-yl)-
ethyl}-p-toluenesulfonamide](η5-pentamethylcyclopentadienyl) 
iridium(III) C.11 
 
Triethylamine (8 µL, 0.06 mmol, 2.00 eq) was added to a stirred solution of 
(R,R)-L.11 (25 mg, 0.06 mmol, 2.00 eq) and 36 (24 mg, 0.03 mmol, 1.00 eq) 
in iso-propanol (5 mL) and stirred at 40 °C under nitrogen for 16 hours. The 
solvent was removed from the yellow solution and the orange solid was 
recrystallized from DCM in petrol to give orange microcrystals (47 mg, 0.06 
mmol, 96%). mp; 171.9–179.2 °C. ESIMS m/z = M+(-Cl) 781.1972, Theoretical 
Mass = 781.1954.  1H NMR (500 MHz, CDCl3)  8.54 (s, 1H, CH-1), 7.95 (s, 
1H, CH-2), 7.45 – 6.87 (m, 14H, CH-Ph), 5.72 (d, J = 9.3 Hz, 1H, CH-3), 5.62 
(br s, 1H, NH), 5.20 (d, J = 9.3 Hz, 1H, CH-4), 2.32 (s, 3H, CH3-23), 1.37 (s, 
15H, CH3-24). 13C NMR {1H} (500 MHz, CDCl3) ; 156.31 (C-1), 149.04 (C-2), 
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144.79 (C-20), 139.16 (C-5), 134.08 (C-17), 132.30 (C-11) 130.22 (C-19/21), 
129.21 (C-12/16), 128.50 (C-Ph), 128.26 (C-Ph), 127.34 (C-18/22), 127.07 (C-
Ph), 125.77 (C-Ph), 124.93 (C-6/10), 85.97 (C-24), 43.99 (C-3), 40.92 (C-4), 
21.65 (C-23), 9.34 (C-24). IR (cm-1): 3062, 2978, 2920, 2604, 2498, 1599, 
1523, 1455, 1327, 1156. 
5.4.6. Synthesis of (R,R)-N-{1,2-Diphenyl-2-(4-methyl-1,2,4-triazol-4-ium-
1-yl)-ethyl}-p-toluenesulfonamide iodide L.12 
 
(R,R)-L.11 (13 mg, 0.03 mmol, 1.00 eq) was stirred in an excess of 
iodomethane (2 mL) at room temperature for 3 d. The yellow solution was 
diluted with acetonitrile (5 mL) and the solvent was removed in vacuo to give 
the product as a yellow powder (16 mg, 0.03 mmol, 95%). mp; 116.5–119.7 
°C. ESIMS m/z = M+-I 433.1688, Theoretical Mass = 433.1698.  1H NMR (500 
MHz, d6-DMSO)  9.99 (s, 1H, CH-1), 9.03 (s, 1H, CH-2), 8.65 (d, J = 10.0 
Hz, 1H, NH), 7.70 – 7.61 (m, 2H, CH-8/10), 7.46 – 7.40 (m, 2H, CH-7/11), 7.21 
(d, J = 8.4 Hz, 2H, CH-19/23), 7.19 – 7.05 (m, 6H, CH-Ph), 7.02 (d, J = 8.4 Hz, 
2H, CH-20/22), 6.09 (d, J = 10.7 Hz, 1H, CH-4), 5.32 (t, J = 10.7 Hz, 1H, CH-
5), 3.67 (s, 3H, CH3-3), 2.25 (s, 3H, CH3-24). 13C NMR {1H} (101 MHz, d6-
DMSO) ; 146.33 (C-2), 143.48 (C-1), 142.52 (C-21), 138.36 (C-18), 137.29 
(C-12), 134.38 (C-6), 129.43 (C-8/10), 129.33 (C-20/22), 129.08 (C-Ph), 
128.69 (C-7/11), 128.13 (C-9), 127.56 (C-Ph), 127.51 (C-15), 126.51 (C-
19/23), 69.04 (C-4), 59.51 (C-5), 34.66 (C-3), 21.31 (C-24). IR (cm-1): 3062, 
2958, 2922, 2854, 1598, 1577, 1496, 1324, 1153. 
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5.4.7. Synthesis of Iodo[(R,R)-1-{1′,2′-Diphenyl-2′-(p-oluenesulfonamido) 
-ethyl}-1,2,4-triazol-2-ylidene](η5-pentamethylcyclopentadienyl) 
iridium(III) iodide C.12  
 
 (R,R)-L.12 (45 mg, 0.08 mmol, 2.00 eq) and 210 (47 mg, 0.04 mmol, 1.00 eq) 
in DCM (5 mL) and stirred at 40 °C for 16 hours. The solvent was removed 
from the red solution to give a red crystalline solid, which was recrystallized 
from DCM and petrol to give the product as dark orange crystals (44 mg, 0.04 
mmol, 54%). mp; 110.9–113.8 °C. ESIMS m/z = 538.0295 [M+ – C21H21NO2S], 
Theoretical Mass = 538.0331, m/z = 496.0100 [M+ – L.12 + MeCN], Theoretical 
Mass = 496.0113, m/z = 454.9845 [M+ – L.12], Theoretical Mass = 454.9848, 
m/z = 434.1726 [L.12 + H], Theoretical Mass = 434.1771. 1H NMR (500 MHz, 
CDCl3)  10.80 (s, 1H, CH-2), 7.94 – 7.73 (m, 2H, CH-Ph), 7.41 – 7.19 (m, 
8H, CH-Ph), 7.09 – 6.94 (m, 2H, CH-Ph), 6.90 (d, J = 7.4 Hz, 2H, CH-Ph), 6.73 
(d, J = 10.0 Hz, 1H, CH-4), 5.38 (t, J = 10.0 Hz, 1H, CH-5), 3.75 (s, 1H, CH3-
3), 2.26 (s, 1H, CH3-24), 1.85 (s, 1H, CH3-25). 13C NMR {1H} (101 MHz, CDCl3) 
; 150.58 (C-2), 144.32 (C-1), 142.90 (C-21), 137.04 (C-18), 135.73 (C-12), 
132.95 (C-6), 129.71 (C-p-Ph), 129.62 (C-Ph), 129.38 (C-Ph), 129.10 (C-Ph), 
128.83 (C-Ph), 128.73 (C-Ph), 128.26 (C-p-Ph), 127.87 (C-Ph), 126.82 (C-Ph), 
88.04 (C-25), 68.68 (C-4), 60.67 (C-5), 32.70 (C-3), 21.41 (C-24), 10.66 (C-
25). IR (cm-1): 3396, 3029, 2908, 1668, 1576, 1549, 1454, 1373, 1154. 
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5.4.8. Synthesis of (R,R)-N-{1,2-Diphenyl-2-(1,2,4-triazol-4-yl)-ethyl}-p- 
toluenesulfonamide L.13 
 
5.4.8.1. Method 1 
Following a modified route from Herrmann and Kühn,129 triethyl orthoformate 
(3.1 mL, 18.8 mmol, 4.00 eq) was added to a stirred solution of 231 (565 mg, 
9.40 mmol, 2.00 eq) in ethanol (20 mL) and stirred at 90 °C in a sealed Ace 
pressure tube for 3 hours. The reaction was cooled to room temperature and 
(R,R)-162 (1.72 g, 4.70 mmol, 1.00 eq) was added to the reaction mixture. The 
reaction was resealed and stirred at 100 °C for 66 hours. The solvent was 
removed in vacuo to give a crude colourless oil. Compounds L.13, 235 and 
236 were isolated and purified using column chromatography (ethyl 
acetate/petrol 1:1). The fractions for L.13 resulted in an impure pink oil. The oil 
was recrystallized from iso-propanol to give the product as colourless prisms 
(165 mg, 0.39 mmol, 8%). The remaining compounds were recrystallized from 
ethyl acetate and petrol to give 236 as colourless needles (499 mg, 1.27 mmol, 
27%), and 235 as colourless plates (409 mg, 1.09 mmol, 23%). 
5.4.8.2. Method 2 
Triethyl orthoformate (3.1 mL, 18.8 mmol, 4.00 eq) was added to a stirred 
solution of 231 (565 mg, 9.40 mmol, 2.00 eq) in ethanol (20 mL) and heated in 
a microwave to 110 °C for 1 hour. (R,R)-162 (1.72 g, 4.70 mmol, 1.00 eq) was 
added to the reaction mixture and reacted in a microwave at 110 °C for 10 
hours. The solvent was removed in vacuo to give a crude colourless oil, which 
was purified by recrystallization from iso-propanol and ethyl acetate, to give 
the product as colourless prisms (201 mg, 0.48 mmol, 10%). The ethyl acetate 
filtrate was treated with petrol to recrystallize 236 as colourless needles (1.14 
g, 2.88 mmol, 60%) 
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5.4.8.3. Analytical Data for L.13 
HPLC; 95% (tR = 8.931 min). Rf: 0.10 (ethyl acetate : petrol, 1:1). mp; 246.1–
249.7 °C. ESIMS m/z = M+ 419.1555, Theoretical Mass = 419.1536.  1H NMR 
(500 MHz, d6-DMSO)  8.82 (s, 2H, CH-1), 8.56 (d, J = 10.4 Hz, 1H, S-NH), 
7.35 (dd, J = 7.9, 1.5 Hz, 2H, CH-5/9), 7.26 (d, J = 8.2 Hz, 2H, CH-17/21), 7.18 
– 7.08 (m, 3H, CH-6–8), 7.00 (d, J = 8.2 Hz, 2H, CH-18/20), 6.98 (dd, J = 7.4, 
2.0 Hz, 2H, CH-11/15), 6.94 – 6.87 (m, 3H, CH-12–14), 5.61 (d, J = 10.4 Hz, 
1H, CH-2), 5.33 (t, J = 10.4 Hz, 1H, CH-3), 2.22 (s, 3H, CH3-11). 13C NMR {1H} 
(101 MHz, d6-DMSO) ; 142.82 (C-1/1′), 142.35 (C-19), 138.65 (C-16), 137.70 
(C-4), 137.27 (C-10), 129.30 (C-18/20), 128.89 (C-6/8), 128.63 (C-7), 128.56 
(C-5/9), 128.15 (C-12/14), 128.00 (C-11/15), 127.49 (C-13), 126.58 (C-17/21), 
64.05 (C-2), 60.42 (C-3), 21.29 (C-22). IR (cm-1): 3143, 3123, 3071, 2880, 
1600, 1516, 1457, 1457, 1329, 1160. X-ray crystal data for this compound can 
be found in the appendix. 
 
5.4.8.4. Analytical Data for N-[(R,R)-2-(p-Toluenesulfonamido)-1,2-
diphenylethyl]formamide 236 
 
HPLC; 72% (tR = 9.424 min). Rf: 0.23 (ethyl acetate/petrol, 1:1). mp; 136.6–
143.8 °C. ESIMS m/z = M+ 395.1426, Theoretical Mass = 395.1424.  1H NMR 
(500 MHz, CDCl3)  8.19 (s, 1H, CH-1), 7.41 (d, J = 8.3 Hz, 2H, CH-17/21), 
7.13 – 7.06 (m, 3H, CH-6–8), 7.02 – 6.96 (m, 3H, CH-13/18/20), 6.95 – 6.89 
(m, 4H, CH-5/9/12/14), 6.71 (d, J = 7.2 Hz, 2H, CH-11/15), 6.50 (d, J = 7.9 Hz, 
1H, amide-NH), 5.80 (d, J = 8.1 Hz, 1H, S-NH), 5.18 (dd, J = 10.0, 7.9 Hz, 1H, 
CH-2), 4.50 (dd, J = 10.0, 8.1 Hz, 1H, CH-3), 2.25 (s, 1H, CH3-22). 13C NMR 
{1H} (126 MHz, CDCl3) ; 161.91 (C-1), 143.17 (C-19), 137.67 (C-16), 137.56 
(C-4), 137.34 (C-10), 129.32 (C-18/20), 128.67 (C-6/8), 128.30 (C-12/14), 
128.10 (C-13), 127.79 (C-7), 127.39 (C-5/9), 127.32 (C-11/15), 126.90 (C-
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17/21), 63.17 (C-3), 57.43 (C-2), 21.42 (C-22). IR (cm-1): 3302, 3110, 3034, 
2917, 2800, 2706, 1661, 1602, 1497, 1456, 1322, 1156. 
5.4.8.5. Analytical Data for (R,R)-1-(p-Toluenesulfonyl)-4,5-diphenyl-4,5-
dihydroimidazole 235 
 
HPLC; 91% (tR = 9.433 min). Rf: 0.68 (ethyl acetate/petrol, 1:1). mp; 181.3–
182.8 °C. ESIMS m/z = 417.1245 [M++MeCN], Theoretical Mass = 417.1511, 
m/z = 395.1430 [M++H3O], Theoretical Mass = 395.1429. 1H NMR (500 MHz, 
CDCl3)  7.79 (d, J = 2.0 Hz, 1H, CH-1), 7.53 (d, J = 8.3 Hz, 2H, CH-17/21), 
7.40 – 7.20 (m, 8H, CH-Ph), 7.19 – 7.09 (m, 2H, CH-5/9), 6.85 (d, J = 7.8 Hz, 
2H, CH-11/15), 5.07 (dd, J = 7.4, 2.0 Hz, 1H, CH-2), 4.54 (d, J = 7.4 Hz, 1H, 
CH-3), 2.45 (s, 3H, CH-22). 13C NMR {1H} (126 MHz, CDCl3) ; 148.48 (C-1), 
144.67 (C-19), 140.76 (C-4), 139.16 (C-10), 134.49 (C-16), 129.83 (C-18/20), 
128.85 (C-m-Ph), 128.72 (C-m-Ph), 128.24 (C-p-Ph), 127.89 (C-p-Ph), 127.41 
(C-17/21), 126.88 (C-5/9), 126.31 (C-11/15), 82.25 (C-2), 69.83 (C-3), 21.57 
(C-22). IR (cm-1): 3350, 3309, 3066, 3037, 2929, 1661, 1597, 1500, 1325, 
1158. 
5.4.9. Synthesis of Dichloro[(R,R)-N-{1,2-Diphenyl-2-(1,2,4-triazol-4-yl)-
ethyl}-p-toluenesulfonamide](η5-pentamethylcyclopentadienyl) 
iridium(III) C.13 
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Triethylamine (17 µL, 0.12 mmol, 2.00 eq) was added to a stirred solution of 
(R,R)-L.13 (50 mg, 0.12 mmol, 2.00 eq) and 36 (48 mg, 0.06 mmol, 1.00 eq) 
in iso-propanol (5 mL) and stirred at 40 °C for 16 hours. The solvent was 
removed from the red solution to give a brown crystalline solid (94 mg, 0.12 
mmol, 96%). mp; 196.8–202.7 °C. ESIMS m/z = M+-Cl 781.1777, Theoretical 
Mass = 781.1955. NMR spectra contains a mixture of a major and minor 
species at 1.15:1.00 respectively. The signals were separated where possible. 
Major: 1H NMR (500 MHz, CDCl3)  9.32 (d, J = 11.1 Hz, 1H, NH), 8.87 (s, 
1H, CH-1), 8.75 (s, 1H, CH-2), 7.43 (d, J = 8.2 Hz, 2H, CH-18/22), 6.15 (d, J = 
11.1 Hz, 1H, CH-3), 5.05 (t, J = 11.1 Hz, 1H, CH-4), 2.20 (s, 3H, CH3-23), 1.74 
(s, 15H, CH3-24). 13C NMR {1H} (126 MHz, CDCl3) ; 145.86 (C-1), 141.74 (C-
17), 141.67 (C-20), 141.31 (C-2), 135.66 (C-5), 135.32 (C-11), 128.66 (C-
19/21), 128.27 (C-12/16), 127.98 (C-6/10), 126.73 (C-18/22), 88.01 (C-24), 
63.87 (C-3), 61.15 (C-4), 21.29 (C-23), 8.85 (C-24). Minor: 1H NMR (500 MHz, 
CDCl3)  10.06 (d, J = 10.5 Hz, 1H, NH), 9.69 (s, 1H, CH-1), 8.48 (s, 1H, CH-
2), 7.57 (d, J = 8.2 Hz, 2H, CH-18/22), 6.25 (d, J = 10.5 Hz, 1H, CH-3), 5.20 
(t, J = 10.5 Hz, 1H, CH-4), 2.22 (s, 3H, CH3-23), 1.83 (s, 15H, CH3-24). 13C 
NMR {1H} (126 MHz, CDCl3) ; 146.41 (C-1), 141.74 (C-17), 141.67 (C-20), 
142.03 (C-2), 135.66 (C-5), 135.32 (C-11), 128.68 (C-19/21), 128.46 (C-
12/16), 127.42 (C-6/10), 127.10 (C-18/22), 89.45 (C-24), 64.99 (C-3), 61.63 
(C-4), 21.29 (C-23), 9.49 (C-24).  IR (cm-1): 3030, 2979, 2863, 2604, 2497, 
1598, 1534, 1495, 1325, 1156. Unassigned signals: 1H NMR (500 MHz, 
CDCl3)  7.24 – 7.01 (m, CH-Ph), 6.99 – 6.80 (m, CH-Ph). 13C NMR {1H} (126 
MHz, CDCl3) ; 128.94 (C-Ph), 128.89 (C-Ph), 128.85 (C-Ph), 128.68 (C-Ph), 
128.04 (C-Ph), 127.74 (C-Ph). 
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5.4.10. Synthesis of (R,R)-N-{1,2-Diphenyl-2-(1-methyl-1,2,4-triazol-1-
ium-4-yl)-ethyl}-p-toluenesulfonamide iodide L.14 
 
Iodomethane (15 µL, 0.24 mmol, 2.00 eq) was added to a stirred solution of 
(R,R)-L.13 (50 mg, 0.12 mmol, 1.00 eq) in acetonitrile (5 mL) and stirred at 50 
°C for 2 days. The reaction was cooled to room temperature and the solvent 
was removed in vacuo to give the product as yellow crystals (53 mg, 0.09 
mmol, 79%). mp; 123.1–125.4 °C. ESIMS m/z = M+-I 433.1690, Theoretical 
Mass = 433.1698. 1H NMR (500 MHz, d6-DMSO)  10.40 (s, 1H, CH-1), 9.52 
(s, 1H, CH-2), 8.69 (d, J = 9.2 Hz, 1H, NH), 7.55 (d, J = 7.6 Hz, 2H, CH-7/11), 
7.44 (d, J = 8.2 Hz, 2H, CH-19/23), 7.32 – 7.22 (m, 3H, CH-8–10), 7.18 (d, J = 
8.2 Hz, 2H, CH-20/22), 7.07 – 6.98 (m, 5H, CH-13–17), 6.09 (d, J = 11.3 Hz, 
1H, CH-4), 5.28 (dd, J = 11.3, 9.2 Hz, 1H, CH-5), 4.11 (s, 3H, CH3-3), 2.31 (s, 
3H, CH3-24). 13C NMR {1H} (101 MHz, d6-DMSO) ; 144.45 (C-2), 143.20 (C-
21), 142.92 (C-1), 138.16 (C-18), 136.57 (C-12), 133.92 (C-6), 129.83 (C-9),, 
129.68 (C-20/22), 129.37 (C-8/10),, 129.24 (C-7/11),, 128.57 (C-14/16),, 
128.27 (C-15),, 128.06 (C-13/17),, 126.78 (C-19/23), 66.44 (C-4), 60.25 (C-5), 
39.56 (C-24),, 21.36 (C-11). IR (cm-1): 3031, 2926, 2859, 1657, 1596, 1573, 
1494, 1330, 1156. 
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5.4.11. Synthesis of Diiodo[(R,R)-4-{1′,2′-Diphenyl-2′-(p-toluene 
sulfonamido)-ethyl}-1,2,4-triazol-2-ylidene](η5-pentamethylcyclo 
pentadienyl)iridium(III) C.14 
 
Triethylamine (20 µL, 0.14 mmol, 3.50 eq) was added to a stirred solution of 
(R,R)-L.14 (43 mg, 0.08 mmol, 2.00 eq) and 210 (47 mg, 0.04 mmol, 1.00 eq) 
in DCM (5 mL) and stirred at room temperature for 18 hours. The solvent was 
removed from the dark red solution to give the product as red crystals (66 mg, 
0.07 mmol, 93%). mp; 189.1–191.2 °C. ESIMS m/z = M+-I 887.1194, 
Theoretical Mass = 887.1468.  1H NMR (500 MHz, CDCl3)  8.51 (s, 1H, CH-
2), 7.39 (d, J = 11.4 Hz, 1H, CH-4), 7.24 (d, J = 8.3 Hz, 2H, CH-19/23), 7.12 
(d, J = 7.2 Hz, 2H, CH-13/17), 7.07 (dd, J = 15.5, 7.6 Hz, 2H, CH-8/10), 7.02 
– 6.91 (m, 6H, CH-9/14–16/20/22), 6.78 (br s, 1H, NH), 6.42 (d, J = 7.6 Hz, 
2H, CH-7/11), 4.94 (d, J = 11.4 Hz, 1H, CH-5), 4.14 (s, 3H, CH, CH3-3), 2.23 
(s, 3H, CH3-24), 1.48 (s, 15H, CH3-25). 13C NMR {1H} (101 MHz, CDCl3) ; 
156.24 (C-1), 142.67 (C-2), 142.35 (C-21), 138.05 (C-18), 137.01 (C-12), 
135.65 (C-6), 129.23 (C-20/22), 128.85 (C-13/17), 128.41 (C-15), 128.17 (C-
8/10), 127.96 (C-9), 127.94 (C-14/16), 127.46 (C-7/11), 126.33 (C-19/23), 
90.97 (C-25), 65.27 (C-4), 63.51 (C-5), 45.64 (C-3), 21.40 (C-24), 10.50 (C-
25). IR (cm-1): 3179, 3032, 3914, 2667, 2476, 1662, 1597, 1553, 1493, 1331, 
1156. X-ray crystal data for this compound can be found in the appendix. 
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5.5. Catalyst Testing Experiments 
5.5.1. Transfer Dehydrogenation of Benzyl Alcohol 39 
 
39 (103 μL, 1.00 mmol, 1.00 eq) was added to a solution of 36 (8 mg, 10.0 
μmol, 1.0 mol%, 2.0 mol% Ir) and K2CO3 (14 mg, 0.10 mmol, 10 mol%) in 
acetone (30 mL) and stirred at room temperature under nitrogen for 6 hours. 
The solvent was removed in vacuo from the yellow solution to give a brown oil. 
The reaction was analysed using 1H NMR, which gave 67% conversion to 
product. 
5.5.1.1. Orthogonal-Relay Catalysis Experiment 
Triethylamine (21 L, 0.15 mmol, 30 mol%) was added to a solution of 36 (10 
mg, 12.5 μmol, 2.5 mol%, 5.0 mol% Ir), (R,R)-162 (9 mg, 25.0 μmol, 5.0 mol%) 
and 130 (5 mg, 25 μmol, 5.0 mol%) in acetone (5 mL) at 60 °C for 30 minutes. 
39 (52 L, 0.50 mmol, 1.00 eq) was added to the yellow solution and stirred at 
60 °C under nitrogen for 16 hours. The reaction was analysed using GC. 0% 
conversion after 16 hours. 
 
5.5.1.2. Sequential Catalysis Experiment – Thiazolium Addition 
Triethylamine (150 L, 1.20 mmol, 50 mol%) and decane (97 μL, 0.50 mmol, 
20 mol%) were added to a solution of 36 (50 mg, 0.06 mmol, 2.5 mol%, 5.0 
mol% Ir) and (R,R)-162 (44 mg, 0.12 mmol, 5.0 mol%) in acetone (5 mL) and 
stirred at 40 °C for 30 minutes. 39 (250 L, 2.40 mmol, 1.00 eq) was added to 
the orange solution and stirred at 40 °C in air for 6 hours. 130 (25 mg, 0.12 
mmol, 5.0 mol%) was added after the reaction had proceeded for 30 minutes. 
The reaction was followed using GC (Figure 69). 18% conversion after 90 
minutes. 
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Figure 69 The conversion (%) of 67 against time (min) for the transfer 
dehydrogenation reaction of 39 with thiazolium 130 added at 30 minutes. The 
reaction was followed using GC with decane as an internal standard. 
 
5.5.1.3. Sequential Catalysis Experiment – Thiazole Addition 
Triethylamine (150 L, 1.20 mmol, 50 mol%) and decane (97 μL, 0.50 mmol, 
20 mol%) were added to a solution of 36 (50 mg, 0.06 mmol, 2.5 mol%, 5.0 
mol% Ir) and (R,R)-162 (44 mg, 0.12 mmol, 5.0 mol%) in acetone (5 mL) and 
stirred at 40 °C for 30 minutes. 39 (250 L, 2.40 mmol, 1.00 eq) was added to 
the orange solution and stirred at 40 °C for 6 hours. 169 (11 L, 0.12 mmol, 
5.0 mol%) was added after the reaction had proceeded for 30 minutes. The 
reaction was followed using GC (Figure 70). 39% conversion after 90 minutes. 
 
0
10
20
30
40
50
0 10 20 30 40 50 60 70 80 90 100
C
o
n
v
er
si
o
n
/%
Time/min
Benzaldehyde Thiazolium Addition
 199 
 
 
Figure 70 The conversion (%) of 67 against time (min) for the transfer 
dehydrogenation reaction of 39 with thiazole 169 added at 30 minutes. The reaction 
was followed using GC with decane as an internal standard. 
 
 
5.5.2. Benzoin Condensation of Benzaldehyde 67 
 
5.5.2.1. General procedure 
67 (1.00 eq) was added to a solution of catalyst (x mol%) in EtOH (30 mL). 
Base (x eq) was added to the reaction and stirred at reflux. The reaction was 
cooled to room temperature and concentrated in vacuo. The crude was 
washed with DCM (2x 20 mL) and extracted with water (2 x 20 mL) and brine 
(20 mL). The combined organics were dried with MgSO4, filtered and the 
solvent was removed in vacuo to give the product as a yellow oil. The oil was 
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recrystallized from DCM and petrol to give the product as yellow needles 
(Table 31). 
 
Table 31 The catalyst tests for the benzoin condensation of 67 to 129 
 
a Reaction carried out in MeCN. 
 
5.5.3. Transfer Hydrogenation of Benzoin 129 
 
129 (212 mg, 1.00 mmol, 1.00 eq), 36 (8 mg, 10.0 μmol, 1.0 mol%, 2.0 mol% 
Ir) and (R,R)-162 (7 mg, 20.0 μmol, 2.0 mol%) in a mixture of formic acid  and 
triethylamine (1.5 mL, 2:1 v/v respectively), at 40 °C under nitrogen for 24 
hours. The reaction was allowed to cool to room temperature and diluted with 
water (5 mL). The precipitate was filtered and washed with water (10 mL). The 
brown solid was dried for 16 hours to give a brown powder, which was washed 
with DCM (10 mL) and dried in air to give a colourless powder (62 mg, 0.29 
mmol, 29%). 1H NMR gave 46% conversion after 24 hours. 
 
Entry Catalyst
Catalyst Loading 
(mol%)
Base
Base Loading     
(mol%)
Time                 
(h)
Yield        
(%)
1 169 5 Et3N 30 24 0
2 169 20 DBU 30 24 0
3 124 5 Et3N 30 1.5 5
4 124 5 Et3N 30 1.5 13
5 124 5 KO
t
Bu 30 4 0
6 130 10 K2CO3 10 24 0
a
7 130 2 Et3N 60 5 0
8 130 20 Et3N 60 5 68
 201 
 
5.6.   Transfer Dehydrogenation Experiments 
 
5.6.1. Initial Test with TsDPEN Iridium(III) Catalyst 161 
36 (10 mg, 12.5 μmol, 2.5 mol%, 5.0 mol% Ir) and (R,R)-162 (9 mg, 25.0 μmol, 
5.0 mol%) were dissolved in acetone (2 mL) and stirred under nitrogen at room 
temperature. 39 (52 L, 0.50 mmol, 1.00 eq) and triethylamine (25 L, 0.15 
mmol, 30 mol%) were added to the orange solution and stirred at 70 °C under 
nitrogen for 20 hours. The reaction was analysed using GC-MS. 54% 
conversion after 20 hours. 
 
5.6.2. Initial Test with C.1 
39 (52 L, 0.50 mmol, 1.00 eq) and triethylamine (25 L, 0.15 mmol, 30 mol%) 
were added to a solution of C.1 (20 mg, 25.0 μmol, 5.0 mol%) in acetone (5 
mL) and stirred under nitrogen at 70 °C under nitrogen for 22 hours. The 
reaction was analysed using GC-MS. 0% conversion after 22 hours.  
 
5.6.3. Initial Test with C.2 
Triethylamine (42 L, 0.30 mmol, 30 mol%) was added to a solution of C.2 (43 
mg, 50.0 μmol, 5.0 mol%) in acetone (5 mL) and stirred at 40 °C for 30 minutes. 
39 (103 L, 1.00 mmol, 1.00 eq) was added to the orange solution and stirred 
at 80 °C for 18 hours. The reaction was analysed using 1H NMR. 10% 
conversion after 18 hours. 
  
5.6.4. General Procedure for Parallel Control Reactions 
Decane (97 μL, 0.50 mmol, 10 mol%) was added to a solution of catalyst (43 
mg, 50.0 μmol, 1.0 mol%) and K2CO3 (70 mg, 0.50 mmol, 10 mol%) in acetone 
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(5 mL) and stirred at room temperature for 30 minutes. 39 (514 L, 5.00 mmol, 
1.00 eq) was added and the reaction was stirred at 60 °C for 24 hours. The 
reaction was analysed using GC (Table 32). 
 
Table 32 Catalyst tests with control and novel catalysts. 
 
a Conversion calculated from the corrected peak integrals using decane as an 
internal standard for GC at 24 hours. 
5.6.5. Aldol Experiment with C.2 
 
C.2 (43 mg, 50.0 μmol, 1.0 mol%), K2CO3 (70 mg, 0.50 mmol, 10 mol%) and 
biphenyl (77 mg, 0.50 mmol, 10 mol%) were stirred in acetone (5 mL) at 40 °C 
for 30 minutes. 39 (514 L, 5.00 mmol, 1.00 eq) was added and the reaction 
was stirred at 60 °C for 24 hours. The reaction was followed using GC (Figure 
71). 67; 8%, 242; 8%, after 5 hours. 
Entry Catalyst
Conversion             
(%)
a
1 36 16
2 36 + (R ,R )-162 18
3 C.2 14
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Figure 71 The conversion of 39 to 67 and the aldol reaction of 67 with acetone to 
give 242 and further products 243 and 244 with catalyst C.2. Samples quantified 
using GC with biphenyl as an internal standard. 
 
5.6.6. Aldol Experiment with [Cp*IrCl2]2 36  
36 (20 mg, 25.0 μmol, 1.0 mol% Ir), K2CO3 (70 mg, 0.50 mmol, 10 mol%) and 
biphenyl (77 mg, 0.50 mmol, 10 mol%) were stirred in acetone (5 mL) at 40 °C 
for 30 minutes. 39 (514 L, 5.00 mmol, 1.00 eq) was added and the reaction 
was stirred at 60 °C for 24 hours. The reaction was followed using GC (Figure 
72). 67; 16%, 242; 14%, 243; <1% after 5 hours. 
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Figure 72 The conversion of 39 to 67 and the aldol reaction of 67 with acetone to 
give 242 and further products 243 and 244 with catalyst 36. Samples quantified 
using GC with biphenyl as an internal standard. 
 
5.6.7. 39 Control Test 
K2CO3 (70 mg, 0.50 mmol, 10 mol%) and biphenyl (77 mg, 0.50 mmol, 10 
mol%) were stirred in acetone (5 mL) at 40 °C for 30 minutes. 39 (514 L, 5.00 
mmol, 1.00 eq) was added and the reaction was stirred at 60 °C for 5 hours. 
The reaction was analysed using GC. 0% conversion after 5 hours. 
 
5.6.8. Aldol Background Experiment 
 
K2CO3 (70 mg, 0.50 mmol, 10 mol%) and biphenyl (77 mg, 0.50 mmol, 10 
mol%) were stirred in acetone (5 mL) at 40 °C for 30 minutes. 67 (514 L, 5.00 
mmol, 1.00 eq) was added and the reaction was stirred at 60 °C for 5 hours. 
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The reaction was analysed using GC. 67; 27%, 242; 55%, 243; 16%, 244; 2%, 
after 5 hours. 
5.6.9. General Procedure – Acetone Experiments 
 
Catalyst (1.0 mol%), K2CO3 (70 mg, 0.50 mmol, 10 mol%) and biphenyl (77 
mg, 0.50 mmol, 10 mol%) were stirred in acetonitrile (5 mL) at 40 °C for 30 
minutes. 39 (514 L, 5.00 mmol, 1.00 eq) and acetone (x eq) were added and 
the reaction was stirred at 60 °C for 24 hours. The reaction was followed with 
GC (Table 33, Figure 73). 
 
Table 33 The conversions to 67 with varied acetone equivalents. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. b 5 equivalents added evenly over a period of 5 
hours. c Conversion calculated at 6 hours.d 0.5 mol% catalyst.  
Entry Catalyst
Acetone                
(eq)
Conversion             
(%)
a
1 C.2 0 1
2 C.2 1 5
3 C.2 5
b
7
c
4 C.1 1 3
5 C.3
d 2 12
6 C.4 1 5
7 C.5
d 2 3
8 C.6
d 2 5
9 C.7.1
d 2 4
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Figure 73 Conversion (%) to 67 against reaction time (hours) with three different 
conditions (entries 1–3, Table 33). 
5.6.10. General Procedure – Comparison of Catalysts 
Catalyst (x mol%), K2CO3 (35 mg, 0.25 mmol, 10 mol%) and biphenyl (39 mg, 
0.25 mmol, 10 mol%) were stirred in acetonitrile (2.5 mL) at 40 °C for 30 
minutes. HMA (x eq) and 39 (257 L, 2.50 mmol, 1.00 eq) were added to the 
reaction and stirred at 50 °C for 24 hours. The reaction was followed with GC 
(Table 34). 
 
Table 34 Catalyst tests with HMA as the hydrogen acceptor. 
 
 
a Conversion calculated at 24 hours using GC from the corrected peak integrals with 
biphenyl as an internal standard. 
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Entry
Catalyst Loading  
(mol%)
HMA                   
(eq)
Temperature          
(°C)
Conversion             
(%)
a
1 1.0 2.0 50 5
2 0.7 2.0 75 9
3 0.5 solvent 60 1
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5.6.11. General Procedure – Acetone and Base Optimisation 
 
C.3 (11 mg, 0.013 mmol, 5.0 mol%), base (x eq) and biphenyl (4 mg, 25.0 
μmol, 10 mol%) were stirred in acetonitrile (2 mL) at 40 °C for 30 minutes. 
Acetone (x eq) and 39 (27 L, 0.26 mmol, 1.00 eq) were added to the reaction 
and stirred at 50 °C for 24 hours. The reaction was followed using GC (Table 
35, Figure 74). 
 
Table 35 Catalyst tests with varied base, base loading and acetone equivalents. 
 
a Conversion calculated from the corrected peak integrals using biphenyl as an 
internal standard for GC at 24 hours. b MeCN (1 mL). c Conversion calculated at 4 
hours. 
Entry Base
Base Loading 
(eq)
Acetone        
(eq)
Conversion             
(%)
a
1 K2CO3 0.1 5 8
b
2 Et3N 0.5 5 11
b
3 Et3N 1.0 10 8
4 Et3N 5.0 10 4
c
5 Et3N 1.0 20 12
6 K2CO3 1.0 10 11
7 K2CO3 1.0 20 26
8 K2CO3 1.0 30 24
9 K2CO3 1.0 40 25
10 K2CO3 1.0 50 30
11 KO
t
Bu 1.0 50 4
12 AcOH 1.0 50 3
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Figure 74 Conversion (%) against time (hours) for catalyst tests (entries 6–10, 
Table 35). 
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5.6.12. General Procedure – Water and NaHSO3 Addition 
 
A solution of 39 (27 L, 0.26 mmol, 1.00 eq) and acetone (955 L, 13.0 mmol, 
50.0 eq) was added to a solution of C.3 (11 mg, 13.0 μmol, 5.0 mol%), K2CO3 
(x eq), sodium bisulfite (x eq) and biphenyl (4 mg, 25.0 μmol, 10 mol%) in 
acetonitrile (x mL) and water (x mL) at 50 °C and stirred for 24 hours. The 
coloured reaction was analysed using GC (Table 36). 
 
Table 36 Catalyst tests with sodium bisulfite to trap 67. 
 
a Conversion calculated from the corrected peak integrals using biphenyl as an 
internal standard for GC at 24 hours. 
 
 
 
 
 
 
Entry
K2CO3             
(eq)
MeCN         
(mL)
Water          
(mL)
NaHSO3          
(eq)
Conversion 
(%)
a
1 0 2 0 0 9
2 1 2 0 1 16
3 0 2 0 1 9
4 0 1 1 0 8
5 0 1 1 1 9
6 1 1 1 0 12
b
7 1 1 1 1 13
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5.6.13. Experiment with a Second Addition of Catalyst 
C.3 (11 mg, 12.5 μmol, 5.0 mol%), K2CO3 (36 mg, 0.26 mmol, 1.00 eq) and 
biphenyl (4 mg, 25.0 μmol, 10 mol%) were stirred in acetonitrile (2 mL) at 40 
°C for 30 minutes. Acetone (764 L, 10.4 mmol, 40.0 eq) and 39 (27 L, 0.26 
mmol, 1.00 eq) were added and the reaction was stirred at 50 °C. After 1 hour, 
a second portion of catalyst was added (11 mg, 12.5 μmol, 5.0 mol%) and the 
reaction was stirred at 50 °C for 23 hours. The reaction was followed using GC 
(Figure 75). 16% conversion after 24 hours. 
 
 
 
Figure 75 Catalyst test with a second addition of catalyst (5 mol%) after 1.5 hours. 
 
 
 
 
 
5.6.14. Portioned Addition of Substrate 
C.3 (22 mg, 26.0 μmol, 5.0 mol%), K2CO3 (72 mg, 0.52 mmol, 1.00 eq) and 
biphenyl (8 mg, 52.0 μmol, 10 mol%) were stirred in acetonitrile (4 mL) at 40 
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°C for 30 minutes. Acetone (1.5 mL, 20.8 mmol, 40.0 eq) and 39 (6 L, 52.0 
μmol, 10 mol%) were added to the reaction and stirred at 50 °C for 24 hours. 
A further 9 portions of substrate (6 L, 52.0 μmol, 10 mol%) were added after 
30 minutes with intervals of 30 minutes. The reaction was followed using GC. 
32% conversion after 24 hours (Figure 76). 
 
 
 
Figure 76 Conversion (%) against time (hours) with 39 (0.1 eq) added every 30 
minutes for 5 hours. 
 
 
 
5.6.15. Experiment Starting with 1:1 Substrate/Product 
A solution of 39 (14 L, 0.13 mmol, 0.50 eq) and 67 (13 L, 0.13 mmol, 0.50 
eq) in acetone (955 L, 13.0 mmol, 50.0 eq) was added to a solution of C.3 
(11 mg, 13.0 μmol, 5.0 mol%), K2CO3 (36 mg, 0.26 mmol, 1.00 eq) and 
biphenyl (4 mg, 25.0 μmol, 10 mol%) in acetonitrile (2 mL) at 50 °C and stirred 
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for 24 hours. The reaction was followed using GC; 10% increase in 67 
concentration and 10% decrease in 39 after 24 hours (Figure 77). 
 
 
 
Figure 77 Catalyst test with a starting equimolar mixture of 39 and 67. 
 
 
 
 
 
 
5.6.16. Distillation Experiment with Syringe Pump Addition 
A solution of 39 (270 L, 2.90 mmol, 1.00 eq) and acetone (4.8 mL, 65.0 mmol, 
25 eq) was added to a solution of C.3 (55 mg, 65 μmol, 2.5 mol%), K2CO3 (360 
mg, 2.60 mmol, 1.00 eq) and biphenyl (40 mg, 0.26 mmol, 10 mol%) in 
acetonitrile (20 mL) and heated at 110 °C (distillation temperature; 70 °C). A 
solution of acetonitrile and acetone (8:1, v/v) was continuously added to the 
reaction via syringe pump at a rate equalling the rate of distillation (~200 L 
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per minute). The reaction was followed using GC; 11% conversion after 24 
hours (Figure 78).  
 
 
Figure 78 The distillation reaction was followed using GC with biphenyl as an 
internal standard. The distillation was stopped after four hours and the reaction was 
continued at 50 °C. 
 
 
 
5.6.17. Catalyst Addition Experiment – No Base 
In a flame dried Schlenk tube, a solution of 39 (26 L, 0.25 mmol, 1.00 eq) and 
acetone (918 L, 12.5 mmol, 50.0 eq) was added to a solution of biphenyl (4 
mg, 25.0 μmol, 10 mol%) in acetonitrile (2 mL) at 50 °C and stirred for 1 hour. 
A solution of catalyst C.3 (11 mg, 12.5 μmol, 5.0 mol%) in acetonitrile (1 mL) 
was prepared in a flame dried Schlenk tube under nitrogen and the solution 
was added to the reaction in four equal portions with one hour intervals. The 
reaction was analysed with GC. 9% conversion after 24 hours. 
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5.6.18. Catalyst Addition Experiment – Base in Reaction 
In a flame dried Schlenk tube, a solution of 39 (26 L, 0.25 mmol, 1.00 eq) and 
acetone (918 L, 12.5 mmol, 50.0 eq) was added to a solution of K2CO3 (35 
mg, 0.25 mmol, 1.00 eq) and biphenyl (4 mg, 25.0 μmol, 10 mol%) in 
acetonitrile (2 mL) at 50 °C and stirred for 1 hour. A solution of catalyst C.3 (11 
mg, 12.5 μmol, 5.0 mol%) in acetonitrile (1 mL) was prepared in a flame dried 
Schlenk tube under nitrogen and the solution was added to the reaction in four 
equal portions with one hour intervals. The reaction was followed using GC. 
17% conversion after 24 hours. 
 
5.6.19. Catalyst Addition Experiment – Pre-stirred with Base 
In a flame dried Schlenk tube, a solution of 39 (26 L, 0.25 mmol, 1.00 eq) and 
acetone (918 L, 12.5 mmol, 50.0 eq) was added to a solution of biphenyl (4 
mg, 25.0 μmol, 10 mol%) in acetonitrile (2 mL) at 50 °C under nitrogen and 
stirred for 1 hour. A solution of catalyst C.3 (11 mg, 12.5 μmol, 5.0 mol%) and 
K2CO3 (35 mg, 0.25 mmol, 1.00 eq) in acetonitrile (1 mL) was prepared in a 
flame dried Schlenk tube under nitrogen and the solution was added to the 
reaction in four equal portions with one hour intervals. The reaction was 
analysed using GC. 13% conversion after 24 hours.  
 
5.6.20. General Procedure for Condition Optimisation 
 
In a flame dried Schlenk tube, triethylamine (35 L, 0.25 mmol, 1.00 eq) was 
added to a solution of C.3 (x mol%) and biphenyl (4 mg, 25.0 μmol, 10 mol%) 
in acetonitrile (x mL) and acetone (x mL) under nitrogen at 50 °C and stirred 
for 1 hour. 39 (27 L, 0.26 mmol, 1.00 eq) was added to the reaction and stirred 
for 24 hours. The pink homogeneous reaction was analysed using GC (Table 
37). 
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Table 37 Catalysts tests investigating the amount of acetone and catalyst loading. 
 
a Conversion calculated from the corrected peak integrals using biphenyl as an 
internal standard for GC at 24 hours. b Base added after 1 hour. c Reaction carried 
out at room temperature. d Reaction turned pale yellow with one equivalent of base, 
after 1 hour a second equivalent of base added, reaction returned to a pink solution. 
 
 
Figure 79 Concentration (M) against time (h) for the transfer dehydrogenation of 67 
(entry 9, Table 37). 
 
Entry Catalyst
Catalyst Loading 
(mol%)
Base
Acetone 
(mL)
MeCN    
(mL) 
Conversion 
(%)
a
1 C.3 5.0 K2CO3 1 2 21
2 C.5 5.0 K2CO3 1 2 7
3 C.6 5.0 K2CO3 1 2 11
4 C.3 5.0 Et3N 2 - 47
b
5 C.3 5.0 Et3N 2 - 51
6 C.3 5.0 Et3N 4 - 62
7 C.3 5.0 Et3N 4 - 18
c
8 C.3 5.0 Et3N 6 - 58
9 C.3 5.0 Et3N 4 - 48
10 C.3 2.5 Et3N 4 - 22
11 C.3 10.0 Et3N 4 - 47
d
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5.6.21. Transfer Dehydrogenation with [Cp*IrCl2]2 36 
Triethylamine (35 L, 0.25 mmol, 1.00 eq) was added to a solution of 36 (5 
mg, 6.25 μmol, 2.5 mol%, 5.0 mol% Ir) and biphenyl (4 mg, 25.0 μmol, 10 
mol%) in acetone (4 mL) at 50 °C and stirred for 1 hour. 39 (27 L, 0.26 mmol, 
1.00 eq) was added to the reaction and stirred for 24 hours. The orange 
homogeneous reaction was followed with GC; 77% conversion after 24 hours 
(Figure 80). 
 
Figure 80 Catalyst control test with 36 with inert conditions. 
5.6.22. Acetonitrile Addition Test 
Triethylamine (35 L, 0.25 mmol, 1.00 eq) was added to a solution of C.3 (11 
mg, 12.5 μmol, 5.0 mol%) and biphenyl (4 mg, 25.0 μmol, 10 mol%) in acetone 
(4 mL) at 50 °C and stirred for 1 hour. 39 (27 L, 0.26 mmol, 1.00 eq) was 
added to the reaction and stirred for 24 hours. Acetonitrile (1 mL) was added 
to the reaction after 90 minutes. The pink homogeneous reaction was followed 
with GC; 41% conversion after 24 hours (Figure 81). 
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Figure 81 Transfer dehydrogenation of 39 with the addition of MeCN at 1.5 hours. 
5.6.23. 1H NMR Monitored Experiment 
Triethylamine (35 L, 0.25 mmol, 1.00 eq) was added to a solution of C.3 (11 
mg, 12.5 μmol, 5.0 mol%) and biphenyl (4 mg, 25.0 μmol, 10 mol%) in d6-
acetone (4 mL) at 50 °C and stirred for 1 hour. 39 (27 L, 0.26 mmol, 1.00 eq) 
was added to the reaction and the solution transferred to an NMR tube under 
nitrogen. The pink homogeneous reaction was followed with 1H NMR; 6% 
conversion after 24 hours (Figure 82). 
 
 
 
Table 38 Transfer dehydrogenation of 39, followed using 1H NMR in d6-acetone. 
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a Intergration of 39 CH2 signal at 4.53 ppm with the 67 CHO signal at 9.96 ppm set 
to an integral of 1.00; spectra normalised using residual solvent peak for d6-acetone. 
b Conversion calculated from: (1 / (1 + (i / 2)) × 100, where i is the integral of 39 CH2 
signal at 4.53 ppm. 
 
 
Figure 82 Transfer dehydrogenation of 39 followed using 1H NMR in d6-acetone. 
 
5.7. Transfer Hydrogenation of Benzoin 129 with Benzyl 
Alcohol 39 
 
Spectrum Time Stamp
Time                   
(h)
39 CH2  
Integral
a     
Conversion             
(%)
b
1 14:40 1.0 188.28 1.05
2 15:39 2.0 124.73 1.58
3 17:00 3.3 90.65 2.16
4 18:00 4.3 77.34 2.52
5 22:08 8.5 56.55 3.42
6 02:01 12.4 46.65 4.11
7 09:20 19.7 37.25 5.10
8 10:31 20.9 35.6 5.32
9 12:00 22.3 33.98 5.56
10 12:26 22.8 33.69 5.60
11 13:31 24.0 32.24 5.84
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Triethylamine (35 μL, 0.25 mmol, 1.00 eq) and 39 (1.3 mL, 12.5 mmol, 50.0 
eq) were added to a stirred solution of C.4 (9 mg, 12.5 μmol, 5.0 mol%) and 
129 (53 mg, 0.25 mmol, 1.00 eq) in acetonitrile (2.7 mL) under nitrogen and 
stirred at 50 °C for 24 hours. The reaction was analysed using 1H NMR with 
mesitylene (0.17 M) as an external standard. 0% conversion after 24 hours. 
 
5.8. Control Test for Side Reactions using an IR Probe 
A solution of K2CO3 (3.45 mg, 25.0 mmol, 1.00 eq) in acetonitrile (25 mL) was 
monitored with an IR probe (resolution 4; scans 16; interval 60 s; Horizon MB) 
for 30 minutes at 50 °C. 67 (2.55 mL, 25.0 mmol, 1 eq) was added and the 
peak corresponding to the carbonyl stretch at 1702 cm-1 was constant. After 
30 minutes, 39 (2.60 mL, 25.0 mmol, 1.00 eq) was added and the mixture 
monitored for 3.5 hours at 50 °C (Figure 83). The peak areas remained 
constant. 
 
Figure 83 Overlayed IR spectra (time in minutes) with separate additions of 67 and 
39 at 0 and 30 minutes. 
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5.9. Benzoin Condensation with Benzaldehyde 67 
 
5.9.1. General Procedure 
67 (50 mL, 0.50 mmol, 1.00 eq) was added to a solution of catalyst (x mol%) 
and base (x eq) in solvent (0.25 M) and stirred at temperature for 24 hours. 
The reaction was cooled to room temperature and concentrated in vacuo and 
the organic layer was washed with DCM (2 x 20 mL) and extracted with brine 
(2 x 20 mL). The organics were combined and the solvent was removed in 
vacuo to give a crude oil. The oil was recrystallized from DCM and petrol to 
give the product as yellow needles (Table 39). 
 
 
 
 
 
Table 39 Catalyst tests for the benzoin condensation of 67 to 129. 
 
 
5.10. Transfer Hydrogenation 
 
Entry Catalyst
Catalyst Loading  
(mol%)
Base      
(eq)
Solvent
Temp      
(°C)
Yield     
(%)
1 C.4 1.0 K2CO3 (0.1) MeCN 40 0
2 C.1 5.0 Et3N (0.6) EtOH 70 0
3 C.1 5.0 Et3N (0.6)
i
PrOH 70 0
4 C.7.1 3.0 Et3N (5.0) MeCN 50 0
5 L.7 5.0 Et3N (2.0) MeCN 80 93
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5.10.1.  
Complex C.2 (21 mg, 25.0 μmol, 1.0 mol%), K2CO3 (35 mg, 0.25 mmol, 10 
mol%) and biphenyl (GC standard, 39 mg, 0.25 mmol, 0.10 eq) were stirred in 
acetonitrile (2.5 mL) at 40 °C for 30 minutes. 67 (252 L, 2.50 mmol, 1.00 eq) 
was added and the reaction was stirred at 50 °C for 24 hours. The reaction 
was analysed using GC. 0% conversion after 24 hours. 
5.10.2.  
Catalyst C.3 (11 mg, 12.5 μmol, 5.0 mol%), K2CO3 (36 mg, 0.26 mmol, 1.00 
eq) and biphenyl (4 mg, 25.0 μmol, 10 mol%) were stirred in acetonitrile (2 mL) 
at 40 °C for 30 minutes. iso-Propanol (750 L, 10.4 mmol, 40.0 eq) and 67 (27 
L, 0.26 mmol, 1.00 eq) were added and the reaction was stirred at 50 °C for 
24 hours. The reaction was followed using GC. 91% conversion after 24 hours. 
 
5.11. Reactions using a Carousel Reactor 
5.11.1. General Procedure for the Transfer Dehydrogenation of 39 
 
Catalyst (12.5 μmol, 5.0 mol%) was added to a Radley’s carousel tube and 
flushed with nitrogen for 30 minutes. A solution of biphenyl (4 mg, 25.0 μmol, 
10 mol%) in acetone (4 mL) was prepared under nitrogen, added to the catalyst 
and stirred at 50 °C for 30 minutes. Triethylamine (35 L, 0.25 mmol, 1.00 eq) 
was added to the reaction and stirred for 30 minutes. 39 (25 L, 0.25 mmol, 
1.00 eq) was added to the reaction and stirred for 24 hours. The homogeneous 
reaction was sampled for GC. The solvent was removed in vacuo and analysed 
using 1H NMR (500 μL, 0.17 M mesitylene in CDCl3) (Table 40). 
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Table 40 The average conversions of the duplicate catalyst tests for the transfer 
dehydrogenation of 39, analysed using GC (with biphenyl as an internal standard) 
and 1H NMR spectroscopy (with mesitylene as an external standard). 
 
a Conversion calculated from the average of two results with biphenyl (10 mol%) as 
an internal standard. b Standard deviation of the two results for both methods of 
analysis. c Conversion calculated from the average of two results with mesitylene 
(0.17 M) as an external standard.   
5.11.2. General Procedure for the Transfer Hydrogenation of 67 
 
Catalyst (12.5 μmol, 5.0 mol%) was added to a Radley’s carousel tube and 
flushed with nitrogen for 30 minutes. A solution of biphenyl (4 mg, 25.0 μmol, 
Entry Catalyst
GC Conversion 
(%)
a s.d
b
1
H NMR Conversion 
(%)
c s.d
b
1 None 0 0 0 0
2 36 81 0 78 1
3 161 29 1 22 1
4 62 51 8 49 1
5 168 29 5 27 6
6 C.1 7 2 3 0
7 C.2 16 0 11 0
8 C.3 23 2 16 2
9 C.4 78 2 73 4
10 C.5 11 3 7 3
11 C.6 69 6 65 12
12 C.7.2 1 0 0 0
13 C.8 27 2 22 2
14 C.9 3 1 1 0
15 C.11 60 0 56 0
16 C.12 13 1 8 1
17 C.13 66 1 62 2
18 C.14 0 0 2 0
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10 mol%) in iso-propanol (4 mL) was prepared under nitrogen, added to the 
catalyst and stirred at 50 °C for 30 minutes. Triethylamine (35 L, 0.25 mmol, 
1.00 eq) was added to the reaction and stirred for 30 minutes. 67 (25 L, 0.25 
mmol, 1.00 eq) was added to the reaction and stirred for 24 hours. The 
homogeneous reaction was sampled for GC. The solvent was removed in 
vacuo and analysed using 1H NMR (500 μL, 0.17 M mesitylene in CDCl3) 
(Table 41). 
 
Table 41 The average conversions of the duplicate catalyst tests for the transfer 
hydrogenation of 67, analysed using GC (with biphenyl as an internal standard) and 
1H NMR spectroscopy (with mesitylene as an external standard). 
 
a Conversion calculated from the average of two results with biphenyl (10 mol%) as 
an internal standard. b Standard deviation of the two results for both methods of 
analysis. c Conversion calculated from the average of two results with mesitylene 
(0.17 M) as an external standard.   
 
Entry Catalyst
GC Conversion 
(%)
a s.d
b
1
H NMR Conversion 
(%)
c s.d
b
1 None 2 0 0 0
2 36 99 0 quant. 0
3 161 99 0 quant. 0
4 62 98 0 quant. 0
5 168 99 0 quant. 0
6 C.1 12 1 17 2
7 C.2 79 8 89 6
8 C.3 65 1 83 2
9 C.4 99 0 quant. 0
10 C.5 76 2 88 1
11 C.6 quant. 0 99 1
12 C.7.2 1 0 2 1
13 C.8 quant. 0 quant. 0
14 C.9 17 1 28 2
15 C.11 98 0 quant. 0
16 C.12 98 0 quant. 0
17 C.13 97 0 quant. 0
18 C.14 2 0 0 0
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5.12. Scope 
 
5.12.1. General Procedure 
Catalyst (12.5 μmol, 5.0 mol%) was added to a Radley’s carousel tube and 
flushed with nitrogen for 30 minutes. A solution of alcohol (0.25 mmol, 1.00 eq) 
in acetone (4 mL) was prepared under nitrogen, added to the catalyst and 
stirred at 50 °C for 30 minutes. Triethylamine (35 L, 0.25 mmol, 1.00 eq) was 
added to the reaction and stirred for 24 hours. The homogeneous reaction was 
sampled for GC-MS. The solvent was removed in vacuo and analysed using 
1H NMR (500 μL, 0.17 M mesitylene in CDCl3) (Table 42). 
 
Table 42 Transfer dehydrogenation with catalysts C.4, C.6 and C.13. 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. b 0.17 M mesitylene in d6-acetone used as an external 
standard for solubility. c Substrate condensed with acetone; no oxidation product 
observed. 
C.4 C.6 C.13
248 99 97 60
249 97 97 69
250 89 84 45
39 78 69 60
251 50 40 13
252 0 0 0
51 100 - 52
253 0 - -
254 0 - -
Conversion (%)
a
Substrate
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5.13. Transfer Dehydrogenation of (R)- and (S)-1-
Phenylethanol 51  with Complex C.13 
 
 
Triethylamine (35 μL, 0.25 mmol, 1.00 eq) and either (R)-51 or (S)-51 (30 μL, 
0.25 mmol, 1.00 eq) were added to a stirred solution of C.13 (10 mg, 12.5 
μmol, 5.0 mol%) in acetone (4 mL) under nitrogen and stirred at 50 °C for 24 
hours. The reaction was analysed using 1H NMR with mesitylene (0.17 M in 
CDCl3) as an external standard. After 24 hours, (R)-51 and (S)-51 reached 
98% and 97% conversion respectively.  
 
5.14. Transfer Dehydrogenation of Benzyl Alcohol 39: Catalyst 
Loading Tests 
 
 
5.14.1. General Procedure 
Catalyst C.4 (x mol%) was added to a Radley’s carousel tube and flushed with 
nitrogen for 30 minutes. A solution of benzyl alcohol (169 μL, 1.64 mmol, 1.00 
eq) in acetone (10 mL) was prepared under nitrogen, added to the catalyst and 
stirred at 50 °C for 30 minutes. Triethylamine (226 L, 1.64 mmol, 1.00 eq) 
was added to the reaction and stirred for 24 hours. The homogeneous reaction 
was sampled for 1H NMR (500 μL sample with solvent removed in vacuo and 
500 μL of 0.17 M mesitylene in CDCl3). After 24 hours, the solvent was 
 226 
 
removed in vacuo and followed using 1H NMR (500 μL, 0.17 M mesitylene in 
CDCl3) (Table 43, Figure 84). 
 
Table 43 The catalyst tests with varied catalyst loadings. 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. b Result taken from a previous reaction.  
 
 
Figure 84 The conversion caluclated from 1H NMR spectroscopy with mesitylene as 
an external standard of 39 to 67 with varied catalyst loading (mol%). The 5.00 mol% 
result was taken from a previous experiment. 
 
 
 
Entry
Catalyst Loading 
(mol%)
Conversion             
(%)
a
1 5.00 73
b
2 3.60 62
3 0.90 55
4 0.18 37
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5.15. Transfer Dehydrogenation of 1-Phenylethanol 51: 
Catalyst Loading Tests  
 
5.15.1. General Procedure 
Catalyst C.4 (x mol%) was added to a Radley’s carousel tube and flushed with 
nitrogen for 30 minutes. A solution of 1-phenylethanol (169 μL, 1.40 mmol, 
1.00 eq) in acetone (10 mL) was prepared under nitrogen, added to the catalyst 
and stirred at 50 °C for 30 minutes. Triethylamine (194 L, 1.40 mmol, 1.00 
eq) was added to the reaction and stirred for 24 hours. The homogeneous 
reaction was sampled for GC-MS and 1H NMR (1 mL sample with solvent 
removed in vacuo and 500 μL of 0.17 M mesitylene in CDCl3). After 24 hours, 
the solvent was removed in vacuo and analysed using 1H NMR (500 μL, 0.17 
M mesitylene in CDCl3). After 24 hours, the solvent was removed in vacuo and 
followed using 1H NMR (500 μL, 0.17 M mesitylene in CDCl3) (Table 44, Figure 
85). 
 
Table 44 The transfer dehydrogenation of 51 with catalyst C.4 with varied catalyst 
loadings. 
 
a Conversion calculated from the 1H NMR spectra with 0.17 M mesitylene in CDCl3 
as an external standard. b The average conversion of two results. 
Entry
Catalyst Loading 
(mol%)
Conversion             
(%)
a
1 5.00 100
2 1.00 97
b
3 0.20 93
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Figure 85 The conversion caluclated from 1H NMR spectroscopy with mesitylene as 
an external standard of 51 to 49 with varied catalyst loading (mol%). 
 
5.16. Analytical Data for Catalysis Products 
5.16.1. Benzaldehyde 67 
 
GCMS m/z = M+ 106.0, Theoretical Mass = 106.0. 1H NMR (300 MHz, CDCl3) 
10.05 (s, 1H, CH-1), 7.91 (d, J = 7.7 Hz, 2H, CH-3/7), 7.73 – 7.61 (m, 1H, 
CH-5), 7.56 (t, J = 7.7 Hz, 2H, CH-4/6). 13C NMR {1H} (126 MHz, CDCl3) ; 
192.45 (C-1), 136.42 (C-2), 134.49 (C-5), 129.79 (C-4/6), 129.02 (C-3/7). IR 
(cm-1); 3063, 2819, 2736, 1696, 1653, 1596, 1583. Spectral data is consistent 
with the literature.158 
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5.16.2. Benzoin 129 
 
mp: 129.7–132.5 °C (Lit. 133–135 °C).159 GCMS m/z = M+ 212.0, Theoretical 
Mass = 212.1. 1H NMR (300 MHz, CDCl3) ; 7.92 (dd, J = 8.5, 1.3 Hz, 2H, CH- 
Ph), 7.66 – 7.47 (m, 1H, CH- Ph), 7.45 – 7.14 (m, 7H, CH-Ph), 5.96 (d, J = 6.1 
Hz, 1H, CH-2), 4.58 (d, J = 6.1 Hz, 1H, OH). 13C NMR {1H} (126 MHz, d6-
DMSO) ; 199.14 (C-10), 139.71 (C-5), 134.71 (C-4), 133.18 (C-8), 128.80 (C-
6), 128.55 (C-7), 128.43 (C-3), 127.66 (C-1), 127.23 (C-2), 75.65 (C-9). IR (cm-
1); 3405, 3059, 3028, 2932, 1678, 1594, 1577, 1448. Spectral data is 
consistent with the literature.159 
5.16.3. Hydrobenzoin 237 
 
mp: 145.4–147.6 °C (Lit. 138 °C)160. GCMS: m/z = M+-H2O 196.2, Theoretical 
Mass = 196.2. 1H NMR (300 MHz, CDCl3)  7.92 (d, J = 7.4 Hz, 4H, CH-
3/3′/7/7′), 7.52 (t, J = 7.4 Hz, 2H, CH-5/5′), 7.40 (t, J = 7.4 Hz, 4H, CH-4/4′/6/6′), 
4.71 (s, 2H, CH-1/1′), 4.57 (br s, 2H, OH). 13C NMR {1H} (126 MHz, d6-DMSO) 
; 142.32 (C-5), 127.24 (C-4), 127.13 (C-3), 126.65 (C-2), 77.64 (C-7). IR (cm-
1); 3496, 3386, 2893, 1491, 1451, 1383. Spectral data is consistent with the 
literature.160 
 
5.16.4. Benzyl alcohol 39 
 
 230 
 
GCMS: m/z = M+ 108.0, Theoretical Mass = 108.1. 1H NMR (500 MHz, CDCl3) 
7.51 – 7.37 (m, 5H, CH-Ph), 4.63 (d, J = 5.6 Hz, 2H, CH2-1), 4.53 (t, J = 5.6 
Hz, 1H, OH). Spectral data is consistent with the literature.161 
 
5.16.5. p-Hydroxybenzaldehyde 255 
 
GCMS: m/z = M+ 122.0, Theoretical Mass = 122.0.  1H NMR (500 MHz, d6-
acetone)  9.85 (s, 1H, CH-1), 8.34 (br s, 1H, OH), 7.79 (d, J = 8.4 Hz, 2H, 
CH-3/7), 7.03 (d, J = 8.4 Hz, 2H, CH-4/6). Spectral data is consistent with the 
literature.162 
 
5.16.6. p-Methoxybenzaldehyde 256 
 
GCMS: m/z = M+ 136.0, Theoretical Mass = 136.1.  1H NMR (500 MHz, CDCl3) 
 9.78 (s, 1H, CH-1), 7.74 (d, J = 8.8 Hz, 2H, CH-3/7), 6.91 (d, J = 8.8 Hz, 2H, 
CH-4/6), 3.79 (s, 3H, CH3-8). Spectral data is consistent with the literature.163 
 
5.16.7. p-Methylbenzaldehyde 257 
 
GCMS: m/z = M+ 120.0, Theoretical Mass = 120.1.  1H NMR (500 MHz, CDCl3) 
 9.95 (s, 1H, CH-1), 7.77 (d, J = 8.0 Hz, 2H, CH-3/7), 7.33 (d, J = 8.0 Hz, 2H, 
CH-4/6), 2.43 (s, 3H, CH3-8). Spectral data is consistent with the literature.164 
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5.16.8. p-Iodobenzaldehyde 258 
 
GCMS: m/z = M+ 231.9, Theoretical Mass = 231.9.  1H NMR (500 MHz, CDCl3) 
 9.92 (s, 1H, CH-1), 7.88 (d, J = 8.4 Hz, 2H, CH-3/7), 7.56 (d, J = 8.4 Hz, 2H, 
CH-4/6). Spectral data is consistent with the literature.163 
 
5.16.9. Acetophenone 49 
 
GCMS: m/z = M+ 120.0, Theoretical Mass = 120.1.  1H NMR (500 MHz, CDCl3) 
 7.92 – 7.82 (m, 2H, CH-4/8), 7.53 – 7.44 (m, 1H, CH-6), 7.43 – 7.32 (m, 2H, 
CH-5/7), 2.52 (s, 3H, CH3-1). Spectral data is consistent with the literature.165 
 
5.16.10. N-(iso-Propylidene)benzylamine 260 
 
GCMS: m/z = M+ 147.1, Theoretical Mass = 147.1. 1H NMR (500 MHz, CDCl3) 
7.32 – 7.26 (m, 1H, CH-6/7/9/10), 7.23 – 7.17 (m, 1H, CH-8), 4.43 (s, 2H, 
CH2-4), 2.07 (s, 3H, CH3-1), 1.91 (s, 3H, CH3-2). Spectral data is consistent 
with the literature.166, 167 
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5.16.11. iso-Propylidene-(1-phenylethyl)-amine 261 
 
GCMS: m/z = M+ 161.1, Theoretical Mass = 161.1. 1H NMR (500 MHz, CDCl3) 
 7.40 – 7.30 (m, 4H, CH-7/8/10/11), 7.24 – 7.20 (m, 1H, CH-9), 4.61 (q, J = 
6.6 Hz, 1H, CH-4), 2.07 (s, 3H, CH3-1), 1.88 (s, 3H, CH3-2), 1.49 (d, J = 6.6 
Hz, 3H, CH3-5). Spectral data is consistent with the literature.168 
 
5.17. GC Calibration Data 
GC method: oven temperature of 60 °C with a ramp of 15°C/min to 140°C and 
then 30 °C/min to 280 °C. Column: HP-5 column, length 30 m, internal 
diameter 320 m. GC samples were filtered through a plug of silica prior to 
loading. Solutions were made up with 50 μL of sample in 1 mL MeCN or MeOH. 
 
Table 45 Retention times for compounds associated with the catalysis experiments. 
 
a A sample was not available for calibration. 
 
Compound t R (min)
Benzyl alcohol 39 2.84
Benzaldehyde 67 2.13
Benzoin 129 8.75
4-Hydroxy-4-phenylbutan-2-one 242 6.18
a
Benzylideneacetone 243 5.99
Dibenzylideneacetone 244 9.62
Biphenyl (standard) 6.10
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Figure 86 GC calibration plots for benzyl alcohol, benzaldehyde and biphenyl and 
the ratios of the gradients with respect to the internal standard which act as 
conversion factors. 
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7. Appendix 
X-Ray Crystal Structure Data 
L.1 
 
Identification code exp_1564 
Empirical formula C25H25N3O2S2 
Formula weight 463.60 
Temperature/K 120.02(10) 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.46792(10) 
b/Å 18.8677(3) 
c/Å 44.1959(8) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 4559.56(14) 
Z 8 
ρcalcg/cm3 1.351 
μ/mm-1 2.339 
F(000) 1952.0 
Crystal size/mm3 0.29 × 0.14 × 0.09 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.16 to 147.774 
Index ranges -6 ≤ h ≤ 6, -21 ≤ k ≤ 23, -45 ≤ l ≤ 54 
Reflections collected 17185 
Independent reflections 8967 [Rint = 0.0417, Rsigma = 0.0571] 
Data/restraints/parameters 8967/0/595 
Goodness-of-fit on F2 1.053 
Final R indexes [I>=2σ (I)] R1 = 0.0417, wR2 = 0.0965 
Final R indexes [all data] R1 = 0.0465, wR2 = 0.0990 
Largest diff. peak/hole / e Å-3 0.30/-0.37 
Flack parameter -0.011(11) 
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C.3 
 
Identification code pic1 
Empirical formula C38H47ClIrN3O3S2 
Formula weight 885.55 
Temperature/K 119.97(13) 
Crystal system monoclinic 
Space group P21 
a/Å 17.2721(6) 
b/Å 12.4309(3) 
c/Å 17.9981(8) 
α/° 90 
β/° 105.818(4) 
γ/° 90 
Volume/Å3 3718.0(2) 
Z 4 
ρcalcg/cm3 1.582 
μ/mm-1 3.815 
F(000) 1784.0 
Crystal size/mm3 0.24 × 0.07 × 0.05 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.868 to 59.58 
Index ranges -20 ≤ h ≤ 24, -17 ≤ k ≤ 16, -23 ≤ l ≤ 23 
Reflections collected 48320 
Independent reflections 18059 [Rint = 0.0609, Rsigma = 0.0846] 
Data/restraints/parameters 18059/973/879 
Goodness-of-fit on F2 1.030 
Final R indexes [I>=2σ (I)] R1 = 0.0466, wR2 = 0.0788 
Final R indexes [all data] R1 = 0.0714, wR2 = 0.0878 
Largest diff. peak/hole / e Å-3 1.39/-1.93 
Flack parameter -0.017(7) 
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C.4 
 
Identification code JM124_Mo 
Empirical formula C22H29N2O2S2Cl2Ir 
Formula weight 680.69 
Temperature/K 120.01(17) 
Crystal system monoclinic 
Space group P21/c 
a/Å 21.2275(18) 
b/Å 7.2138(4) 
c/Å 16.0785(10) 
α/° 90.00 
β/° 101.968(7) 
γ/° 90.00 
Volume/Å3 2408.6(3) 
Z 4 
ρcalcg/cm3 1.877 
μ/mm-1 5.961 
F(000) 1336.0 
Crystal size/mm3 0.16 × 0.09 × 0.03 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.98 to 56.58 
Index ranges -22 ≤ h ≤ 28, -9 ≤ k ≤ 7, -21 ≤ l ≤ 13 
Reflections collected 15540 
Independent reflections 5970 [Rint = 0.0501, Rsigma = 0.0641] 
Data/restraints/parameters 5970/0/263 
Goodness-of-fit on F2 1.088 
Final R indexes [I>=2σ (I)] R1 = 0.0466, wR2 = 0.0768 
Final R indexes [all data] R1 = 0.0603, wR2 = 0.0817 
Largest diff. peak/hole / e Å-3 2.24/-2.09 
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[Cp*IrI2(DMSO)] 
 
Identification code JAM170_Mo 
Empirical formula C12H21I2IrOS 
Formula weight 659.35 
Temperature/K 120.00(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 13.6118(4) 
b/Å 12.8985(3) 
c/Å 19.2732(5) 
α/° 90.00 
β/° 96.212(3) 
γ/° 90.00 
Volume/Å3 3363.95(15) 
Z 8 
ρcalcg/cm3 2.604 
μ/mm-1 11.719 
F(000) 2400.0 
Crystal size/mm3 0.22 × 0.11 × 0.08 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.02 to 62.72 
Index ranges -19 ≤ h ≤ 19, -18 ≤ k ≤ 15, -27 ≤ l ≤ 28 
Reflections collected 28601 
Independent reflections 9767 [Rint = 0.0610, Rsigma = 0.0771] 
Data/restraints/parameters 9767/0/321 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0442, wR2 = 0.0671 
Final R indexes [all data] R1 = 0.0692, wR2 = 0.0795 
Largest diff. peak/hole / e Å-3 1.69/-1.80 
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C.7.1 
 
Identification code JAM170_2_Mo 
Empirical formula C40H52Cl15.55I1.45Ir2N3O2S3 
Formula weight 1822.68 
Temperature/K 120.03(10) 
Crystal system triclinic 
Space group P-1 
a/Å 12.8968(2) 
b/Å 13.1630(2) 
c/Å 21.0772(6) 
α/° 92.2184(19) 
β/° 98.7805(19) 
γ/° 106.1231(16) 
Volume/Å3 3384.65(14) 
Z 2 
ρcalcg/cm3 1.788 
μ/mm-1 5.328 
F(000) 1744.0 
Crystal size/mm3 0.32 × 0.21 × 0.09 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.888 to 62.452 
Index ranges -18 ≤ h ≤ 17, -19 ≤ k ≤ 19, -30 ≤ l ≤ 30 
Reflections collected 56431 
Independent reflections 19383 [Rint = 0.0683, Rsigma = 0.0917] 
Data/restraints/parameters 19383/118/679 
Goodness-of-fit on F2 1.033 
Final R indexes [I>=2σ (I)] R1 = 0.0667, wR2 = 0.1632 
Final R indexes [all data] R1 = 0.1040, wR2 = 0.1880 
Largest diff. peak/hole / e Å-3 2.30/-2.24 
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L.8 
 
Identification code JAM2_251_Mo_a_twin1_hklf4 
Empirical formula C10H11N3O2S2 
Formula weight 269.34 
Temperature/K 119.97(13) 
Crystal system triclinic 
Space group P-1 
a/Å 7.9036(6) 
b/Å 7.9397(5) 
c/Å 11.3310(9) 
α/° 70.084(7) 
β/° 82.973(7) 
γ/° 62.293(7) 
Volume/Å3 591.31(9) 
Z 2 
ρcalcg/cm3 1.513 
μ/mm-1 0.443 
F(000) 280.0 
Crystal size/mm3 0.32 × 0.19 × 0.15 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.828 to 62.658 
Index ranges -11 ≤ h ≤ 11, -11 ≤ k ≤ 11, -16 ≤ l ≤ 16 
Reflections collected 7823 
Independent reflections 7823 [Rint = ?, Rsigma = 0.0494] 
Data/restraints/parameters 7823/0/160 
Goodness-of-fit on F2 1.007 
Final R indexes [I>=2σ (I)] R1 = 0.0743, wR2 = 0.2102 
Final R indexes [all data] R1 = 0.1036, wR2 = 0.2306 
Largest diff. peak/hole / e Å-3 1.38/-0.58 
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C.10 
 
Identification code JAM3_316_Mo_b 
Empirical formula C21H27Cl2IIrN3O2S2 
Formula weight 807.57 
Temperature/K 120.00(16) 
Crystal system monoclinic 
Space group P21 
a/Å 15.8194(4) 
b/Å 9.79020(18) 
c/Å 17.4568(3) 
α/° 90 
β/° 95.879(2) 
γ/° 90 
Volume/Å3 2689.41(10) 
Z 4 
ρcalcg/cm3 1.995 
μ/mm-1 6.489 
F(000) 1544.0 
Crystal size/mm3 0.29 × 0.05 × 0.03 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.272 to 62.908 
Index ranges -23 ≤ h ≤ 22, -14 ≤ k ≤ 14, -25 ≤ l ≤ 25 
Reflections collected 72851 
Independent reflections 16246 [Rint = 0.0655, Rsigma = 0.0659] 
Data/restraints/parameters 16246/1/589 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0414, wR2 = 0.0669 
Final R indexes [all data] R1 = 0.0546, wR2 = 0.0720 
Largest diff. peak/hole / e Å-3 2.05/-1.95 
Flack parameter 0.5 
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L.13 
 
Identification code JAM2_277_4_Cu 
Empirical formula C23H22N4O2S 
Formula weight 418.50 
Temperature/K 119.99(15) 
Crystal system orthorhombic 
Space group P212121 
a/Å 9.26295(12) 
b/Å 10.76616(15) 
c/Å 21.8237(3) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2176.40(5) 
Z 4 
ρcalcg/cm3 1.277 
μ/mm-1 1.535 
F(000) 880.0 
Crystal size/mm3 0.17 × 0.09 × 0.08 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.102 to 148.608 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 13, -27 ≤ l ≤ 26 
Reflections collected 22649 
Independent reflections 4442 [Rint = 0.0444, Rsigma = 0.0301] 
Data/restraints/parameters 4442/0/276 
Goodness-of-fit on F2 1.019 
Final R indexes [I>=2σ (I)] R1 = 0.0282, wR2 = 0.0696 
Final R indexes [all data] R1 = 0.0303, wR2 = 0.0712 
Largest diff. peak/hole / e Å-3 0.24/-0.28 
Flack parameter -0.007(7) 
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C.14 
 
 
 
Identification code JAM2_285_Mo_a 
Empirical formula C35.3H42.3Cl2.6I2IrN4O2.35S 
Formula weight 1130.46 
Temperature/K 119.98(18) 
Crystal system monoclinic 
Space group P21 
a/Å 10.0659(5) 
b/Å 21.3806(11) 
c/Å 19.0488(9) 
α/° 90 
β/° 90.185(5) 
γ/° 90 
Volume/Å3 4099.6(4) 
Z 4 
ρcalcg/cm3 1.832 
μ/mm-1 5.019 
F(000) 2176.0 
Crystal size/mm3 0.19 × 0.04 × 0.02 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.952 to 56.564 
Index ranges -13 ≤ h ≤ 9, -28 ≤ k ≤ 28, -25 ≤ l ≤ 25 
Reflections collected 54860 
Independent reflections 20325 [Rint = 0.0737, Rsigma = 0.1003] 
Data/restraints/parameters 20325/865/878 
Goodness-of-fit on F2 1.030 
Final R indexes [I>=2σ (I)] R1 = 0.0544, wR2 = 0.1085 
Final R indexes [all data] R1 = 0.0727, wR2 = 0.1184 
Largest diff. peak/hole / e Å-3 4.85/-1.26 
Flack parameter -0.027(4) 
